Kiora Pharmaceuticals (KPRX) 10-K/A 6 Jul 22 2021 FY Annual report (amended) Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2021	Jul. 03, 2022	Jun. 30, 2021
Cover [Abstract]
Document Type	10-K/A
Amendment Description	Amendment No. 1
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2021
Entity File Number	001-36672
Entity Registrant Name	KIORA PHARMACEUTICALS, INC
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	98-0443284
Entity Address, Address Line One	1371 East 2100 South
Entity Address, Address Line Two	Suite 200
Entity Address, City or Town	Salt Lake City
Entity Address, State or Province	UT
Entity Address, Postal Zip Code	84105
City Area Code	781
Local Phone Number	788-8869
Title of 12(b) Security	Common Stock, $0.01 par value
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Trading Symbol	KPRX
Entity Public Float			$ 45,594,207
Entity Common Stock, Shares Outstanding		13,067,426
Entity Central Index Key	0001372514
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Amendment Flag	true
Auditor Name	EISNERAMPER LLP
Auditor Firm ID	274
Auditor Location	New York

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Current Assets:
Cash and Cash Equivalents	$ 7,854,690	$ 1,185,677
Prepaid Expenses and Other Current Assets	606,520	449,569
Other Receivables	529,560	90,975
Total Current Assets	8,990,770	1,726,221
Non-Current Assets:
Property and Equipment, Net	73,999	30,566
Restricted Cash	45,000	45,000
Goodwill	0	3,631,212
Intangible Assets and In-Process R&D, Net	10,768,164	9,730,164
Operating Lease Assets with Right-of-Use	209,411	83,928
Other Assets	42,964	57,073
Total Assets	20,130,308	15,304,164
Current Liabilities:
Accounts Payable	160,621	434,763
Loan Payable		212,281
Accrued Expenses	1,330,141	1,289,261
Operating Lease Liabilities	118,846	48,303
Total Current Liabilities	1,609,608	1,984,608
Non-Current Liabilities:
Contingent Consideration	3,048,955	2,547,074
Deferred Tax Liability	802,131	728,926
Paycheck Protection Program Loan		278,190
Non-Current Operating Lease Liabilities	90,566	35,625
Total Non-Current Liabilities	3,941,652	3,589,815
Total Liabilities	5,551,260	5,574,423
Commitments and Contingencies (Note 14)
Stockholders' Equity:
Preferred Stock, $0.01 Par Value: 10,000,000 shares authorized at December 31, 2021 and 2020; 3,750 designated Series A, 0 shares issued and outstanding at December 31, 2021 and 2020, 10,000 designated Series B, 0 shares issued and outstanding at December 31, 2021 and 2020; 10,000 shares designated Series C, 0 shares issued and outstanding at December 31, 2021 and 2020, 20,000 shares designated Series D, 7 and 4,138 shares issued and outstanding at December 31, 2021 and 2020, respectively		41
Common Stock, $0.01 Par Value: 50,000,000 shares authorized at December 31, 2021 and 2020; 12,663,965 and 5,556,394 shares issued and outstanding at December 31, 2021 and 2020, respectively	126,640	55,564
Additional Paid-In Capital	135,418,188	116,783,602
Accumulated Deficit	(120,879,349)	(107,108,664)
Accumulated Other Comprehensive Income	(86,431)	(802)
Total Stockholders' Equity	14,579,048	9,729,741
Total Liabilities and Stockholders' Equity	$ 20,130,308	$ 15,304,164

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2021	Dec. 31, 2020
Common Stock, Par or Stated Value Per Share	$ 0.01	$ 0.01
Common Stock, Shares Authorized	50,000,000	50,000,000
Common Stock, Shares, Issued	12,663,965	5,556,394
Common Stock, Shares, Outstanding	12,663,965	5,556,394
Preferred Stock, Par or Stated Value Per Share	$ 0.01	$ 0.01
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Series A Preferred Stock
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Preferred Stock Designated Shares	3,750	3,750
Series B Preferred Stock
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Preferred Stock Designated Shares	10,000	10,000
Series C Preferred Stock
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Preferred Stock Designated Shares	10,000	10,000
Series D Preferred Stock
Preferred Stock, Shares Issued	7	4,138
Preferred Stock, Shares Outstanding	7	4,138
Preferred Stock Designated Shares	20,000	20,000

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
Collaboration Revenue		$ 0	$ 12,059
Operating Expenses:
Research and Development		5,350,264	3,566,045
General and Administrative		5,323,649	4,658,769
Goodwill Impairment		4,037,811	0
Change in fair value of contingent consideration		(475,956)	(1,230,170)
Gain on Disposal of Foreign Entity		0	(113,717)
Total Operating Expenses		14,235,768	6,880,927
Operating Loss Before Other Income		(14,235,768)	(6,868,868)
Other Income, Net:
Gain on Forgiveness of Loan		278,190	0
Interest Income		1,141	23,339
Interest Expense		(6,851)	(4,186)
Total Other Income, Net		272,480	19,153
Loss Before Income Tax Benefit (Expense)		(13,963,288)	(6,849,715)
Income Tax Benefit (Expense)		192,603	(12,055)
Net Loss		$ (13,770,685)	$ (6,861,770)
Net Loss per Common Share - Basic		$ (1.43)	$ (1.49)
Net Loss per Common Share - Diluted	$ (0.89)	$ (1.43)	$ (1.49)
Weighted Average Shares Outstanding - Basic		9,643,961	4,591,491
Weighted Average Shares Outstanding - Diluted	8,504,465	9,643,961	4,591,491
Other Comprehensive Loss:
Net Loss		$ (13,770,685)	$ (6,861,770)
Dissolution of Foreign Entity		0	(113,717)
Foreign Currency Translation Adjustments		(85,629)	(26,550)
Comprehensive Loss		$ (13,856,314)	$ (7,002,037)

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)	Preferred Stock Series C Preferred Stock	Preferred Stock Series D Preferred Stock	Preferred Stock	Common Stock Series C Preferred Stock	Common Stock Series D Preferred Stock	Common Stock Private Placement	Common Stock Registered direct offering	Common Stock	Additional Paid-In Capital Series C Preferred Stock	Additional Paid-In Capital Series D Preferred Stock	Additional Paid-In Capital Private Placement	Additional Paid-In Capital Registered direct offering	Additional Paid-In Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Private Placement	Registered direct offering	Total
Balance at Dec. 31, 2019			$ 41					$ 40,778					$ 106,689,065	$ 139,465	$ (100,246,894)			$ 6,622,455
Balance (in shares) at Dec. 31, 2019			4,092					4,077,755
Stock-Based Compensation													723,856					723,856
Issuance of Common Stock from Warrants, Net								$ 454					217,546					218,000
Issuance of Common Stock from Warrants, Net (in shares)								45,417
Issuance of Common Stock in Offerings, Net of Offering Costs								$ 5,000					4,496,313					4,501,313
Issuance of Common Stock in Offerings, Net of Offering Costs (in shares)								500,000
Shares Issued to Panoptes Stockholders at Acquisition								$ 8,842					4,657,312					4,666,154
Shares Issued to Panoptes Stockholders at Acquisition (in shares)			46					884,222
Dissolution of Foreign Entity														(113,717)				(113,717)
Issuance of Common Stock from Restricted Stock Award Grants								$ 490					(490)
Issuance of Common Stock from Restricted Stock Award Grants (in shares)								49,000
Foreign Currency Translation Adjustment														(26,550)				(26,550)
Net Loss															(6,861,770)			(6,861,770)
Balance at Dec. 31, 2020			$ 41					$ 55,564					116,783,602	(802)	(107,108,664)			9,729,741
Balance (in shares) at Dec. 31, 2020			4,138					5,556,394
Balance at Dec. 31, 2020			$ 41					$ 55,564					116,783,602	(802)	(107,108,664)			9,729,741
Balance (in shares) at Dec. 31, 2020			4,138					5,556,394
Balance at Dec. 31, 2020			$ 41					$ 55,564					116,783,602	(802)	(107,108,664)			9,729,741
Balance (in shares) at Dec. 31, 2020			4,138					5,556,394
Balance at Dec. 31, 2020			$ 41					$ 55,564					116,783,602	(802)	(107,108,664)			9,729,741
Balance (in shares) at Dec. 31, 2020			4,138					5,556,394
Stock-Based Compensation													842,475					842,475
Issuance of Common Stock from Warrants, Net								$ 104					49,897					50,001
Issuance of Common Stock from Warrants, Net (in shares)								10,417
Conversion of Preferred Stock into Common Stock	$ (41)			$ 8,525	$ 109				$ (8,484)	$ (109)
Conversion of Preferred Stock into Common Stock (in shares)	(4,092)	(39)		852,500	10,911
Issuance of Common Stock in Offerings, Net of Offering Costs						$ 15,311	$ 46,689				$ 7,973,550	$ 9,709,659				$ 7,988,861	$ 9,756,348
Issuance of Common Stock in Offerings, Net of Offering Costs (in shares)						1,531,101	4,668,844
Shares issued to Bayon Shareholders at Acquisition								$ 338					67,598					67,936
Shares issued to Bayon Shareholders at Acquisition (in shares)								33,798
Dissolution of Foreign Entity																		0
Foreign Currency Translation Adjustment														(85,629)				(85,629)
Net Loss															(13,770,685)			(13,770,685)
Balance at Dec. 31, 2021			$ 0					$ 126,640					$ 135,418,188	$ (86,431)	$ (120,879,349)			$ 14,579,048
Balance (in shares) at Dec. 31, 2021			7					12,663,965

CONSOLIDATED STATEMENTS OF ST_2

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Offering Costs		$ 498,687
Private Placement
Offering Costs	$ 11,142
Registered direct offering
Offering Costs	$ 993,666

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Operating Activities
Net Loss	$ (13,770,685)	$ (6,861,770)
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:
Depreciation and Amortization of Intangible Assets	45,296	33,399
Reduction of Right-of-Use Assets	181,977	166,822
Stock-Based Compensation	842,475	723,856
Change in fair value of contingent consideration	(505,675)	(1,230,170)
Expiration of Prepaid Agreement	0	159,848
Deferred Taxes	(192,603)	12,055
Paycheck Protection Program Loan Forgiveness	(278,190)	0
Goodwill Impairment Loss	4,037,811	0
Changes in Operating Assets and Liabilities, Net of Effects of Business Acquired:
Prepaid Expenses and Other Current Assets	(156,951)	(146,971)
Refundable Tax Credit Receivable	(441,196)	(18,957)
Other Assets	14,111	18,916
Accounts Payable	(310,665)	136,697
Lease Liabilities	(181,977)	(166,822)
Deferred Revenue	0	0
Accrued Expenses	40,882	(144,072)
Net Cash Used in Operating Activities	(10,675,390)	(7,317,169)
Investing Activities:
Purchase of Property and Equipment	(63,865)	(20,077)
Acquisitions, net of cash acquired	(93,155)	(110,644)
Dissolution of Foreign Entity	0	(113,717)
Net Cash Used in Investing Activities	(157,020)	(244,438)
Financing Activities:
Proceeds from Stock Offerings	18,750,016	5,000,000
Stock Issuance Costs	(1,004,809)	(498,687)
Exercise of Warrants	50,001	218,000
Paycheck Protection Program Loan Proceeds	0	278,190
Net Cash Provided by Financing Activities	17,582,926	4,997,503
Effect of Exchange Rate Changes on Cash	(81,503)	(26,931)
Net Increase (Decrease) in Cash	6,669,013	(2,591,035)
Cash, Including Restricted Cash, Beginning of Year	1,230,677	3,821,712
Cash, Including Restricted Cash, End of Year	7,899,690	1,230,677
Supplemental Disclosures of Noncash Operating and Financing Activities:
Conversion of Series C Preferred Stock into Common Stock	8,525	0
Conversion of Series D Preferred Stock into Common Stock	109	0
Creation of Right-of-Use Assets and Related Lease Liabilities	313,312	166,824
Grant of Restricted Stock Awards	$ 0	$ 490

Organization, Business, and Liq

Organization, Business, and Liquidity	12 Months Ended
	Dec. 31, 2021
Organization, Business, and Liquidity
Organization, Business, and Liquidity	1. Organization, Business, and Liquidity Kiora is a clinical-stage specialty pharmaceutical company developing and commercializing therapies for the treatment of ophthalmic diseases. On November 5, 2021, Kiora Pharmaceuticals, Inc. (formerly known as EyeGate Pharmaceuticals, Inc.) (“Kiora” or the “Company”) filed with the Secretary of State of the State of Delaware, a Certificate of Ownership and Merger, merging its wholly-owned Delaware subsidiary, Kiora Pharmaceuticals, Inc., (incorporated in October 2021) into the Company and amending the Company’s certificate of incorporation to change its name to “Kiora Pharmaceuticals, Inc.” effective November 8, 2021 (the “Name Change”). The Company also amended and restated its bylaws to reflect the change to the Company’s name (the “Bylaws Amendment”). The Name Change and the Bylaws Amendment each became effective on November 8, 2021. The Company’s common shares commenced trading on the Nasdaq Capital Market under the new ticker symbol “KPRX” and a new CUSIP number (49721T101) effective at the market open on November 8, 2021. Our lead product is KIO-301 with an initial focus on patients with later stages of disease progression due to Retinitis Pigmentosa (any and all sub-forms). KIO-301 is a potential vision-restoring small molecule that acts as a “photoswitch” specifically designed to restore vision in patients with inherited and age-related degenerative retinal diseases. The molecule is specifically designed to restore the eyes’ ability to perceive and interpret light in visually impaired patients. It selectively enters viable downstream retinal ganglion cells (no longer receiving electrical input due to degenerated rods and cones) and is intended to turn them into light sensing cells, capable of signaling the brain as to the presence or absence of light. We expect to initiate a Phase 1b clinical trial in the third quarter of 2022. On March 17, 2022, we were granted Orphan Drug Designation from the U.S. FDA for the Active Pharmaceutical Ingredient (“API”) in KIO-301. KIO-301 (formerly known as B-203) was acquired through the Bayon Therapeutics, Inc. (“Bayon”) transaction which closed October 21, 2021. KIO-101 is a product that focuses on patients with Ocular Presentation of Rheumatoid Arthritis (“OPRA”) In addition, we are developing KIO-201, for patients undergoing PRK surgery for corneal wound repair after refractive surgery. KIO-201 is a modified form of the natural polymer hyaluronic acid, designed to protect the ocular surface to permit re-epithelialization of the cornea and improve and maintain ocular surface integrity. KIO-201 has unique properties that help hydrate and protect the ocular surface. Since its inception, Kiora has devoted substantially all of its efforts to business planning, research and development, and raising capital. The accompanying Consolidated Financial Statements have been prepared assuming that Kiora will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. At December 31, 2021, Kiora had unrestricted Cash and Cash Equivalents of $7.9

Restatement of Financial Statem

Restatement of Financial Statements	12 Months Ended
	Dec. 31, 2021
Restatement of Financial Statements
Restatement of Financial Statements	2. Restatement of Financial Statements Based on management’s evaluation, management and the Audit Committee, in consultation with the Company’s financial and legal advisors, the Company have concluded that restatement of its previously issued financial statements as of and for the years ended December 31, 2021 and 2020 is necessary to correct certain misstatements in accounting. As a result, the Company is amending its Annual Report on Form 10-K/A, originally filed with the SEC on April 15, 2022, for each of the two years ended December 31, 2021 and 2020. Specifically, the restatement is necessary to correct misstatements related to the Company’s accounting for its acquisitions including related contingent consideration, valuation of goodwill and in-process R&D, subsequent assessment of goodwill and intangible assets for impairment, and the corresponding effects on net income (loss) and stockholders’ equity. The restatement also impacts the unaudited quarterly periods for the three months ended March 31, 2021, and the three months and year to date periods ended June 30, 2021 and September 30, 2021. Refer to Note 17. See below for the adjustments related to each of the three prior acquisitions. In connection with the Company’s acquisition of Panoptes Pharma Ges.m.b.H (“Panoptes”) in December 2020, shares of the Company’s common stock that were held back at closing and that will be issued on the 18-month anniversary of the acquisition, subject to deduction for any indemnification claims, post-closing adjustments and other specified matters (the “Holdback Shares”), were originally accounted for as contingent consideration and recorded as a liability of $1.353 million. Upon further evaluation, the Company determined that the Holdback Shares should not have been accounted for as contingent consideration and instead recorded as equity as the shares are issuable due to the passage of time. Additionally, upon acquisition, the Company classified an assumed loan payable within contingent consideration that should have been classified as a current liability of $0.212 million. The Company is correcting these misstatements as of December 18, 2020, the acquisition date resulting in an increase in additional paid-in capital of $1.500 million, an increase in goodwill of $0.147 million, and a decrease in contingent consideration of $1.353 million. The Company will be required to pay the former shareholders of Panoptes cash earnout payments in the event developmental milestones are achieved. Due to the effects of a re-evaluation of the probability of success and discount rate for the in-process research and development (“IPR&D”) assets acquired, the Company is recording a reduction in the estimated fair value of the contingent consideration for the year ended December 31, 2021, in the amount of $0.474 million. The fair value of the contingent consideration is re-assessed at each respective balance sheet date with a corresponding adjustment to earnings until the contingency is resolved. In connection with the Company’s acquisition of Jade Therapeutics, Inc. (“Jade”) in March 2016, the Company is required to pay the former shareholders of Jade a cash earnout payment in the event any product developed by Jade prior to its acquisition, or derivative of such product, subsequently receives FDA approval. However, since a determination, which was made effective in the fourth quarter of fiscal 2020, the Company’s KIO-201 product candidate is now being developed as a drug rather than a device, and the expected development time for KIO-201 has been extended. As a result of that extended timeline, the Company is recording a reduction in the estimated fair value of the contingent consideration for KIO-201 as of December 31, 2020. This reduction in estimated probability weighted fair value resulted in a change in the carrying value of the liability and correspondingly to the change in fair value of contingent consideration as of and for each of the years ended December 31, 2021 and 2020 in the amount of $0.100 million and $1.230 million respectively. The fair value of the contingent consideration is re-assessed at each respective balance sheet date with the corresponding adjustment to earnings until the contingency is resolved. In addition, the Company is re-establishing the fair value of IPR&D for KIO-201 in the amount of $3.912 million by reversing the impairment originally recorded. In connection with the Company’s acquisition of Bayon Therapeutics, Inc. (“Bayon”) in October 2021, the Company determined that the estimated fair value of in-process R&D initially recorded was misstated due to an error in utilizing outdated probability of success rates and discount rates. To correct the misstatement, the Company reevaluated the fair value assigned to the in-process R&D at the acquisition date and updated the probability of success as it relates to cash earnout payments in the event developmental milestones are achieved, updated the discount rate, and adjusted the expected future income. This resulted in an increase to the in-process R&D of $0.302 million and deferred tax liability of $0.076 million and a reduction to goodwill of $0.607 million, and contingent consideration of $0.381 million. After reflecting the corrections above, the Company reperformed its impairment analysis of indefinite-lived intangible assets and goodwill. Goodwill was determined to be fully impaired and since goodwill is evaluated at the reporting unit level, this resulted in the impairment of the goodwill recently acquired in the acquisition of Bayon of $0.407 million. Within the restated consolidated financial statements, the Company has also corrected immaterial errors related to the classification of the change in fair value of contingent consideration and gain on disposal of a foreign entity from other income to operating income within the accompanying consolidated statement of operations and comprehensive loss for the years ended December 31, 2021 and 2020. In summary, the Company’s intangible assets including in-process R&D, goodwill, and contingent consideration from the above acquisitions have all been corrected as of the respective date of the acquisitions and then subsequently to reflect any updated information and estimates that become available in each of the subsequent periods. In addition, the Company’s annual assessment of goodwill and intangible asset impairment were also updated to reflect these corrections for the years ended December 31, 2021 and 2020. The related footnotes have also been updated for the restatements. The following tables summarize the effect of the restatement on each financial statement line items as of the dates, and for the period, indicated: Balance sheet as of December 31, 2020 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, 2020 ​ ​ As Previously ​ ​ 2020 Restatement ​ ​ ​ Balance Sheet Reported ​ Adjustment As Restated Total Current Assets ​ $ 1,726,221 ​ ​ — ​ $ 1,726,221 Property and Equipment, Net ​ 30,566 ​ — ​ 30,566 Restricted cash ​ 45,000 ​ — ​ 45,000 Goodwill ​ 3,484,607 ​ $ 146,605 ​ 3,631,212 Intangible Assets and In-process R&D, Net ​ 9,730,164 ​ — ​ 9,730,164 Operating Leases Assets with Right-of-Use ​ 83,928 ​ — ​ 83,928 Other Assets ​ 57,073 ​ — ​ 57,073 Total assets $ 15,157,559 ​ 146,605 $ 15,304,164 Liabilities and stockholders’ equity ​ ​ ​ Total current liabilities $ 1,772,327 ​ 212,281 $ 1,984,608 Contingent Consideration ​ 5,342,950 ​ (2,795,876) ​ 2,547,074 Deferred Tax Liability ​ 728,926 ​ — ​ 728,926 Paycheck Protection Program Loan ​ 278,190 ​ — ​ 278,190 Non-current Operating Lease Liabilities ​ 35,625 ​ — ​ 35,625 Total Non-Current Liabilities ​ 6,385,691 ​ (2,795,876) ​ 3,589,815 Total liabilities ​ 8,158,018 ​ ​ (2,583,595) ​ 5,574,423 Stockholders’ equity ​ ​ ​ Preferred Stock, $0.01 par value ​ 41 ​ — ​ 41 Common Stock, $0.01 par value ​ 55,564 ​ — ​ 55,564 Additional paid-in-capital ​ 115,283,572 ​ 1,500,030 ​ 116,783,602 Accumulated deficit ​ (108,338,834) ​ 1,230,170 ​ (107,108,664) Accumulated Other Comprehensive Income ​ (802) ​ — ​ (802) Total stockholders’ equity ​ 6,999,541 ​ 2,730,200 ​ 9,729,741 Total liabilities and stockholders’ equity $ 15,157,559 ​ $ 146,605 $ 15,304,164 ​ Statement of Operations and Comprehensive Income for the year ended December 31, 2020 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the year ended December 31, 2020 ​ ​ As Previously ​ 2020 Restatement ​ ​ ​ Statement of Operations and Comprehensive Loss Reported Adjustment As restated Collaboration Revenue $ 12,059 ​ ​ — $ 12,059 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Research and Development ​ 3,566,045 ​ ​ — ​ 3,566,045 General and Administrative ​ 4,658,769 ​ ​ — ​ 4,658,769 Change in Fair Value of Contingent Consideration ​ — ​ $ (1,230,170) ​ (1,230,170) Gain on Disposal of Foreign Entity ​ — ​ ​ (113,717) ​ (113,717) Total Operating Expenses ​ 8,224,814 ​ (1,343,887) ​ 6,880,927 Operating Loss before Other Income ​ (8,212,755) ​ 1,343,887 ​ (6,868,868) Other Income, net: ​ ​ ​ Gain on Disposal of Foreign Entity ​ 113,717 ​ (113,717) ​ — Interest Income ​ 23,339 ​ — ​ 23,339 Interest Expense ​ (4,186) ​ — ​ (4,186) Total other (expense) income ​ 132,870 ​ (113,717) ​ 19,153 Loss before Income Tax Benefit (Expense) ​ (8,079,885) ​ 1,230,170 ​ (6,849,715) Income Tax Benefit (Expense) ​ (12,055) ​ — ​ (12,055) Net loss $ (8,091,940) $ 1,230,170 $ (6,861,770) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Average Shares Outstanding - Basic and Diluted ​ 4,576,058 ​ ​ 15,433 ​ 4,591,491 Basic and Diluted net loss per share ​ $ (1.77) ​ ​ ​ ​ $ (1.49) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Other comprehensive loss: ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss ​ ​ (8,091,940) ​ $ 1,230,170 ​ ​ (6,861,770) Dissolution of Foreign Entity ​ ​ (113,717) ​ ​ — ​ ​ (113,717) Foreign Currency Translate Adjustments ​ ​ (26,550) ​ ​ — ​ ​ (26,550) Comprehensive loss $ (8,232,207) ​ $ 1,230,170 $ (7,002,037) ​ Stockholders’ Equity as of December 31, 2020 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, 2020 ​ ​ ​ As Previously ​ 2020 Restatement ​ ​ ​ ​ Stockholders’ equity Reported Adjustment As restated ​ Preferred Stock, $0.01 par value $ 41 ​ — $ 41 ​ Common Stock, $0.01 par value ​ 55,564 ​ — ​ 55,564 ​ Additional paid-in-capital ​ 115,283,572 $ 1,500,030 ​ 116,783,602 ​ Accumulated deficit ​ (108,338,834) ​ 1,230,170 ​ (107,108,664) ​ Accumulated Other Comprehensive Income ​ (802) ​ — ​ (802) ​ Total stockholders’ equity $ 6,999,541 $ 2,730,200 $ 9,729,741 ​ ​ Statement of Cash flows for the year ended December 31, 2020 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the year ended December 31, 2020 ​ ​ As Previously ​ 2020 Restatement ​ ​ ​ Statement of Cash Flows Reported Adjustment As restated Operating Activities ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss $ (8,091,940) $ 1,230,170 $ (6,861,770) Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Depreciation and Amortization of Intangible Assets ​ 33,399 ​ — ​ 33,399 Reduction of Right-of-Use Assets ​ 166,822 ​ — ​ 166,822 Stock-Based Compensation ​ 723,856 ​ — ​ 723,856 Change in Fair Value of Contingent Consideration ​ — ​ (1,230,170) ​ (1,230,170) Expiration of a Prepaid Agreement ​ 159,848 ​ — ​ 159,848 Deferred Taxes ​ 12,055 ​ — ​ 12,055 Changes in Operating Assets and Liabilities, Net of Effects of Business Acquired: ​ ​ ​ ​ Prepaid Expenses and Other Current Assets ​ (146,971) ​ — ​ (146,971) Refundable Tax Credit Receivable ​ (18,957) ​ — ​ (18,957) Other Assets ​ 18,916 ​ — ​ 18,916 Accounts Payable ​ 136,697 ​ — ​ 136,697 Lease Liabilities ​ (166,822) ​ — ​ (166,822) Accrued Expenses ​ (144,072) ​ — ​ (144,072) Net cash used in operating activities ​ (7,317,169) ​ — ​ (7,317,169) Net cash used in investing activities ​ (244,438) ​ — ​ (244,438) Net cash provided by financing activities ​ 4,997,503 ​ — ​ 4,997,503 Effects of Exchange Rate Changes on Cash ​ (26,931) ​ — ​ (26,931) Net Cash Increase or decrease ​ (2,591,035) ​ — ​ (2,591,035) Cash, Including Restricted Cash, Beginning of Year ​ 3,821,712 ​ — ​ 3,821,712 Cash, Including Restricted Cash, End of Year $ 1,230,677 ​ — $ 1,230,677 ​ Balance Sheet as of December 31, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, 2021 ​ ​ As Previously ​ 2020 Restatement ​ 2021 Restatement ​ ​ ​ Balance Sheet Reported Adjustment Adjustment As Restated Total Current Assets $ 8,990,770 ​ — ​ — $ 8,990,770 ​ Property and Equipment, Net ​ 73,999 ​ — ​ — ​ 73,999 ​ Restricted cash ​ 45,000 ​ — ​ — ​ 45,000 ​ Goodwill ​ — $ 146,605 $ (146,605) ​ — ​ Intangible Assets and In-process R&D, Net ​ 8,695,850 ​ — ​ 2,072,314 ​ 10,768,164 ​ Operating Leases Assets with Right-of-Use ​ 209,411 ​ — ​ — ​ 209,411 ​ Other Assets ​ 42,964 ​ — ​ — ​ 42,964 ​ Total assets $ 18,057,994 $ 146,605 $ 1,925,709 $ 20,130,308 ​ Liabilities and stockholders’ equity ​ ​ ​ ​ ​ Total current liabilities ​ 1,609,608 ​ — ​ — ​ 1,609,608 ​ Contingent Consideration ​ 6,518,770 ​ (2,583,595) ​ (886,220) ​ 3,048,955 ​ Deferred Tax Liability ​ 614,436 ​ — ​ 187,695 ​ 802,131 ​ Non-current Operating Lease Liabilities ​ 90,566 ​ — ​ — ​ 90,566 ​ Total Non-Current Liabilities ​ 7,223,772 ​ (2,795,876) ​ (698,525) ​ 3,941,652 ​ Total liabilities ​ 8,833,380 ​ (2,583,595) ​ (698,525) ​ 5,551,260 ​ Stockholders’ equity ​ ​ ​ ​ ​ Preferred Stock, $0.01 par value ​ — ​ — ​ — ​ — ​ Common Stock, $0.01 par value ​ 126,640 ​ — ​ — ​ 126,640 ​ Additional paid-in-capital ​ 133,918,158 ​ 1,500,030 ​ — ​ 135,418,188 ​ Accumulated deficit ​ (124,733,753) ​ 1,230,170 ​ 2,624,234 ​ (120,879,349) ​ Accumulated Other Comprehensive Income ​ (86,431) ​ — ​ — ​ (86,431) ​ Total stockholders’ equity ​ 9,224,614 ​ 2,730,200 ​ 2,624,234 ​ 14,579,048 ​ Total liabilities and stockholders’ equity $ 18,057,994 $ 146,605 $ 1,925,709 $ 20,130,308 ​ ​ Statement of Operations and Comprehensive Loss for the year ended December 31, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the year ended December 31, 2021 ​ ​ As Previously ​ 2021 Restatement ​ ​ ​ Statement of Operations and Comprehensive Loss Reported Adjustment As restated Research and Development $ 5,350,264 ​ — $ 5,350,264 General and Administrative ​ 5,323,649 ​ — ​ 5,323,649 Goodwill Impairment ​ 4,498,234 $ (460,423) ​ 4,037,811 Intangible Asset Impairment ​ 1,770,314 ​ (1,770,314) ​ — Change in Fair Value of Contingent Consideration ​ ​ — ​ ​ (475,956) ​ ​ (475,956) Total Operating Expenses ​ 16,942,461 ​ (2,706,693) ​ 14,235,768 Operating Loss before Other Income ​ (16,942,461) ​ 2,706,693 ​ (14,235,768) Other income, net: ​ ​ ​ Gain on Forgiveness of Loan ​ 278,190 ​ — ​ 278,190 Change in Fair Value of Contingent Consideration ​ (29,719) ​ 29,719 ​ — Interest Expense ​ ​ (6,851) ​ ​ — ​ ​ (6,851) Interest Income ​ 1,141 ​ — ​ 1,141 Total other income ​ 242,761 ​ 29,719 ​ 272,480 Loss before Income Tax Benefit (Expense) ​ (16,699,700) ​ 2,736,412 ​ (13,963,288) Income Tax Benefit (Expense) ​ 304,781 ​ (112,178) ​ 192,603 Net loss $ (16,394,919) $ 2,624,234 $ (13,770,685) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Average Shares Outstanding - Basic and Diluted ​ 9,240,500 ​ 403,461 ​ 9,643,961 Basic and Diluted net loss per share $ (1.77) ​ — $ (1.43) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Other comprehensive loss: ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss ​ ​ (16,394,919) ​ $ 2,624,234 ​ ​ (13,770,685) Foreign Currency Translate Adjustments ​ ​ (85,629) ​ ​ — ​ ​ (85,629) Comprehensive loss ​ $ (16,480,548) ​ $ 2,624,234 ​ $ (13,856,314) ​ Stockholders’ Equity as of December 31, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, 2021 ​ ​ ​ ​ ​ 2020 ​ 2021 ​ ​ ​ ​ ​ As Previously ​ Restatement ​ Restatement ​ ​ ​ Stockholders’ equity Reported Adjustment Adjustment As restated Preferred Stock, $0.01 par value ​ — ​ — ​ — ​ — Common Stock, $0.01 par value $ 126,640 ​ — ​ — $ 126,640 Additional paid-in-capital ​ 133,918,158 $ 1,500,030 ​ — ​ 135,418,188 Accumulated deficit ​ (124,733,753) ​ 1,230,170 $ 2,624,234 ​ (120,879,349) Accumulated Other Comprehensive Income ​ (86,431) ​ — ​ — ​ (86,431) Total stockholders’ equity $ 9,224,614 $ 2,730,200 $ 2,624,234 $ 14,579,048 ​ Statement of Cash Flows for the year ended December 31, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the year ended December 31, 2021 ​ ​ As Previously ​ 2021 Restatement ​ ​ ​ Statement of Cash Flows Reported Adjustment As restated Operating Activities ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss $ (16,394,919) $ 2,624,234 $ (13,770,685) Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Depreciation and Amortization of Intangible Assets ​ 45,296 ​ — ​ 45,296 Reduction of Right-of-Use Assets ​ 181,977 ​ — ​ 181,977 Stock-Based Compensation ​ 842,475 ​ — ​ 842,475 Contingent Consideration ​ (212,281) ​ (293,394) ​ (505,675) Deferred Taxes ​ (304,782) ​ 112,179 ​ (192,603) Paycheck Protection Program Loan Forgiveness ​ (278,190) ​ — ​ (278,190) Goodwill Impairment Loss ​ 4,498,234 ​ (460,423) ​ 4,037,811 Intangible Asset Impairment Loss ​ 1,770,314 ​ (1,770,314) ​ — Changes in Operating Assets and Liabilities, Net of Effects of Business Acquired: ​ ​ ​ ​ Prepaid Expenses and Other Current Assets ​ (156,951) ​ — ​ (156,951) Refundable Tax Credit Receivable ​ (441,196) ​ — ​ (441,196) Other Assets ​ 14,111 ​ — ​ 14,111 Accounts Payable ​ (310,665) ​ — ​ (310,665) Lease Liabilities ​ (181,977) ​ — ​ (181,977) Accrued Expenses ​ 40,882 ​ — ​ 40,882 Net cash used in operating activities ​ (10,887,672) ​ 212,282 ​ (10,675,390) Net cash used in investing activities ​ (157,020) ​ — ​ (157,020) Financing Activities ​ ​ ​ ​ ​ ​ ​ ​ ​ Proceeds stock offerings ​ ​ 18,750,016 ​ ​ — ​ ​ 18,750,016 Stock Issuance costs ​ ​ (1,004,809) ​ ​ — ​ ​ (1,004,809) Exercise Warrants ​ ​ 50,001 ​ ​ — ​ ​ 50,001 Repayment of Loan Payable ​ ​ — ​ ​ (212,282) ​ ​ (212,282) Net cash provided by financing activities ​ 17,795,208 ​ (212,282) ​ 17,582,926 Effects of Exchange Rate Changes on Cash ​ (81,503) ​ — ​ (81,503) Net Cash Increase or decrease ​ 6,669,013 ​ — ​ 6,669,013 Cash, Including Restricted Cash, Beginning of Year ​ 1,230,677 ​ — ​ 1,230,677 Cash, Including Restricted Cash, End of Year $ 7,899,690 ​ — $ 7,899,690 ​

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	3. Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation The accompanying Consolidated Financial Statements include the accounts of the Company and its subsidiaries, EyeGate Pharma S.A.S. (through its dissolution on December 30, 2020), Jade Therapeutics, Inc. (“Jade”), Kiora Pharmaceuticals GmbH (“Kiora GmbH”) (formerly known as Panoptes Pharma Ges.m.b.H or “Panoptes”) (effective December 18, 2020 when the Company acquired all of the capital stock of Panoptes), Bayon (effective October 21, 2021 when the Company acquired all of the capital stock of Bayon), and Kiora Pharmaceuticals Pty Ltd (“Kiora Pty”) (formerly known as Bayon Therapeutics Pty Ltd), collectively referred to as “the Company”. All inter-company balances and transactions have been eliminated in consolidation. These Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of expenses during the reporting periods. The Company makes significant estimates and assumptions in recording the accruals for the Company’s clinical trial and research activities, establishing the useful lives of intangible assets and property and equipment, conducting impairment reviews of goodwill, IPR&D, revenue recognition, stock-based compensation, and contingent considerations payable. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances. Although the Company monitors and regularly assesses these estimates, actual results could differ significantly from these estimates. The Company records changes in estimates in the period that it becomes aware of the change. Foreign Currency Translation Operations of Kiora GmbH are, and prior to its dissolution on December 31, 2020, operations of EyeGate Pharma S.A.S. were, conducted in euros which represent its functional currency. Operations of Kiora Pty are conducted in Australian dollars, which represent its functional currency. Balance sheet accounts of such subsidiaries were translated into U.S. dollars at the exchange rate in effect at the balance sheet date and income statement accounts were translated to the average rate of exchange prevailing during the period. Translation adjustments resulting from this process, are included in accumulated other comprehensive loss on the Consolidated Balance Sheets. Cash and Cash Equivalents and Restricted Cash The Company considers all highly liquid investments purchased with a maturity of 90 days or less when acquired that are not restricted as to withdrawal, to be the equivalent of cash for the purpose of balance sheet and statement of cash flows presentation. The Company invests its cash in either U.S. government or treasury money market funds with maturities of 90 days or less. At December 31, 2021 and 2020, the Company has classified $0.045 million as restricted cash. Property and Equipment Property and equipment is stated at cost less accumulated depreciation. Depreciation is provided for on a straight-line basis over the estimated useful life of 2 to 5 years for all assets. Maintenance and repair costs are expensed as incurred. The Company reviews its property and equipment whenever events or changes in circumstances indicate that the carrying value of certain assets might not be recoverable and recognizes an impairment loss when it is probable that the estimated cash flows are less than the carrying value of the asset. Impairment of Long-Lived Assets The Company evaluates potential impairment of long-lived assets and long-lived assets to be disposed of and considers whether long-lived assets held for use have been impaired whenever events or changes in circumstances indicate that the related carrying amount may not be recoverable, or that the period of their recovery may have changed. Management makes significant estimates and assumptions regarding future sales, cost trends, productivity and market maturity in order to test for impairment. Management reports those long-lived assets to be disposed of and assets held for sale at the lower of carrying amount or fair value less cost to sell. Based on current facts, estimates and assumptions, management believes that no assets are impaired at December 31, 2021. There is no assurance that management’s estimates and assumptions will not change in future periods. Research and Development Expenses The Company expenses research and development (“R&D”) expenditures as incurred. R&D expenses are comprised of costs incurred in performing R&D activities, including salaries, benefits, facilities, research-related overhead, sponsored research costs, contracted services, license fees, expenses related to generating, filing, and maintaining intellectual property and other external costs. Because the Company believes that, under its current process for developing its products, the viability of the products is essentially concurrent with the establishment of technological feasibility, no costs have been capitalized to date. Goodwill Goodwill is the excess of the acquisition cost of a business over the fair value of the identifiable net assets acquired. In 2021, this consists of the goodwill of the Company’s subsidiaries Jade, Kiora GmbH, and Bayon. In 2020, this consists of the goodwill of the Company’s subsidiaries Jade and Kiora GmbH. Goodwill is not amortized and is tested for impairment on an annual basis in the fourth quarter of each fiscal year and whenever events or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. The Company performed qualitative and quantitative impairment evaluations on its goodwill as of December 31, 2021. Goodwill as of December 31, 2021 was reduced to zero after taking an impairment loss of $4.037 In-Process Research and Development The Company records in-process R&D projects acquired in asset acquisitions that have not reached technological feasibility and which have no alternative future use. For in-process R&D projects acquired in business combinations, the Company capitalizes the in-process R&D project and periodically evaluates this asset for impairment until the R&D process has been completed. Once the R&D process is complete, the Company amortizes the R&D asset over its remaining useful life. At December 31, 2021 and 2020, there is $10.599 million and $9.536 million respectively of in-process R&D as part of intangible asset and in-process R&D on the Consolidated Balance Sheets. Accrued Clinical Expenses As part of the Company’s process of preparing the Consolidated Financial Statements, the Company is required to estimate its accrued expenses. This process includes reviewing open contracts and purchase orders, communicating with its applicable personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated costs incurred for the service when the Company has not yet been invoiced or otherwise notified of actual costs. The majority of the Company’s service providers invoice monthly in arrears for services performed. The Company makes estimates of its accrued expenses as of each balance sheet date in the financial statements based on facts and circumstances known at the time. The Company periodically confirms the accuracy of these estimates with the service providers and makes adjustments if necessary. Business Segment and Geographical Information The Company identifies operating segments as components of the enterprise for which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business as fully integrated and operating in one business segment (research and development), and the Company operates in three geographic segments. Income Taxes The Company will record a deferred income tax asset and liability for the expected future income tax consequences of events that have been recognized in the Company’s Consolidated Financial Statements and income tax returns. The Company will record a deferred income tax asset and liability based on differences between the financial statement carrying, or “book”, amounts of assets and liabilities, and the tax bases of the assets and liabilities using the enacted income tax regulations in effect in the years in which the differences are expected to reverse. A valuation allowance against deferred income tax asset will be recorded if, based on the weight of available evidence, it is more likely than not that some or all of the deferred income tax assets will not be realized. As of December 31, 2021 and 2020, all of the Company’s net deferred income tax assets were subject to a full valuation allowance. As of December 31, 2021 and 2020, the Company has a net deferred tax liability of $0.802 million and $0.729 million, respectively. The Company recognizes the impact of an uncertain income tax position in the financial statements if it believes that the position is more likely than not to be sustained by the relevant taxing authority. As of December 31, 2021, the Company had no unrecognized uncertain income tax positions. Refunds for Research and Development Kiora, through its Kiora GmbH subsidiary, is entitled to receive certain refunds associated with its research and development expenses in Austria. These refunds are realized in the form of a cash payment in the year following the incurred research & development expenses. The Company records the refundable payment as a reduction in expense in the year in which the research and development expenses are incurred. Concentration of Credit Risk and Off-Balance-Sheet Risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash and cash equivalents. The Company invests cash in accredited financial institutions and cash equivalents in widely held money market funds. Consequently, such funds are subject to minimal credit risk. The Company has no significant off-balance-sheet risk such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Comprehensive Loss Comprehensive loss is defined as the change in stockholders’ equity during a period from transactions and other events and circumstances from non-owner sources. The foreign currency translation adjustments are the Company’s only component of other comprehensive loss. Stock-Based Compensation Stock-based compensation represents the cost related to stock-based awards granted to employees and others. The Company measures stock-based compensation cost to employees at grant date, based on the estimated fair value of the award, and recognizes the cost as expense on a straight-line basis over the employee requisite service period. The Company estimates the fair value of stock options using the Black-Scholes valuation model. The Company recognizes compensation expense for non-employee stock option grants at the fair value of the goods or services received or the equity instruments issued, whichever is more reliably measurable. The Company recorded compensation expense for non-employee awards with graded vesting using the accelerated expense attribution method. The Company’s policy is to record forfeitures as they occur. Net Loss per Share – Basic and Diluted Basic and diluted net loss per share is computed by dividing net loss available to common shareholders by the weighted-average number of common shares outstanding for the period, which, for basic net loss per share, does not include the weighted-average unvested restricted common stock that has been issued but is subject to forfeiture of 41,216 shares for year ended December 31, 2021 and 77,262 shares for the year ended December 31, 2020. Dilutive common equivalent shares consist of stock options, warrants, and preferred stock and are calculated using the treasury stock method, which assumes the repurchase of common shares at the average market price during the period. Under the treasury stock method, options and warrants will have a dilutive effect when the average price of common stock during the period exceeds the exercise price of options or warrants. Common equivalent shares do not qualify as participating securities. In periods where the Company records a net loss including the years ended December 31, 2021 and 2020, unvested restricted common stock and potential common stock equivalents are not included in the calculation of diluted net loss per share as their effect would be anti-dilutive. All shares of Common Stock that may potentially be issued in the future are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2021 2020 Common Stock Warrants ​ 6,757,180 ​ 2,726,700 Employee Stock Options ​ 515,922 ​ 246,893 Preferred Stock ​ 2,089 ​ 865,500 Total Shares of Common Stock Issuable ​ 7,275,191 ​ 3,839,093 ​ Related-Party Transactions During the year ended December 31, 2021, the Company entered into certain related-party transactions, making payments for services to one vendor and six consultants, all of whom also are stockholders of the Company. These transactions generally are ones that involve a stockholder or option holder of the Company to whom the Company also makes payments during the year, typically as a consultant or a service provider. Additionally, on January 6, 2021, the Company completed a private placement of 1,531,101 shares of Common Stock and warrants to purchase up to 1,531,101 shares of Common Stock to an affiliate of Armistice Capital, LLC, with a combined purchase price per share and warrant of $5.225. Steven J. Boyd and Keith Maher, each of whom were members of the Company’s board of directors through August 3, 2021, are affiliates of Armistice Capital, LLC, and Mr. Boyd held voting and investment power over such entity. The total net proceeds from the private placement were approximately $8.0 million. Lastly, on October 21, 2021, the Company acquired Bayon of which the Company’s CEO, Brian Strem, was a Co-Founder and Managing Director. Except for the private placement and Bayon acquisition as described previous, the transactions with related parties during the year ended December 31, 2021 are not material to the accompanying Consolidated Financial Statements. During the year ended December 31, 2020, the Company entered into certain related-party transactions, making payments for services to two vendors, seven consultants and two public universities, all of whom also are stockholders of the Company. The Company made payments related to manufacturing services to one vendor in the amount of approximately $502,000. Except for the manufacturing services as described previous, the transactions with related parties during the year ended December 31, 2020 are not material to the accompanying Consolidated Financial Statements. Fair Value of Financial Instruments Each period we revalue our contingent consideration obligations associated with business acquisitions to their fair value. The estimate of the fair value of contingent consideration is determined by applying probability of success, discount rate, and updated timing of the payment. The outstanding payments relate to obligation from acquisitions made by the Company. Below is the list of obligations for each relevant transaction are as of December 31, 2021 as follows: ​ ​ ​ ​ ​ ​ ​ Acquisition Milestone Achievement Condition Contingent Consideration Payable Bayon ​ ​ ​ ​ ​ ​ Successful completion of Phase 1b ​ $ 0.495 million ​ ​ Successful completion of Phase 2 ​ $ 0.990 million ​ ​ Successful completion of Phase 3 ​ $ 4.000 million ​ ​ FDA approval ​ $ 1.650 million ​ ​ ​ ​ ​ ​ Panoptes ​ ​ ​ ​ ​ Beginning of Phase 3 ​ $ 4.750 million ​ ​ FDA approval ​ $ 4.750 million ​ ​ ​ ​ ​ ​ Jade: ​ ​ ​ ​ ​ FDA approval ​ $ 2.164 million ​ Changes in the fair value of contingent consideration are included within “Operating Expenses” in our consolidated statements of operations and comprehensive loss. Below are the status of each transactions contingent consideration: Bayon: As of December 31, 2021, the Company had contingent consideration at fair value of $0.876 million as a result of the Bayon acquisition which closed on October 21, 2021. Panoptes: The Panoptes transaction closed December 18, 2020. As of December 31, 2020, the Company recorded contingent consideration of $2.067 million. During the year ended December 31, 2021, the Company recorded a decrease in estimated fair value of $0.474 million. The estimated fair value of contingent consideration as of December 31, 2021 was $1.593 million. Jade: As of December 31, 2020, the Company had a fair value of contingent consideration of $0.480 million. During the year ended December 31, 2021, the contingent consideration was increased by $0.100 million for a change in fair value. As of December 31, 2021, the Company had fair value of contingent consideration of $0.580 million. At December 31, 2021 and 2020, the Company had no other assets or liabilities that are subject to fair value methodology and estimation in accordance with U.S. GAAP. Recent Accounting Pronouncements None noted.

Fair Value

Fair Value	12 Months Ended
	Dec. 31, 2021
Fair Value
Fair Value	4. Fair Value There were no assets measured at fair value on a recurring basis and there were no liabilities valued at fair value using Level 1 or 2 inputs. The following table provides information for liabilities measured at fair value on a recurring basis using Level 3 inputs: ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2021 December 31, 2020 Contingent Consideration: ​ ​ ​ ​ ​ ​ Current ​ — ​ — Noncurrent ​ 3,048,955 ​ 2,547,074 Total Contingent Consideration ​ $ 3,048,955 ​ $ 2,547,074 ​ The Company initially values contingent consideration related to business combinations using a probability-weighted calculation of potential payment scenarios discounted at rates reflective of the risks associated with the expected future cash flows for certain milestones. Key assumptions used to estimate the fair value of contingent consideration include projected financial information, market data and the probability and timing of achieving the specific targets as discussed in Note 16. Acquisitions. After the initial valuation, the Company generally uses its best estimate to measure contingent consideration at each subsequent reporting period using the following unobservable Level 3 inputs: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Valuation Technique Unobservable Inputs 2021 Range 2020 Range ​ Discounted cash flow Payment discount rate ​ 13.1 % 12.6 % Bayon ​ ​ Payment period ​ 2023 - 2028 — ​ Panoptes ​ ​ Payment period ​ 2024 - 2028 2023 - 2025 ​ Jade ​ ​ ​ Payment period ​ 2026 ​ 2026 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Bayon ​ ​ ​ Probability of Success for payment ​ 12% - 72% ​ — ​ Panoptes ​ ​ ​ Probability of Success for payment ​ 17% - 36% ​ 20% - 45% ​ Jade ​ ​ Probability of Success for payment ​ 47 % 45 % ​ Significant changes in these assumptions could result in a significantly higher or lower fair value. The contingent consideration reported in the above table resulted is adjusted quarterly based upon the passage of time or the anticipated success or failure of achieving certain milestones. The changes in contingent consideration of $0.502 million as of December 31, 2021, was primarily driven by probability of success and timing of milestone payments and was recorded as a change in fair value of contingent consideration within the consolidated statements of operation and comprehensive loss.

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2021
Property and Equipment
Property and Equipment	5. Property and Equipment Property and equipment at December 31, 2021 and 2020 consists of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Estimated Useful ​ ​ ​ ​ ​ ​ Life ​ ​ ​ ​ ​ ​ ​ (Years) 2021 2020 Laboratory Equipment 3 ​ $ 88,399 ​ $ 82,653 Office Equipment ​ 3 ​ ​ 3,614 ​ ​ 3,888 Office Furniture 5 ​ 72,549 ​ 14,430 Leasehold Improvements 2 ​ 22,569 ​ 22,569 Total Property and Equipment, Gross ​ 187,131 ​ 123,540 Less Accumulated Depreciation ​ 113,132 ​ 92,974 Total Property and Equipment, Net ​ $ 73,999 ​ $ 30,566 ​ Depreciation expense was $20,296 and $8,399 for the years ended December 31, 2021 and 2020, respectively.

Accrued Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2021
Accrued Expenses
Accrued Expenses	6. Accrued Expenses Accrued expenses consist of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2021 2020 Payroll and Benefits ​ $ 937,970 ​ $ 629,465 Professional Fees ​ 194,425 ​ 328,420 Clinical Trials ​ 168,785 ​ 203,646 Other ​ 28,961 ​ 127,730 Total Accrued Expenses ​ $ 1,330,141 ​ $ 1,289,261 ​

Debt

Debt	12 Months Ended
	Dec. 31, 2021
Debt
Debt	7. Debt In May 2020, the Company received loan funds (the “Loan”) from the Paycheck Protection Program (“PPP”) of $0.278 million. In April 2021, the Company was notified by the Small Business Administration (“SBA”) that this Loan was forgiven in full. The Company has no additional indebtedness at December 31, 2021 and 2020.

Intangible Assets and In-Proces

Intangible Assets and In-Process R&D	12 Months Ended
	Dec. 31, 2021
Intangible Assets and In-Process R&D
Intangible Assets and In-Process R&D	8. Intangible Assets and In-Process R&D Intangible assets at December 31, 2021 consist of the rights to trade-secrets and know-how related to the manufacturing of KIO-201. During the third quarter of 2018, the Company entered into an intellectual property license agreement with SentrX Animal Care, Inc. (“SentrX”) with respect to certain rights relating to the manufacturing of KIO-201. The intangible assets were recorded at $0.250 million, representing the upfront payment paid to SentrX. Additionally, SentrX is eligible to receive milestone payments totaling up to $4.750 million, upon and subject to the achievement of certain specified development and commercial milestones. These future milestone payments to SentrX will increase the carrying value of the intangible assets. The Company’s intangible assets are amortized on a straight-line basis over the estimated useful lives. Additionally, in-process R&D as of December 31, 2021 and December 31, 2020 consists of projects acquired from the acquisitions of Jade, Bayon and Panoptes that have not reached technological feasibility and which have no alternative future use. Once the R&D process is complete, the Company will amortize the R&D asset over its remaining useful life. The Company periodically evaluates these assets for impairment. Intangible assets and in-process R&D at December 31, 2021 and 2020 consists of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Estimated Useful ​ ​ ​ ​ ​ Life (Years) 2021 2020 Trade Secrets 10 ​ $ 250,000 ​ $ 250,000 Less: Accumulated Amortization ​ (81,250) ​ (56,250) Intangible Assets, Net ​ 168,750 ​ 193,750 In-Process R&D ​ 10,599,414 ​ 9,536,414 Total Intangible Assets and In-Process R&D, Net ​ $ 10,768,164 ​ $ 9,730,164 ​ Amortization expense on intangible assets was $25,000 for each of the years ended December 31, 2021 and 2020.

Capital Stock

Capital Stock	12 Months Ended
	Dec. 31, 2021
Capital Stock
Capital Stock	9. Capital Stock On January 3, 2020, the Company completed a registered direct offering with institutional investors for 500,000 shares of Common Stock with a purchase price of $10.00 per share. The total net proceeds to the Company, after deducting the placement agent fees and offering expenses, were approximately $4.5 million. On June 25, 2020, following the Company’s 2020 Annual Meeting of Stockholders, the Company filed a Certificate of Amendment to its Restated Certificate of Incorporation that decreased the number of authorized shares of the Company’s common stock from 120,000,000 to 50,000,000. In connection with the Panoptes acquisition, on December 18, 2020, the Company filed a Certificate of Designation of Preferences, Rights and Limitations for up to 20,000 shares of Series D Convertible Preferred Stock with the Delaware Secretary of State. The Series D Convertible Preferred Stock has a stated value of $1,000 per share and a conversion price of $3.5321 per share but may not be converted until stockholder approval is obtained. The Series D Preferred Stock is only entitled to dividends in the event dividends are paid on the Company’s shares of Common Stock and does not have any preferences over the Company’s shares of Common Stock or any voting rights, except in limited circumstances. On January 6, 2021, the Company completed a private placement of 1,531,101 shares of Common Stock and warrants to purchase up to 1,531,101 shares of Common Stock to an affiliate of Armistice Capital, LLC, with a combined purchase price per share and warrant of $5.225. The total net proceeds from the private placement were approximately $8.0 million. The warrants have an exercise price of $5.225 per share, subject to adjustments as provided under the terms of the warrants and will be exercisable on the six-month anniversary of their issuance date. The warrants are exercisable for five years from the issuance date. On July 27, 2021, a holder elected to convert 4,092 shares of Series C Preferred stock that were issued in a public offering on April 17, 2018 into 852,500 shares of Common Stock. On August 11, 2021, the Company completed a registered direct offering priced at-the-market under Nasdaq Rules for 4,668,844 shares of Common Stock with a purchase price of $2.3025 per share. The Company also completed a concurrent private placement of unregistered warrants to purchase up to an aggregate of 2,334,422 shares of Common Stock at an exercise price of $2.24 per share that are exercisable immediately upon issuance and will expire five On September 17, 2021, holders elected to convert 39 shares of Series D Preferred stock that were issued in connection with the Panoptes acquisition into 10,911 shares of Common Stock.

Warrants

Warrants	12 Months Ended
	Dec. 31, 2021
Warrants
Warrants	10. Warrants At December 31, 2021 and 2020, the following warrants were outstanding: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ Weighted ​ ​ ​ ​ Average ​ Average ​ ​ Number of ​ Exercise ​ Remaining ​ Awards Price Term in Years ​ ​ ​ ​ ​ ​ ​ ​ Outstanding at December 31, 2019 2,875,006 ​ $ 14.14 ​ 3.37 Issued 25,000 ​ 12.50 ​ 4.01 Exercised (45,417) ​ 4.80 ​ 2.29 Expired ​ (127,889) ​ ​ 139.28 ​ — Outstanding at December 31, 2020 2,726,700 ​ $ 8.41 ​ 2.45 Issued 4,098,965 ​ 3.39 ​ 4.68 Exercised (10,417) ​ 4.80 ​ 1.29 Expired ​ (58,068) ​ ​ 52.50 ​ — Outstanding at December 31, 2021 6,757,180 ​ $ 4.99 ​ 3.42 ​ All of the warrant agreements provide for a cashless exercise in the event a registration statement covering the issuance of the shares of common stock underlying the warrants is not effective, whereby the number of shares to be issued upon exercise of such warrants will be reduced based on the exercise price and the market value of the shares at the time of exercise. The outstanding warrants expire from 2022 through 2027.

Panoptes Holdback shares

Panoptes Holdback shares	12 Months Ended
	Dec. 31, 2021
Panoptes Holdback shares
Panoptes Holdback shares	11. Panoptes Holdback shares In connection with the Company’s acquisition of Panoptes Pharma Ges.m.b.H in December 2020, 1,500 shares of Series D Convertible Preferred Stock which is convertible into 424,685 shares of the Company’s common stock were held back at closing. These shares will be issued in common stock, subject to post-closing adjustments and on the 18-month anniversary of the acquisition or June 2022. The shares reflect consideration for the acquisition of Panoptes even as payment was delayed until 18 months post-closing and were valued as of the acquisition date. These shares are classified as equity.

Equity Incentive Plan

Equity Incentive Plan	12 Months Ended
	Dec. 31, 2021
Equity Incentive Plan
Equity Incentive Plan	12. Equity Incentive Plan In 2005, the Company approved the 2005 Equity Incentive Plan (the “2005 Plan”). The 2005 Plan provides for the granting of options, restricted stock or other stock-based awards to employees, officers, directors, consultants, and advisors. During 2010, the maximum number of shares of Common Stock that may be issued pursuant to the 2005 Plan was increased to 59,414 shares. The Board of Directors (the “Board”) is responsible for administration of the 2005 Plan. The Company’s Board determines the term of each option, the option exercise price, the number of shares for which each option is granted and the rate at which each option is exercisable. Incentive stock options may be granted to any officer or employee at an exercise price per share of not less than the fair value per common share on the date of the grant (not less than 110% of fair value in the case of holders of more than 10% of the Company’s voting stock) and with a term not to exceed ten years from the date of the grant (five years for incentive stock options granted to holders of more than 10% of the Company’s voting stock). Nonqualified stock options may be granted to any officer, employee, consultant, or director at an exercise price per share of not less than the par value per share. Following adoption of the 2014 Equity Incentive Plan (the “2014 Plan”), no further grants were made under the 2005 Plan. General terms of the 2014 Plan remain the same as that of the 2005 plan. The Company’s Board adopted the 2014 Plan and the Employee Stock Purchase Plan (the “ESPP”), and the Company’s Stockholders approved the 2014 Plan and the ESPP Plan in February 2015. As of December 31, 2021, the maximum number of shares of Common Stock that may be issued pursuant to the 2014 Plan and the ESPP was 806,005 and 11,371 shares, respectively. In January 2021, the number of shares of common stock issuable under the 2014 Plan automatically increased by 23,333 shares pursuant to the terms of the 2014 Plan. Additionally, in June 2021, the number of shares of common stock issuable under the 2014 Plan was increased by 200,000 shares, as approved by the Company’s Stockholders. These additional shares are included in the total of 806,005 shares issuable under the 2014 Plan. The following is a summary of stock option activity for the years ended December 31, 2021 and 2020: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted-Average ​ ​ Number of ​ Weighted-Average ​ Contractual Life ​ Options Exercise Price (In Years) Outstanding at December 31, 2019 ​ 174,175 ​ $ 27.42 6.22 Granted 93,165 ​ 6.31 ​ Expired (17,114) ​ 10.59 Forfeited (3,333) ​ 7.20 Outstanding at December 31, 2020 246,893 ​ $ 20.90 7.20 Exercisable at December 31, 2020 ​ 142,061 ​ $ 31.58 ​ 5.85 Vested and Expected to Vest at December 31, 2020 ​ 246,893 ​ $ 20.90 ​ 7.20 Granted 345,865 ​ 4.11 ​ Expired (32,544) ​ 25.86 ​ Forfeited (44,292) ​ 6.49 ​ Outstanding at December 31, 2021 515,922 ​ $ 10.43 8.30 Exercisable at December 31, 2021 201,653 ​ $ 22.00 6.37 Vested and Expected to Vest at December 31, 2021 515,922 ​ $ 10.43 8.30 ​ During the years ended December 31, 2021 and 2020, the Board approved the grant of options to purchase 345,865 and 93,165 shares of its Common Stock, respectively. All option grants were pursuant to the 2014 Plan. In general, options granted under the 2014 Plan vest with respect to one ratably For the years ended December 31, 2021 and 2020, the fair value of each option grant has been estimated on the date of grant using the Black-Scholes Option Pricing Model with the following weighted-average assumptions: ​ ​ ​ ​ ​ ​ ​ ​ 2021 2020 Risk-Free Interest Rate 1.82 % 1.82 % Expected Life 10.0 years 10.0 years ​ Expected Average Volatility 140 % 153 % Expected Dividend Yield 0 % 0 % ​ Using the Black-Scholes Option Pricing Model, the estimated weighted average fair value of an option to purchase one share of common stock granted during the years ended December 31, 2021 and 2020 was $4.91 and $6.26, respectively. The following is a summary of restricted stock activity for the years ended December 31, 2021 and 2020: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted-Average ​ ​ Number of ​ Weighted-Average ​ Remaining ​ Shares Grant Date Fair Value Recognition Period Non-vested Outstanding at December 31, 2019 ​ 50,187 ​ $ 8.64 ​ 1.49 Awarded 49,000 ​ 6.55 Vested ​ (31,767) ​ ​ 8.69 ​ ​ Non-vested Outstanding at December 31, 2020 67,420 ​ $ 7.10 1.66 Vested (46,437) ​ 7.33 Forfeited (5,971) ​ 6.66 Non-vested Outstanding at December 31, 2021 15,012 ​ $ 6.55 1.09 ​ During year ended December 31, 2021, 5,971 shares of restricted stock, which had not vested, were forfeited and returned to the Company. During the years ended December 31, 2021 and 2020, the Board approved the grant of 0 and 49,000 restricted shares of Common Stock, respectively. All grants of restricted shares were pursuant to the 2014 Plan. These vest with respect to one ratably ​ The total stock-based compensation expense for employees and non-employees is included in the accompanying Consolidated Statements of Operations and as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2021 2020 ​ ​ ​ ​ ​ ​ ​ Research and Development ​ $ 246,386 ​ $ 197,806 General and Administrative ​ ​ 596,089 ​ ​ 526,050 Total Stock-Based Compensation Expense ​ $ 842,475 ​ $ 723,856 ​ The fair value of options granted for the years ended December 31, 2021 and 2020 was approximately $1.233 million and $0.580 million, respectively. There was no restricted stock granted for the year ended December 31, 2021. As of December 31, 2021 and 2020, there was approximately $1.001 million and $0.780 million of total unrecognized compensation expense related to unvested stock-based compensation arrangements granted, which cost is expected to be recognized over a weighted average period of 2.27 and 1.95 years, respectively. The aggregate intrinsic value of stock options outstanding at December 31, 2021 and 2020 was $0. As of December 31, 2021, there were 110,874 shares of Common Stock available for grant under the 2014 Plan and 7,806 shares available under the Company’s ESPP.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2021
Income Taxes
Income Taxes	13. Income Taxes The components of loss before income taxes are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2021 2020 Domestic ​ $ (10,639,818) ​ $ (6,766,157) Foreign ​ (3,323,470) ​ (83,558) Total Loss Before Income Taxes ​ $ (13,963,288) ​ $ (6,849,715) ​ The components of income tax (benefit) expense are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2021 2020 Deferred Taxes: ​ ​ ​ Federal ​ $ (24,086) ​ $ (529) State ​ (168,517) ​ 12,584 Total Deferred Taxes ​ $ (192,603) ​ $ 12,055 Income Tax (Benefit) Expense ​ $ (192,603) ​ $ 12,055 ​ The difference between the effective rate reflected in the provision (benefit) for income taxes on loss before taxes and the amounts determined by applying the applicable statutory U.S. tax rate are analyzed below: ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2021 2020 United States Federal Income Tax Rate ​ 21.00 % 21.00 % State Taxes, Net of Federal Benefit ​ 3.35 (1.59) ​ Permanent Differences ​ 0.72 (15.00) ​ Goodwill Impairment ​ (6.07) ​ — ​ Change in Valuation Allowance ​ (21.33) 17.53 ​ Research and Development Credits ​ 1.09 1.65 ​ Tax Rate Differential ​ 1.00 (2.12) ​ State Non-Income Based Tax ​ 0.01 ​ 0.01 ​ Stock-Based Compensation ​ — ​ (1.32) ​ Gain on Dissolution of Foreign Subsidiary ​ — (15.81) ​ Other ​ 1.61 (4.50) ​ Effective Tax Rate Expense ​ 1.38 % (0.15) % ​ The Company’s deferred tax assets and liabilities consist of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2021 2020 Net Deferred Tax Liability: ​ ​ ​ ​ ​ ​ Net Operating Loss Carryforwards ​ $ 20,689,134 ​ $ 17,042,422 Research and Development Credit Carryforwards ​ 2,853,598 ​ 2,695,773 Capitalized Research and Development ​ 5,640,428 ​ 6,251,945 Stock-Based Compensation ​ ​ 835,432 ​ ​ 781,252 Cash Versus Accrual Adjustments ​ 128,188 ​ 223,674 Total Deferred Tax Assets ​ 30,146,780 ​ 26,995,066 Valuation Allowance ​ (28,298,339) ​ (25,320,159) Net Deferred Tax Asset ​ 1,848,441 ​ 1,674,907 Depreciation and Amortization ​ ​ (956) ​ ​ (1,083) In-Process Research and Development ​ (2,649,616) ​ (2,402,750) Net Deferred Tax Liability ​ $ (802,131) ​ $ (728,926) ​ As of December 31, 2021, the Company has federal and state net operating loss carryforwards of approximately $72.370 million and $51.930 million, respectively, to offset future federal and state taxable income. Federal NOL carryforwards as of December 31, 2017 totaling $46.054 million, and state NOL carryforwards as of December 31, 2021 totaling $49.894 million will expire at various dates through 2041 and state NOL carryovers as of December 31, 2021 of $2.037 million can be carried forward indefinitely but limited to offset 80% of taxable income. Federal NOL carryforwards generated during the years ended December 31, 2018 and forward totaling $26.316 million will carry forward indefinitely, but their utilization will be limited to 80% of taxable income. The Company has foreign net operating loss carryforwards of $9.405 million as of December 31, 2021, which can be carried forward indefinitely. As of December 31, 2021, the Company also has federal and state research and development tax credit carryforwards of approximately $2.456 million and $0.503 million, respectively, to offset future income taxes, which expire at various times through 2041. The federal and state net operating loss and research tax credit carryforwards may be subject to the limitations provided in the Internal Revenue Code (“IRC”) Sections 382 and 383. Approximately $0.639 million of the federal net operating loss attributable to Jade is subject to a Section 382 limitation. Jade’s carryover of its research and development credits will be subject to the Section 383 limitation. On March 27, 2020, the Coronavirus Aid, Relief and Economic Security Act (the “CARES” Act) was enacted. The CARES Act included several income tax provisions including NOL carryback provisions and other tax benefits. The Company does not expect that the CARES Act will have a material impact on its income tax provision. The Company files United States federal income tax returns and income tax returns in the Commonwealth of Massachusetts, California, North Carolina and Utah, as well as foreign tax returns for its subsidiaries in Austria and Australia. The Company filed all foreign tax returns for its former French subsidiary EyeGate Pharma S.A.S., which was dissolved December 31, 2020. The Company is not under examination by any jurisdiction for any tax year. The Company has recorded a valuation allowance against its United States deferred tax assets in each of the years ended December 31, 2021, and 2020 because the Company’s management believes that it is more likely than not that these assets will not be realized. The valuation allowance increased (decreased) by approximately $2.978 million and $(0.958) million during the years ended December 31, 2021 and 2020, respectively, primarily as a result of the increase in net operating losses and credits, adjustments for accrual to cash basis items, and capitalized research and development expenses. As of December 31, 2021 and 2020, the Company had no unrecognized tax benefits or related interest and penalties accrued. The Company will recognize interest and penalties related to income taxes in income tax expense. The Company has not, as yet, conducted a study of R&D credit carryforwards, which are fully reserved for. This study may result in an adjustment to the Company’s R&D credit carryforwards and related valuation allowance, however, until a study is completed and any adjustment is known, no amounts are being presented as an uncertain tax position. The net operating loss and tax credit carryforwards are subject to review by the Internal Revenue Service in accordance with the provisions of Section 382 of the Internal Revenue Code. Under this Internal Revenue Code section, substantial changes in the Company’s ownership may limit the amount of net operating loss carryforwards that could be utilized annually in the future to offset the Company’s taxable income. Specifically, this limitation may arise in the event of a cumulative change in ownership of the Company of more than 50% within a three-year period. Any such annual limitation may significantly reduce the utilization of the Company’s net operating loss carryforwards before they expire. The closing of the Company’s initial public offering, alone or together with transactions that have occurred or that may occur in the future, may trigger an ownership change pursuant to Section 382, which could limit the amount of research and development tax credit and net operating loss carryforwards that could be utilized annually in the future to offset the Company’s taxable income, if any. Any such limitation as the result of the Company’s additional sales of common stock by the Company could have a material adverse effect on the Company’s results of operations in future years.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies
Commitments and Contingencies	14. Commitments and Contingencies Leases The Company is a party to three real property operating leases for the rental of office or lab space. The Company has office space in Waltham, Massachusetts of up to 4,516 square feet with a term through March 31, 2022. The Company also has office and laboratory space of approximately 3,540 square feet in Salt Lake City, Utah with a term through November 30, 2023, which is now used for its corporate headquarters. The Company has office space in Vienna, Austria of approximately 1,555 square feet with a term through October 31, 2023 as a result of the Panoptes acquisition effective December 18, 2020. Additional right-of-use assets and lease liabilities were recorded upon the new lease agreements or extensions that were effective as of December 31, 2021. Operating lease assets and liabilities are recognized at the lease commencement date at the present value of lease payments to be paid. Operating lease assets represent the Company’s right to use an underlying asset and are based upon the operating lease liabilities adjusted for prepayments or accrued lease payments. To determine the present value of lease payments to be paid, the Company estimated incremental secured borrowing rates corresponding to the maturities of the leases. The Company estimated a rate of 10% based on prevailing financial market conditions, comparable company and credit analysis, and management judgment. The Company recognizes expense for its leases on a straight-line basis over the lease term. Operating lease expense, consisting of the reduction of the right-of-use asset and the imputed interest on the lease liability, totaled $0.215 million and $0.174 million for the years ended December 31, 2021 and 2020, respectively. Maturities of lease liabilities were as follows as of December 31, 2021: ​ ​ ​ ​ ​ ​ Operating Leases 2022 $ 133,339 2023 ​ ​ 95,086 Less: Imputed Interest ​ (19,014) Lease Liabilities ​ $ 209,411 ​ License Agreements The Company is a party to seven license agreements as described below. These license agreements require the Company to pay or receive royalties or fees to or from the licensor based on revenue or milestones related to the licensed technology. On July 2, 2013, the Company (through its subsidiary, Kiora Pharmaceuticals GmbH) entered into a patent and know-how assignment agreement with 4SC Discovery GmbH (“4SC”) transferring to it all patent rights and know-how to the compound KIO-101. The Company is responsible for paying royalties of 3.25% on net sales of KIO-101. On July 2, 2013, the Company (through its subsidiary, Kiora Pharmaceuticals, GmbH) entered into an out-license agreement with 4SC granting 4SC the exclusive worldwide right to commercialize the compound KIO-101 for rheumatoid arthritis and inflammatory bowel disease, including Crohn’s Disease and Ulcerative Colitis. The Company is eligible to receive milestone payments totaling up to 155 million euros, upon and subject to the achievement of certain specified developmental and commercial milestones. We have not received any milestones from 4SC. In addition, the Company is eligible to receive royalties of 3.25% on net sales of KIO-101. On September 12, 2013, the Company (through its subsidiary, Jade Therapeutics, Inc.) entered into an agreement with Lineage Cell Therapeutics, Inc. (“Lineage”), formerly known as BioTime, Inc. granting to the Company the exclusive worldwide right to commercialize cross-linked thiolated carboxymethyl hyaluronic acid (“modified HA”) for ophthalmic treatments in humans. The agreement requires the Company to pay an annual fee of $30,000 and a royalty of 6% on net sales of KIO-201 to Lineage based on revenue relating to any product incorporating the modified HA technology. The agreement expires when patent protection for the modified HA technology lapses in August 2027. On November 17, 2014, we (through our subsidiary Kiora Pharmaceuticals GmbH) entered into an intellectual property and know-how licensing agreement with Laboratoires Leurquin Mediolanum S.A.S. (“Mediolanum”) for the commercialization of KIO-101 (the “Mediolanum agreement”) in specific territories. Under the Mediolanum agreement, we out-licensed rights to commercialize KIO-101 for uveitis, dry eye and viral conjunctivitis in Italy, and France. This Agreement was amended on December 10, 2015 to also include Belgium and The Netherlands. Under the Mediolanum Agreement, Mediolanum is obligated to pay up to approximately $20.0 million EUROs in development and commercial milestones and a 7% royalty on net sales of KIO-101 in the territories through the longer of the expiry of the valid patents covering KIO-101 or 10 years from the first commercial sale. The royalty is reduced to 5% after patent expiry. On September 26, 2018, the Company entered into an intellectual property licensing agreement (the “SentrX Agreement”) with SentrX, a veterinary medical device company that develops and manufactures veterinary wound care products. Under the SentrX Agreement, the Company in-licensed the rights to trade secrets and know-how related to the manufacturing of KIO-201. The SentrX Agreement enables the Company to pursue a different vendor with a larger capacity for manufacturing and an FDA-inspected facility for commercialization of a product for human use. Under the SentrX Agreement, SentrX is eligible to receive milestone payments totaling up to $4.75 million, upon and subject to the achievement of certain specified developmental and commercial milestones. The term of the agreement is until the Product is no longer in the commercial marketplace. On May 1, 2020, the Company (through its subsidiary, Kiora Pharmaceuticals Pty Ltd) entered into an agreement with the University of California (“UC”) granting to the Company the exclusive rights to its pipeline of photoswitch molecules. The agreement requires the Company to pay an annual fee to UC of $5,000, as well as payments to UC upon the achievement of certain development milestone and royalties based on KIO-301 revenue. The Company is obligated to pay royalties on net sales of two percent (2%) of the first $250 million of net sales, one and a quarter percent (1.25%) of net sales between $250 million and $500 million, and one half of one percent (0.5%) of net sales over $500 million. The agreement expires on the date of the last-to-expire patent included in the licensed patent portfolio which is January 2030. On May 1, 2020, the Company (through its subsidiary, Kiora Pharmaceuticals Pty Ltd) entered into an agreement with Photoswitch Therapeutics, Inc. (“Photoswitch”) granting to the Company access to certain patent applications and IP rights with last-to-expire patent terms of January 2030. The agreement calls for payments to Photoswitch upon the achievement of certain development and upon first commercial sale of the product. COVID-19 The continued spread of the COVID-19 pandemic could adversely impact the Company’s clinical studies. In addition, COVID-19 has resulted in significant governmental measures being implemented to control the spread of the virus, including quarantines, travel restrictions, and business shutdowns. COVID-19 has also caused volatility in the global financial markets and threatened a slowdown in the global economy, which could negatively affect the Company’s ability to raise additional capital on attractive terms or at all. The extent to which COVID-19 may impact the Company’s business will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the outbreak, the emergence of new variants, and the effectiveness of actions to contain and treat COVID-19. The Company cannot presently predict the scope and severity of any potential disruptions to its business, including to ongoing and planned clinical studies. Any such shutdowns or other business interruptions could result in material and negative effects to the Company’s ability to conduct its business in the manner and on the timelines presently planned, which could have a material adverse impact on its business, results of operation, and financial condition. As of the date of this report, there have been no material adverse effects to the Company’s ongoing business operations from COVID-19.

Employee Benefit Plans

Employee Benefit Plans	12 Months Ended
	Dec. 31, 2021
Employee Benefit Plans
Employee Benefit Plans	15. Employee Benefit Plans The Company has an employee benefit plan for its United States-based employees under Section 401(k) of the Internal Revenue Code. The Plan allows all eligible employees to make contributions up to a specified percentage of their compensation. Under the Plan, the Company may, but is not obligated to, match a portion of the employee contribution up to a defined maximum. The Company made no matching contribution for the year ended December 31, 2021. As a result of the 401(k) plan compliance review for the year ended December 31, 2020, the Company contributed $25,905 to eligible participants during the third quarter of 2021. As of December 31, 2021, the Company has accrued an additional estimate of $20,334 for contributions likely due as a result of the 401(k) plan compliance review to be performed for the year ended December 31, 2021.

Acquisitions

Acquisitions	12 Months Ended
	Dec. 31, 2021
Acquisitions
Acquisitions	16. Acquisitions Bayon Therapeutics, Inc. Acquisition Effective October 21, 2021, the Company acquired all of the capital stock of Bayon, a privately held ophthalmic specialty pharmaceutical company focused on developing light sensitive small molecules. With the Bayon acquisition, Bayon became a wholly-owned subsidiary of Kiora. The assets acquired and liabilities assumed have been recorded at fair value on the date of the acquisition. The excess of the purchase price over the fair value of the net assets acquired is recorded as goodwill, which is not expected to be deductible for tax purposes. Under the terms of the Bayon acquisition agreement, in consideration for 100% of the outstanding equity interests in Bayon, the Company paid cash in the amount of $0.097 million to certain sellers and creditors and issued 33,798 shares of Kiora common stock. The former stockholders of Bayon are also eligible to receive up to $7.135 million in additional cash or stock payments based on clinical trial and FDA approval milestones for Bayon’s product candidates, as set forth in the Purchase Agreement. If milestone payments are exercised for shares, shares will be issued at a price of $2.01 per share for the Phase 1b milestones. The remaining milestones will be calculated at a $3.30 per share. The cash or stock earn-out payments were recorded as contingent consideration and fair valued at $1.008 million at the acquisition date. The fair value of the shares issued in the Bayon acquisition was approximately $0.068 million based on the average closing price of the Company’s Common Stock for five trading days immediately preceding the closing date, or $2.01 per share. The following table summarizes the preliminary purchase price allocation and the estimated fair value of the net assets acquired and liabilities assumed in the Bayon acquisition at the date of acquisition. ​ ​ ​ ​ ​ ​ Bayon Current Assets (1) ​ $ 5,290 In-Process R&D ​ 1,063,000 Goodwill ​ 406,599 Accounts Payable ​ (36,525) Deferred Tax Liability ​ (265,808) Total Consideration ​ $ 1,172,556 (1) Current Assets include cash and receivables of $3,910 and $1,380, respectively. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Common ​ ​ ​ ​ ​ ​ Shares ​ Price per Share (a) ​ Amount Contingent consideration at fair value ​ — ​ — ​ $ 1,007,556 Cash Consideration — ​ — ​ 97,066 Kiora Common Stock 33,798 ​ $ 2.01 ​ 67,934 Total Fair Value of Consideration ​ ​ ​ ​ $ 1,172,556 ​ Net loss in the Consolidated Statement of Operations for the twelve months ended December 31, 2021 includes net losses of Bayon of $0.128 million from the date of acquisition. The acquired intangible assets, which consist solely of in-process research and development, will not be amortized until the underlying development programs are completed. Upon obtaining regulatory approval, the intangible assets are then accounted for as finite-lived intangible assets and amortized on a straight-line basis over its estimated useful life. The Company recognized approximately $0.090 million of acquisition-related costs for the Bayon acquisition that were expensed in the year ended December 31, 2021 as a component of general and administrative expense. Pro forma disclosure for Bayon acquisition The following table includes the pro forma results for Bayon the year ended December 31, 2021 of the combined companies as though the Bayon Acquisition had been completed as of January 1, 2020. ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended ​ Year Ended ​ ​ December 31, 2021 ​ December 31, 2020 ​ (unaudited) (unaudited) Operating Expenses ​ $ 14,257,347 ​ $ 7,082,768 Net Loss ​ $ (13,792,265) ​ $ (6,873,698) ​ The unaudited pro forma financial information may not necessarily reflect the Company’s future results of operations or what the results of operations would have been had the Company owned and operated Bayon as of the beginning of the period presented. Panoptes Pharma Ges.m.b.H. Acquisition Effective December 18, 2020, the Company acquired all of the capital stock of Panoptes Pharma Ges.m.b.H. (“Panoptes”), a privately held clinical stage biotech company focused on developing a novel proprietary small molecule for the treatment of severe eye diseases with a high unmet medical need, as well as for conditions outside the ocular space. With the Panoptes acquisition, Panoptes became a wholly-owned subsidiary of Kiora. The assets acquired and liabilities assumed have been recorded at fair value on the date of the acquisition. The excess of the purchase price over the fair value of the net assets acquired is recorded as goodwill, which is not expected to be deductible for tax purposes. Under the terms of the Panoptes acquisition agreement, in consideration for 100% of the outstanding equity interests in Panoptes, the Company paid cash in the amount of $0.445 million to certain founders and creditors, issued 884,222 shares of Kiora common stock, and issued 45.893 shares (convertible into 13,000 shares of common stock) of Kiora Series D Convertible Preferred Stock at closing. Additionally, holdback shares in the amount of 1,500 shares of Series D Convertible Preferred Stock (convertible into 424,685 shares of common stock) will be issued after a period of 18 months from closing, subject to post-closing adjustments or indemnification obligations, and are recorded as equity at the acquisition date. A cash payment due to a creditor in December 2021 has been recorded at a fair value of $0.212 million. The Panoptes acquisition also includes milestone payments in cash or stock upon (1) the enrollment and randomization of a first patient into the first FDA Phase III pivotal study of a Panoptes product for $4.750 million and (2) the FDA approval of the first New Drug Application of a Panoptes product for $4.750 million. If milestones are satisfied in shares, the shares will be issued at a price of not less than $2.4725 per share or more than $4.5917 per share. The cash or stock milestone payments were recorded as contingent consideration and fair valued at $2.280 million at the acquisition date. The fair value of the shares issued in the Panoptes acquisition was approximately $3.169 million and the fair value of the holdback shares was approximately $1.500 million based on the 30-day volume weighted average price of the Company’s Common Stock as reported by Bloomberg on the closing date of the acquisition, or $3.5321 per share. The following table summarizes the purchase price allocation and the estimated fair value of the net assets acquired and liabilities assumed in the Panoptes acquisition at the date of acquisition. ​ ​ ​ ​ ​ ​ Panoptes Current Assets ​ $ 410,863 In-Process R&D ​ 5,624,100 Goodwill ​ 2,105,316 Property, Plant and Equipment ​ 2,042 Accounts Payable and Other Liabilities ​ (87,777) Deferred Tax Liability ​ ​ (351,507) Assumed Liabilities ​ (312,852) Total Consideration ​ $ 7,390,185 (1) Current Assets include cash, receivables, and prepaid expenses of $333,860, $73,368, and $3,635, respectively. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Common ​ ​ ​ ​ ​ ​ Shares ​ Price per Share (a) ​ Amount Contingent consideration at fair value ​ — ​ — ​ $ 2,279,525 Cash Consideration — ​ — ​ 441,552 Holdback shares 424,685 ​ $ 3.5321 ​ 1,500,030 Kiora Common Stock 897,222 ​ $ 3.5321 ​ 3,169,078 Total Fair Value of Consideration ​ ​ ​ ​ $ 7,390,185 ​ Net loss in the Consolidated Statement of Operations for the twelve months ended December 31, 2020 includes net losses of Panoptes of $0.034 million from the date of acquisition. The Company’s intangible assets, which consist solely of in-process research and development, will not be amortized until the underlying development programs are completed. Upon obtaining regulatory approval, the intangible assets are then accounted for as finite-lived intangible assets and amortized on a straight-line basis over its estimated useful life. The Company recognized approximately $0.050 million and $0.414 million of acquisition-related costs for the Panoptes acquisition that were expensed in the years ended December 31, 2021 and 2020, respectively, as a component of general and administrative expense. Pro forma disclosure for Panoptes acquisition The following table includes the pro forma results for Panoptes the year ended December 31, 2020 of the combined companies as though the Panoptes Acquisition had been completed as of the beginning of the period presented. ​ ​ ​ ​ ​ ​ ​ Year Ended ​ ​ December 31, 2020 ​ (unaudited) Revenues ​ $ 558,063 Operating Expenses ​ $ 8,498,798 Net Loss ​ $ (7,942,031) ​ The unaudited pro forma financial information may not necessarily reflect the Company’s future results of operations or what the results of operations would have been had the Company owned and operated Panoptes as of the beginning of the period presented.

Quarterly Financial Information

Quarterly Financial Information (Unaudited)	12 Months Ended
	Dec. 31, 2021
Quarterly Financial Information (Unaudited)
Quarterly Financial Information (Unaudited)	17. Quarterly Financial Information (Unaudited) The following tables contain unaudited condensed consolidated quarterly financial information for the quarterly periods ended March 31, June 30, and September 30, 2021, that has been updated to reflect the restatement and revision of the Company’s consolidated financial statements as described in Note 2—Restatement of Financial Statements. The restatement and revision had an impact on net cash flows from financing activities. The Company has not amended its previously filed Quarterly Reports on Form 10-Q for the Affected Periods. The financial information that has been previously filed or otherwise reported for the Affected Periods is superseded by the information in this Annual Report, and the consolidated financial statements and related financial information for the Affected Period contained in such previously filed reports should no longer be relied upon. Balance Sheet as of March 31, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of March 31, 2021 ​ ​ As Previously ​ 2020 ​ ​ 2021 ​ ​ ​ Balance Sheet Reported ​ restatements ​ restatements ​ As Restated Total Current Assets ​ $ 6,991,086 ​ ​ — ​ ​ — ​ $ 6,991,086 Property and Equipment, Net ​ 84,264 ​ — ​ — ​ 84,264 Restricted Cash ​ 45,000 ​ — ​ — ​ 45,000 Goodwill ​ 3,484,607 ​ $ 146,605 ​ — ​ 3,631,212 Intangible Assets and In-process R&D, Net ​ 9,723,914 ​ — ​ — ​ 9,723,914 Operating Leases Assets with Right-of-Use ​ 242,730 ​ — ​ — ​ 242,730 Other Assets ​ 49,001 ​ — ​ — ​ 49,001 Total assets ​ $ 20,620,602 ​ $ 146,605 ​ — ​ $ 20,767,207 Liabilities and stockholders’ equity ​ ​ ​ ​ Total current liabilities ​ $ 1,425,598 ​ 212,281 ​ ​ $ 1,637,879 Contingent Consideration ​ 5,342,950 ​ (2,795,876) ​ $ (570,203) ​ 1,976,871 Deferred Tax Liability ​ 728,926 ​ — ​ — ​ 728,926 Paycheck Protection Program Loan ​ 278,190 ​ — ​ — ​ 278,190 Non-current Operating Lease Liabilities ​ 159,938 ​ — ​ — ​ 159,938 Total liabilities ​ 7,935,602 ​ (2,583,595) ​ (570,203) ​ 4,781,804 Stockholders’ equity ​ ​ ​ ​ Preferred Stock, $0.01 par value ​ 41 ​ — ​ — ​ 41 Common Stock, $0.01 par value ​ 70,979 ​ — ​ — ​ 70,979 Additional paid-in-capital ​ 123,523,964 ​ 1,500,030 ​ — ​ 125,023,994 Accumulated deficit ​ (110,919,655) ​ 1,230,170 ​ 570,203 ​ (109,119,282) Accumulated Other Comprehensive Income ​ 9,671 ​ — ​ — ​ 9,671 Total stockholders’ equity ​ 12,685,000 ​ 2,730,200 ​ 570,203 ​ 15,985,403 Total liabilities and stockholders’ equity ​ $ 20,620,602 ​ $ 146,605 ​ — ​ $ 20,767,207 ​ Statement of Operations and Comprehensive Loss for the 3 months ended March 31, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the 3 months ended March 31, 2021 ​ ​ As Previously ​ 2021 ​ ​ Statement of Operations and Comprehensive Loss ​ Reported ​ restatements ​ As restated Research and Development ​ $ 1,280,242 ​ — ​ $ 1,280,242 General and Administrative ​ 1,300,143 ​ — ​ 1,300,143 Change in Fair Value of Contingent Consideration ​ — ​ $ (570,203) ​ (570,203) Total Operating Expenses ​ 2,580,385 ​ (570,203) ​ 2,010,182 Operating Loss before Other Income ​ (2,580,385) ​ 570,203 ​ (2,010,182) Interest Income ​ ​ 250 ​ ​ — ​ ​ 250 Interest Expense ​ (686) ​ — ​ (686) Total other (expense) income ​ (436) ​ — ​ (436) Loss before Income Tax Benefit (Expense) ​ ​ (2,580,821) ​ ​ 570,203 ​ ​ (2,010,618) Income Tax Benefit (Expense) ​ ​ — ​ ​ — ​ ​ — Net loss ​ $ (2,580,821) ​ $ 570,203 ​ $ (2,010,618) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Average Shares Outstanding - Basic and Diluted ​ 6,954,438 ​ 403,461 ​ 7,357,899 Basic and Diluted net loss ​ $ (0.37) ​ ​ $ (0.27) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Other comprehensive loss: ​ ​ ​ ​ ​ ​ ​ ​ ​ Net Loss ​ $ (2,580,821) ​ $ 570,203 ​ $ (2,010,618) Foreign Currency Translation Adjustments ​ ​ 10,473 ​ ​ — ​ ​ 10,473 Comprehensive Loss ​ $ (2,570,348) ​ $ 570,203 ​ $ (2,000,145) ​ Stockholders’ Equity as of March 31, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of March 31, 2021 ​ ​ As Previously ​ 2020 ​ 2021 ​ ​ ​ Stockholders’ equity Reported restatements restatements As restated Preferred Stock, $0.01 par value ​ $ 41 ​ — ​ — ​ $ 41 Common Stock, $0.01 par value ​ 70,979 ​ — ​ — ​ 70,979 Additional paid-in-capital ​ 123,523,964 ​ $ 1,500,030 ​ — ​ 125,023,994 Accumulated deficit ​ (110,919,655) ​ 1,230,170 ​ $ 570,203 ​ (109,119,282) Accumulated Other Comprehensive Income ​ 9,671 ​ — ​ — ​ 9,671 Total stockholders’ equity ​ $ 12,685,000 ​ $ 2,730,200 ​ $ 570,203 ​ $ 15,985,403 ​ Statement of Cash Flows for the 3 months ended March 31, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of March 31, 2021 ​ ​ 2021 ​ ​ ​ As Previously ​ Restatement ​ ​ Statement of Cash Flows ​ Reported ​ Adjustment ​ As restated Operating Activities ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss ​ $ (2,580,821) ​ $ 570,203 ​ $ (2,010,618) Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Depreciation and Amortization of Intangible Assets ​ 10,599 ​ — ​ 10,599 Reduction of Right-of-Use Assets ​ 39,490 ​ — ​ 39,490 Stock-Based Compensation ​ 216,945 ​ — ​ 216,945 Change in Fair Value of Contingent Consideration ​ — ​ (570,203) ​ (570,203) Deferred Taxes ​ — ​ — ​ — Paycheck Protection Program Loan Forgiveness ​ — ​ — ​ — Goodwill Impairment Loss ​ — ​ — ​ — Intangible Asset Impairment Loss ​ — ​ — ​ — Changes in Operating Assets and Liabilities, Net of Effects of Business Acquired: ​ — ​ — ​ Prepaid Expenses and Other Current Assets ​ 216,078 ​ — ​ 216,078 Refundable Tax Credit Receivable ​ (59,706) ​ — ​ (59,706) Other Assets ​ 8,073 ​ — ​ 8,073 Accounts Payable ​ 22,583 ​ — ​ 22,583 Lease Liabilities ​ (39,490) ​ — ​ (39,490) Accrued Expenses ​ (403,802) ​ — ​ (403,802) Net cash used in operating activities ​ (2,570,051) ​ — ​ (2,570,051) Net cash used in investing activities ​ (58,119) ​ — ​ (58,119) Financing Activities ​ ​ ​ ​ ​ ​ ​ ​ ​ Proceeds from stock offerings ​ 7,988,861 ​ — ​ 7,988,861 Stock issuance costs ​ — ​ — ​ — Exercise warrants ​ 50,001 ​ — ​ 50,001 Repayment of Loan Payable ​ — ​ — ​ — Net cash provided by financing activities ​ 8,038,862 ​ — ​ 8,038,862 Effects of Exchange Rate Changes on Cash ​ 14,123 ​ — ​ 14,123 Net Cash Increase or decrease ​ 5,424,815 ​ — ​ 5,424,815 Cash, Including Restricted Cash, Beginning of Year ​ 1,230,677 ​ ​ ​ 1,230,677 Cash, Including Restricted Cash, End of Year ​ $ 6,655,492 ​ — ​ $ 6,655,492 ​ Balance Sheet as of June 30, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of June 30, 2021 ​ ​ As Previously ​ 2020 ​ ​ 2021 ​ ​ ​ Balance Sheet Reported restatements ​ restatements As Restated Total Current Assets ​ $ 4,415,173 ​ — ​ — ​ $ 4,415,173 Property and Equipment, Net ​ 83,682 ​ — ​ — ​ 83,682 Restricted cash ​ 45,000 ​ — ​ — ​ 45,000 Goodwill ​ 3,484,607 ​ $ 146,605 ​ — ​ 3,631,212 Intangible Assets and In-process R&D, Net ​ 9,717,664 ​ — ​ — ​ 9,717,664 Operating Leases Assets with Right-of-Use ​ 308,013 ​ — ​ — ​ 308,013 Other Assets ​ 45,921 ​ — ​ — ​ 45,921 Total assets ​ $ 18,100,060 ​ $ 146,605 ​ — ​ $ 18,246,665 Liabilities and stockholders’ equity ​ ​ ​ ​ Total current liabilities ​ $ 1,436,440 ​ 212,281 ​ — ​ $ 1,648,721 Contingent Consideration ​ 5,342,950 ​ (2,795,876) ​ $ (496,486) ​ 2,050,588 Deferred Tax Liability ​ 728,926 ​ — ​ — ​ 728,926 Non-current Operating Lease Liabilities ​ 137,957 ​ — ​ — ​ 137,957 Total liabilities ​ 7,646,273 ​ (2,583,595) ​ (496,486) ​ 4,566,192 Stockholders’ equity ​ ​ ​ ​ Preferred Stock, $0.01 par value ​ 41 ​ — ​ — ​ 41 Common Stock, $0.01 par value ​ 70,979 ​ — ​ — ​ 70,979 Additional paid-in-capital ​ 123,786,856 ​ 1,500,030 ​ — ​ 125,286,886 Accumulated deficit ​ (113,388,953) ​ 1,230,170 ​ 496,486 ​ (111,662,297) Accumulated Other Comprehensive Income ​ (15,136) ​ — ​ — ​ (15,136) Total stockholders’ equity ​ 10,453,787 ​ 2,730,200 ​ 496,486 ​ 13,680,473 Total liabilities and stockholders’ equity ​ $ 18,100,060 ​ $ 146,605 ​ — ​ $ 18,246,665 ​ Statement of Operations and Comprehensive Loss for the 3 months ended June 30, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the 3 months ended June 30, 2021 ​ ​ As Previously ​ 2021 ​ ​ ​ Statement of Operations and Comprehensive Loss Reported Restatement As restated Research and Development ​ $ 1,439,922 ​ — ​ $ 1,439,922 General and Administrative ​ 1,305,865 ​ — ​ 1,305,865 Change in Fair Value of Contingent Consideration Expense ​ — ​ $ 73,717 ​ 73,717 Total Operating Expenses ​ 2,745,787 ​ 73,717 ​ 2,819,504 Operating Loss before Other Income ​ (2,745,787) ​ (73,717) ​ (2,819,504) Other (expense) income: ​ ​ ​ Gain on Forgiveness of Loan ​ 278,190 ​ — ​ 278,190 Interest Income ​ 332 ​ — ​ 332 Interest Expense ​ (2,033) ​ — ​ (2,033) Total other (expense) income ​ 276,489 ​ ​ 276,489 Loss before Income Tax Benefit (Expense) ​ ​ (2,469,298) ​ ​ (73,717) ​ ​ (2,543,015) Income Tax Benefit (Expense) ​ ​ — ​ ​ — ​ ​ — Net Loss ​ $ (2,469,298) ​ $ (73,717) ​ $ (2,543,015) Weighted Average Shares Outstanding - Basic and Diluted ​ 7,062,750 ​ 403,461 ​ 7,466,211 Basic and Diluted net loss ​ $ (0.35) ​ ​ $ (0.34) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Other comprehensive loss: ​ ​ ​ ​ ​ ​ ​ ​ ​ Net Loss ​ $ (2,469,298) ​ $ (73,317) ​ $ (2,543,015) Foreign Currency Translation Adjustments ​ ​ (24,807) ​ ​ — ​ ​ (24,807) Comprehensive Loss ​ $ (2,494,105) ​ $ (73,317) ​ $ (2,567,822) ​ Statement of Operations and Comprehensive Loss for the 6 months ended June 30, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the 6 months ended June 30, 2021 ​ As ​ ​ ​ ​ Previously ​ 2021 ​ ​ Statement of Operations and Comprehensive Loss ​ Reported ​ restatements ​ As restated Research and Development ​ $ 2,720,164 ​ ​ — $ 2,720,164 General and Administrative ​ 2,606,008 ​ — ​ 2,606,008 Change in Fair Value of Contingent Consideration ​ — ​ $ (496,486) ​ (496,486) Total Operating Expenses ​ 5,326,172 ​ (496,486) ​ 4,829,686 Operating Loss before Other Income ​ (5,326,172) ​ 496,486 ​ (4,829,686) Other (expense) income: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Gain on Forgiveness of Loan ​ 278,190 ​ — ​ 278,190 Interest Income ​ 582 ​ — ​ 582 Interest Expense ​ (2,719) ​ — ​ (2,719) Total other (expense) income ​ 276,053 ​ — ​ 276,053 Loss before Income Tax Benefit (Expense) ​ ​ (5,050,119) ​ ​ 496,486 ​ ​ (4,553,633) Income Tax Benefit (Expense) ​ ​ — ​ ​ — ​ ​ — Net Loss ​ $ (5,050,119) ​ $ 496,486 ​ $ (4,553,633) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Average Shares Outstanding - Basic and Diluted ​ 7,005,902 ​ ​ 403,461 ​ 7,409,363 Basic and Diluted net loss ​ $ (0.72) ​ ​ ​ ​ $ (0.61) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Other comprehensive loss: ​ ​ ​ ​ ​ ​ ​ ​ ​ Net Loss ​ $ (5,050,119) ​ $ 496,486 ​ $ (4,553,633) Foreign Currency Translation Adjustments ​ (14,334) ​ — ​ (14,334) Comprehensive Loss ​ $ (5,064,453) ​ $ 496,486 ​ $ (4,567,967) ​ Stockholders’ Equity as of June 30, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of June 30, 2021 ​ ​ As Previously ​ 2020 ​ 2021 ​ ​ ​ Stockholders’ equity Reported restatements restatements As restated Preferred Stock, $0.01 par value ​ $ 41 ​ — ​ — ​ $ 41 Common Stock, $0.01 par value ​ 70,979 ​ — ​ — ​ 70,979 Additional paid-in-capital ​ 123,786,856 ​ $ 1,500,030 ​ — ​ 125,286,886 Accumulated deficit ​ (113,388,953) ​ 1,230,170 ​ $ 496,486 ​ (111,662,297) Accumulated Other Comprehensive Income ​ (15,136) ​ — ​ — ​ (15,136) Total stockholders’ equity ​ $ 10,453,787 ​ $ 2,730,200 ​ $ 496,486 ​ $ 13,680,473 ​ Statement of Cash Flows for the 6 months ended June 30, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of June 30, 2021 ​ ​ ​ 2021 ​ ​ ​ ​ As Previously ​ Restatement ​ ​ ​ Statement of Cash Flows ​ Reported ​ Adjustment ​ As restated Operating Activities ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss ​ $ (5,050,119) ​ $ 496,486 ​ $ (4,553,633) Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Depreciation and Amortization of Intangible Assets ​ 23,203 ​ — ​ 23,203 Reduction of Right-of-Use Assets ​ 86,387 ​ — ​ 86,387 Stock-Based Compensation ​ 479,837 ​ — ​ 479,837 Change in Fair Value of Contingent Consideration ​ — ​ (496,486) ​ (496,486) Deferred Taxes ​ — ​ — ​ Paycheck Protection Program Loan Forgiveness ​ ​ ​ ​ (278,190) ​ (278,190) Goodwill Impairment Loss ​ — ​ — ​ — Intangible Asset Impairment Loss ​ — ​ — ​ — Changes in Operating Assets and Liabilities, Net of Effects of Business Acquired: ​ — ​ — ​ Prepaid Expenses and Other Current Assets ​ 8,786 ​ — ​ 8,786 Refundable Tax Credit Receivable ​ (222,645) ​ — ​ (222,645) Other Assets ​ 11,153 ​ — ​ 11,153 Accounts Payable ​ (142,444) ​ — ​ (142,444) Lease Liabilities ​ (86,387) ​ — ​ (86,387) Accrued Expenses ​ (315,196) ​ — ​ (315,196) Net cash used in operating activities ​ (5,207,425) ​ (278,190) ​ (5,485,615) Net cash used in investing activities ​ (63,865) ​ — ​ (63,865) Financing Activities ​ ​ ​ ​ ​ ​ ​ ​ ​ Proceeds from stock offerings ​ 7,988,861 ​ — ​ 7,988,861 Stock Issuance Costs ​ — ​ ​ ​ — PPP Loan Forgiveness ​ (278,190) ​ 278,190 ​ Exercise of Warrants ​ 50,001 ​ — ​ 50,001 Repayment of Loan Payable ​ — ​ — ​ — Net cash provided by financing activities ​ 7,760,672 ​ 278,190 ​ 8,038,862 Effects of Exchange Rate Changes on Cash ​ (11,835) ​ — ​ (11,835) Net Cash Increase or decrease ​ 2,477,547 ​ — ​ 2,477,547 Cash, Including Restricted Cash, Beginning of Year ​ 1,230,677 ​ ​ ​ 1,230,677 Cash, Including Restricted Cash, End of Year ​ $ 3,708,224 ​ $ — ​ $ 3,708,224 ​ Balance Sheet as of September 30, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of September 30, 2021 ​ ​ As Previously ​ 2020 ​ ​ 2021 ​ ​ ​ Balance Sheet Reported restatements ​ Restatement As Restated Total Current Assets $ 11,870,019 ​ — ​ — $ 11,870,019 Property and Equipment, Net ​ 78,833 ​ — ​ — ​ 78,833 Restricted cash ​ 45,000 ​ — ​ — ​ 45,000 Goodwill ​ 3,484,607 $ 146,605 ​ — ​ 3,631,212 Intangible Assets and In-process R&D, Net ​ 9,711,414 ​ — ​ — ​ 9,711,414 Operating Leases Assets with Right-of-Use ​ 259,217 ​ — ​ — ​ 259,217 Other Assets ​ 44,249 ​ — ​ — ​ 44,249 Total assets $ 25,493,339 $ 146,605 ​ — $ 25,639,944 Liabilities and stockholders’ equity ​ ​ ​ ​ Total current liabilities $ 1,958,942 ​ 212,281 ​ — $ 2,171,223 Contingent Consideration ​ 5,342,950 ​ (2,795,876) $ (428,480) ​ 2,118,594 Deferred Tax Liability ​ 728,926 ​ — ​ — ​ 728,926 Non-current Operating Lease Liabilities ​ 114,475 ​ — ​ — ​ 114,475 Total liabilities ​ 8,145,293 ​ (2,583,595) ​ (428,480) ​ 5,133,218 Stockholders’ equity ​ ​ ​ ​ Preferred Stock, $0.01 par value ​ — ​ — ​ — ​ — Common Stock, $0.01 par value ​ 126,193 ​ — ​ — ​ 126,193 Additional paid-in-capital ​ 133,637,500 ​ 1,500,030 ​ — ​ 135,137,530 Accumulated deficit ​ (116,355,777) ​ 1,230,170 ​ 428,480 ​ (114,697,127) Accumulated Other Comprehensive Income ​ (59,870) ​ — ​ — ​ (59,870) Total stockholders’ equity ​ 17,348,046 ​ 2,730,200 ​ 428,480 ​ 20,506,726 Total liabilities and stockholders’ equity $ 25,493,339 $ 146,605 ​ — $ 25,639,944 ​ Statement of Operations and Comprehensive Loss for the 3 months ended September 30, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the 3 months ended September 30, 2021 ​ ​ As Previously ​ Restatement ​ ​ ​ Statement of Operations and Comprehensive Loss ​ Reported ​ Adjustment ​ As restated Research and Development $ 1,628,467 ​ — $ 1,628,467 General and Administrative ​ 1,338,616 ​ — ​ 1,338,616 Change in Fair Value of Contingent Consideration ​ — $ 68,006 ​ 68,006 Total Operating Expenses ​ 2,967,083 ​ 68,006 ​ 3,035,089 Operating Loss before Other Income ​ (2,967,083) ​ (68,006) ​ (3,035,089) Other (expense) income: ​ ​ ​ Interest Income ​ 259 ​ — ​ 259 Total other (expense) income ​ 259 ​ — ​ 259 Loss before Income Tax Benefit (Expense) ​ ​ (2,966,824) ​ ​ (68,006) ​ ​ (3,034,830) Income Tax Benefit (Expense) ​ ​ — ​ ​ — ​ ​ — Net Loss $ (2,966,824) $ (68,006) $ (3,034,830) Weighted Average Shares Outstanding – Basic and Diluted ​ 10,265,108 ​ 403,461 ​ 10,668,569 Basic and Diluted net loss $ (0.29) ​ ​ $ (0.28) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Other comprehensive loss: ​ ​ ​ ​ ​ ​ ​ ​ ​ Net Loss ​ $ (2,966,824) ​ $ (68,006) ​ $ (3,034,830) Foreign Currency Translation Adjustments ​ ​ (44,734) ​ ​ — ​ ​ (44,734) Comprehensive Loss ​ $ (3,011,558) ​ $ (68,006) ​ $ (3,079,564) ​ Statement of Operations and Comprehensive Loss for the 9 months ended September 30, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the 9 months ended September 30, 2021 ​ As Previously 2021 ​ Statement of Operations and Comprehensive Loss ​ Reported ​ restatements ​ As restated Research and Development ​ $ 4,348,631 ​ ​ — ​ $ 4,348,631 General and Administrative ​ ​ 3,944,624 ​ ​ — ​ ​ 3,944,624 Change in Fair Value of Contingent Consideration ​ ​ — ​ $ (428,480) ​ ​ (428,480) Total Operating Expenses ​ ​ 8,293,255 ​ ​ (428,480) ​ ​ 7,864,775 Operating Loss before Other Income ​ ​ (8,293,255) ​ ​ 428,480 ​ ​ (7,864,775) Other (expense) income: ​ ​ ​ ​ ​ ​ Gain on Forgiveness of Loan ​ ​ 278,190 ​ ​ — ​ ​ 278,190 Interest Income ​ ​ 841 ​ ​ — ​ ​ 841 Interest Expense ​ ​ (2,719) ​ ​ — ​ ​ (2,719) Total other (expense) income ​ ​ 276,312 ​ ​ — ​ ​ 276,312 Loss before Income Tax Benefit (Expense) ​ ​ (8,016,943) ​ ​ 428,480 ​ ​ (7,588,463) Income Tax Benefit (Expense) ​ ​ — ​ ​ — ​ ​ — Loss before Income Tax Benefit (Expense) ​ $ (8,016,943) ​ $ 428,480 ​ $ (7,588,463) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Average Shares Outstanding - Basic and Diluted ​ 8,101,004 ​ ​ 403,461 ​ 8,504,465 Basic and Diluted net loss ​ $ (0.99) ​ ​ ​ ​ $ (0.89) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Other comprehensive loss: ​ ​ ​ ​ ​ ​ ​ ​ ​ Net Loss ​ $ (8,016,943) ​ $ 428,480 ​ $ (7,588,463) Foreign Currency Translation Adjustments ​ (59,068) ​ — ​ (59,068) Comprehensive Loss ​ $ (8,076,011) ​ 428,480 ​ $ (7,647,531) ​ Stockholders’ Equity as of September 30, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of September 30, 2021 ​ ​ As Previously ​ 2020 ​ 2021 Restatements ​ ​ ​ Stockholders’ equity Reported Restatements ​ As restated Preferred Stock, $0.01 par value ​ — ​ — ​ — ​ — Common Stock, $0.01 par value $ 126,193 ​ — ​ — $ 126,193 Additional paid-in-capital ​ 133,637,500 $ 1,500,030 ​ — ​ 135,137,530 Accumulated deficit ​ (116,355,777) ​ 1,230,170 $ 428,480 ​ (114,697,127) Accumulated Other Comprehensive Income ​ (59,870) ​ — ​ — ​ (59,870) Total stockholders’ equity $ 17,348,046 $ 2,730,200 $ 428,480 $ 20,506,726 ​ ​ Statement of Cash Flows for the 9 months ended September 30, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of September 30, 2021 ​ ​ 2021 ​ ​ ​ As Previously ​ Restatement ​ ​ Statement of Cash Flows ​ Reported ​ Adjustment ​ As restated Operating Activities ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss ​ $ (8,016,943) ​ $ 428,480 ​ $ (7,588,463) Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Depreciation and Amortization of Intangible Assets ​ ​ 34,260 ​ ​ — ​ 34,260 Reduction of Right-of-Use Assets ​ ​ 133,514 ​ ​ — ​ 133,514 Stock-Based Compensation ​ ​ 629,306 ​ ​ — ​ 629,306 Change in Fair Value of Contingent Consideration ​ ​ — ​ (428,480) ​ (428,480) Deferred Taxes ​ ​ — ​ — ​ — Paycheck Protection Program Loan Forgiveness ​ ​ — ​ (278,190) ​ (278,190) Goodwill Impairment Loss ​ ​ — ​ — ​ — Intangible Asset Impairment Loss ​ ​ — ​ — ​ — Changes in Operating Assets and Liabilities, Net of Effects of Business Acquired: ​ ​ — ​ — ​ — Prepaid Expenses and Other Current Assets ​ ​ 107,940 ​ — ​ 107,940 Refundable Tax Credit Receivable ​ ​ (335,096) ​ — ​ (335,096) Other Assets ​ ​ 12,826 ​ — ​ 12,826 Accounts Payable ​ ​ (9,875) ​ — ​ (9,875) Lease Liabilities ​ ​ (133,514) ​ — ​ (133,514) Accrued Expenses ​ ​ 100,050 ​ — ​ 100,050 Net cash used in operating activities ​ ​ (7,477,532) ​ (278,190) ​ (7,755,722) Net cash used in investing activities ​ ​ (63,865) ​ — ​ (63,865) Financing Activities ​ ​ ​ ​ ​ ​ ​ ​ ​ Proceeds from stock offerings ​ ​ 17,745,207 ​ — ​ 17,745,207 Stock Issuance Costs ​ ​ — ​ — ​ — Exercise of Warrants ​ ​ 50,001 ​ — ​ 50,001 PPP loan forgiveness ​ ​ (278,190) ​ 278,190 ​ — Repayment of Loan Payable ​ ​ — ​ — ​ — Net cash provided by financing activities ​ ​ 17,517,018 ​ 278,190 ​ 17,795,208 Effects of Exchange Rate Changes on Cash ​ ​ (54,371) ​ — ​ (54,371) Net Cash Increase or decrease ​ ​ 9,921,250 ​ — ​ 9,921,250 Cash, Including Restricted Cash, Beginning of Year ​ ​ 1,230,677 ​ — ​ 1,230,677 Cash, Including Restricted Cash, End of Year ​ $ 11,151,927 ​ $ — ​ $ 11,151,927 ​

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2021
Summary of Significant Accounting Policies
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying Consolidated Financial Statements include the accounts of the Company and its subsidiaries, EyeGate Pharma S.A.S. (through its dissolution on December 30, 2020), Jade Therapeutics, Inc. (“Jade”), Kiora Pharmaceuticals GmbH (“Kiora GmbH”) (formerly known as Panoptes Pharma Ges.m.b.H or “Panoptes”) (effective December 18, 2020 when the Company acquired all of the capital stock of Panoptes), Bayon (effective October 21, 2021 when the Company acquired all of the capital stock of Bayon), and Kiora Pharmaceuticals Pty Ltd (“Kiora Pty”) (formerly known as Bayon Therapeutics Pty Ltd), collectively referred to as “the Company”. All inter-company balances and transactions have been eliminated in consolidation. These Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”).
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of expenses during the reporting periods. The Company makes significant estimates and assumptions in recording the accruals for the Company’s clinical trial and research activities, establishing the useful lives of intangible assets and property and equipment, conducting impairment reviews of goodwill, IPR&D, revenue recognition, stock-based compensation, and contingent considerations payable. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances. Although the Company monitors and regularly assesses these estimates, actual results could differ significantly from these estimates. The Company records changes in estimates in the period that it becomes aware of the change.
Foreign Currency Translation	Foreign Currency Translation Operations of Kiora GmbH are, and prior to its dissolution on December 31, 2020, operations of EyeGate Pharma S.A.S. were, conducted in euros which represent its functional currency. Operations of Kiora Pty are conducted in Australian dollars, which represent its functional currency. Balance sheet accounts of such subsidiaries were translated into U.S. dollars at the exchange rate in effect at the balance sheet date and income statement accounts were translated to the average rate of exchange prevailing during the period. Translation adjustments resulting from this process, are included in accumulated other comprehensive loss on the Consolidated Balance Sheets.
Cash and Cash Equivalents and Restricted Cash	Cash and Cash Equivalents and Restricted Cash The Company considers all highly liquid investments purchased with a maturity of 90 days or less when acquired that are not restricted as to withdrawal, to be the equivalent of cash for the purpose of balance sheet and statement of cash flows presentation. The Company invests its cash in either U.S. government or treasury money market funds with maturities of 90 days or less. At December 31, 2021 and 2020, the Company has classified $0.045 million as restricted cash.
Property and Equipment	Property and Equipment Property and equipment is stated at cost less accumulated depreciation. Depreciation is provided for on a straight-line basis over the estimated useful life of 2 to 5 years for all assets. Maintenance and repair costs are expensed as incurred. The Company reviews its property and equipment whenever events or changes in circumstances indicate that the carrying value of certain assets might not be recoverable and recognizes an impairment loss when it is probable that the estimated cash flows are less than the carrying value of the asset.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company evaluates potential impairment of long-lived assets and long-lived assets to be disposed of and considers whether long-lived assets held for use have been impaired whenever events or changes in circumstances indicate that the related carrying amount may not be recoverable, or that the period of their recovery may have changed. Management makes significant estimates and assumptions regarding future sales, cost trends, productivity and market maturity in order to test for impairment. Management reports those long-lived assets to be disposed of and assets held for sale at the lower of carrying amount or fair value less cost to sell. Based on current facts, estimates and assumptions, management believes that no assets are impaired at December 31, 2021. There is no assurance that management’s estimates and assumptions will not change in future periods.
Research and Development Expenses	Research and Development Expenses The Company expenses research and development (“R&D”) expenditures as incurred. R&D expenses are comprised of costs incurred in performing R&D activities, including salaries, benefits, facilities, research-related overhead, sponsored research costs, contracted services, license fees, expenses related to generating, filing, and maintaining intellectual property and other external costs. Because the Company believes that, under its current process for developing its products, the viability of the products is essentially concurrent with the establishment of technological feasibility, no costs have been capitalized to date.
Goodwill	Goodwill Goodwill is the excess of the acquisition cost of a business over the fair value of the identifiable net assets acquired. In 2021, this consists of the goodwill of the Company’s subsidiaries Jade, Kiora GmbH, and Bayon. In 2020, this consists of the goodwill of the Company’s subsidiaries Jade and Kiora GmbH. Goodwill is not amortized and is tested for impairment on an annual basis in the fourth quarter of each fiscal year and whenever events or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. The Company performed qualitative and quantitative impairment evaluations on its goodwill as of December 31, 2021. Goodwill as of December 31, 2021 was reduced to zero after taking an impairment loss of $4.037
In-Process Research and Development	In-Process Research and Development The Company records in-process R&D projects acquired in asset acquisitions that have not reached technological feasibility and which have no alternative future use. For in-process R&D projects acquired in business combinations, the Company capitalizes the in-process R&D project and periodically evaluates this asset for impairment until the R&D process has been completed. Once the R&D process is complete, the Company amortizes the R&D asset over its remaining useful life. At December 31, 2021 and 2020, there is $10.599 million and $9.536 million respectively of in-process R&D as part of intangible asset and in-process R&D on the Consolidated Balance Sheets.
Accrued Clinical Expenses	Accrued Clinical Expenses As part of the Company’s process of preparing the Consolidated Financial Statements, the Company is required to estimate its accrued expenses. This process includes reviewing open contracts and purchase orders, communicating with its applicable personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated costs incurred for the service when the Company has not yet been invoiced or otherwise notified of actual costs. The majority of the Company’s service providers invoice monthly in arrears for services performed. The Company makes estimates of its accrued expenses as of each balance sheet date in the financial statements based on facts and circumstances known at the time. The Company periodically confirms the accuracy of these estimates with the service providers and makes adjustments if necessary.
Business Segment and Geographical Information	Business Segment and Geographical Information The Company identifies operating segments as components of the enterprise for which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business as fully integrated and operating in one business segment (research and development), and the Company operates in three geographic segments.
Income Taxes	Income Taxes The Company will record a deferred income tax asset and liability for the expected future income tax consequences of events that have been recognized in the Company’s Consolidated Financial Statements and income tax returns. The Company will record a deferred income tax asset and liability based on differences between the financial statement carrying, or “book”, amounts of assets and liabilities, and the tax bases of the assets and liabilities using the enacted income tax regulations in effect in the years in which the differences are expected to reverse. A valuation allowance against deferred income tax asset will be recorded if, based on the weight of available evidence, it is more likely than not that some or all of the deferred income tax assets will not be realized. As of December 31, 2021 and 2020, all of the Company’s net deferred income tax assets were subject to a full valuation allowance. As of December 31, 2021 and 2020, the Company has a net deferred tax liability of $0.802 million and $0.729 million, respectively. The Company recognizes the impact of an uncertain income tax position in the financial statements if it believes that the position is more likely than not to be sustained by the relevant taxing authority. As of December 31, 2021, the Company had no unrecognized uncertain income tax positions.
Refunds for Research and Development	Refunds for Research and Development Kiora, through its Kiora GmbH subsidiary, is entitled to receive certain refunds associated with its research and development expenses in Austria. These refunds are realized in the form of a cash payment in the year following the incurred research & development expenses. The Company records the refundable payment as a reduction in expense in the year in which the research and development expenses are incurred.
Concentration of Credit Risk and Off-Balance-Sheet Risk	Concentration of Credit Risk and Off-Balance-Sheet Risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash and cash equivalents. The Company invests cash in accredited financial institutions and cash equivalents in widely held money market funds. Consequently, such funds are subject to minimal credit risk. The Company has no significant off-balance-sheet risk such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.
Comprehensive Loss	Comprehensive Loss Comprehensive loss is defined as the change in stockholders’ equity during a period from transactions and other events and circumstances from non-owner sources. The foreign currency translation adjustments are the Company’s only component of other comprehensive loss.
Stock-Based Compensation	Stock-Based Compensation Stock-based compensation represents the cost related to stock-based awards granted to employees and others. The Company measures stock-based compensation cost to employees at grant date, based on the estimated fair value of the award, and recognizes the cost as expense on a straight-line basis over the employee requisite service period. The Company estimates the fair value of stock options using the Black-Scholes valuation model. The Company recognizes compensation expense for non-employee stock option grants at the fair value of the goods or services received or the equity instruments issued, whichever is more reliably measurable. The Company recorded compensation expense for non-employee awards with graded vesting using the accelerated expense attribution method. The Company’s policy is to record forfeitures as they occur.
Net Loss per Share - Basic and Diluted	Net Loss per Share – Basic and Diluted Basic and diluted net loss per share is computed by dividing net loss available to common shareholders by the weighted-average number of common shares outstanding for the period, which, for basic net loss per share, does not include the weighted-average unvested restricted common stock that has been issued but is subject to forfeiture of 41,216 shares for year ended December 31, 2021 and 77,262 shares for the year ended December 31, 2020. Dilutive common equivalent shares consist of stock options, warrants, and preferred stock and are calculated using the treasury stock method, which assumes the repurchase of common shares at the average market price during the period. Under the treasury stock method, options and warrants will have a dilutive effect when the average price of common stock during the period exceeds the exercise price of options or warrants. Common equivalent shares do not qualify as participating securities. In periods where the Company records a net loss including the years ended December 31, 2021 and 2020, unvested restricted common stock and potential common stock equivalents are not included in the calculation of diluted net loss per share as their effect would be anti-dilutive. All shares of Common Stock that may potentially be issued in the future are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2021 2020 Common Stock Warrants ​ 6,757,180 ​ 2,726,700 Employee Stock Options ​ 515,922 ​ 246,893 Preferred Stock ​ 2,089 ​ 865,500 Total Shares of Common Stock Issuable ​ 7,275,191 ​ 3,839,093
Related-Party Transactions	Related-Party Transactions During the year ended December 31, 2021, the Company entered into certain related-party transactions, making payments for services to one vendor and six consultants, all of whom also are stockholders of the Company. These transactions generally are ones that involve a stockholder or option holder of the Company to whom the Company also makes payments during the year, typically as a consultant or a service provider. Additionally, on January 6, 2021, the Company completed a private placement of 1,531,101 shares of Common Stock and warrants to purchase up to 1,531,101 shares of Common Stock to an affiliate of Armistice Capital, LLC, with a combined purchase price per share and warrant of $5.225. Steven J. Boyd and Keith Maher, each of whom were members of the Company’s board of directors through August 3, 2021, are affiliates of Armistice Capital, LLC, and Mr. Boyd held voting and investment power over such entity. The total net proceeds from the private placement were approximately $8.0 million. Lastly, on October 21, 2021, the Company acquired Bayon of which the Company’s CEO, Brian Strem, was a Co-Founder and Managing Director. Except for the private placement and Bayon acquisition as described previous, the transactions with related parties during the year ended December 31, 2021 are not material to the accompanying Consolidated Financial Statements. During the year ended December 31, 2020, the Company entered into certain related-party transactions, making payments for services to two vendors, seven consultants and two public universities, all of whom also are stockholders of the Company. The Company made payments related to manufacturing services to one vendor in the amount of approximately $502,000. Except for the manufacturing services as described previous, the transactions with related parties during the year ended December 31, 2020 are not material to the accompanying Consolidated Financial Statements.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Each period we revalue our contingent consideration obligations associated with business acquisitions to their fair value. The estimate of the fair value of contingent consideration is determined by applying probability of success, discount rate, and updated timing of the payment. The outstanding payments relate to obligation from acquisitions made by the Company. Below is the list of obligations for each relevant transaction are as of December 31, 2021 as follows: ​ ​ ​ ​ ​ ​ ​ Acquisition Milestone Achievement Condition Contingent Consideration Payable Bayon ​ ​ ​ ​ ​ ​ Successful completion of Phase 1b ​ $ 0.495 million ​ ​ Successful completion of Phase 2 ​ $ 0.990 million ​ ​ Successful completion of Phase 3 ​ $ 4.000 million ​ ​ FDA approval ​ $ 1.650 million ​ ​ ​ ​ ​ ​ Panoptes ​ ​ ​ ​ ​ Beginning of Phase 3 ​ $ 4.750 million ​ ​ FDA approval ​ $ 4.750 million ​ ​ ​ ​ ​ ​ Jade: ​ ​ ​ ​ ​ FDA approval ​ $ 2.164 million ​ Changes in the fair value of contingent consideration are included within “Operating Expenses” in our consolidated statements of operations and comprehensive loss. Below are the status of each transactions contingent consideration: Bayon: As of December 31, 2021, the Company had contingent consideration at fair value of $0.876 million as a result of the Bayon acquisition which closed on October 21, 2021. Panoptes: The Panoptes transaction closed December 18, 2020. As of December 31, 2020, the Company recorded contingent consideration of $2.067 million. During the year ended December 31, 2021, the Company recorded a decrease in estimated fair value of $0.474 million. The estimated fair value of contingent consideration as of December 31, 2021 was $1.593 million. Jade: As of December 31, 2020, the Company had a fair value of contingent consideration of $0.480 million. During the year ended December 31, 2021, the contingent consideration was increased by $0.100 million for a change in fair value. As of December 31, 2021, the Company had fair value of contingent consideration of $0.580 million. At December 31, 2021 and 2020, the Company had no other assets or liabilities that are subject to fair value methodology and estimation in accordance with U.S. GAAP.
Recent Accounting Pronouncements	Recent Accounting Pronouncements None noted.

Restatement of Financial Stat_2

Restatement of Financial Statements (Tables)	12 Months Ended
	Dec. 31, 2021
Restatement of Financial Statements
Summary of restatement on balance sheet, statement of operations and comprehensive loss, shareholders' equity, statement of cash flows	Balance sheet as of December 31, 2020 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, 2020 ​ ​ As Previously ​ ​ 2020 Restatement ​ ​ ​ Balance Sheet Reported ​ Adjustment As Restated Total Current Assets ​ $ 1,726,221 ​ ​ — ​ $ 1,726,221 Property and Equipment, Net ​ 30,566 ​ — ​ 30,566 Restricted cash ​ 45,000 ​ — ​ 45,000 Goodwill ​ 3,484,607 ​ $ 146,605 ​ 3,631,212 Intangible Assets and In-process R&D, Net ​ 9,730,164 ​ — ​ 9,730,164 Operating Leases Assets with Right-of-Use ​ 83,928 ​ — ​ 83,928 Other Assets ​ 57,073 ​ — ​ 57,073 Total assets $ 15,157,559 ​ 146,605 $ 15,304,164 Liabilities and stockholders’ equity ​ ​ ​ Total current liabilities $ 1,772,327 ​ 212,281 $ 1,984,608 Contingent Consideration ​ 5,342,950 ​ (2,795,876) ​ 2,547,074 Deferred Tax Liability ​ 728,926 ​ — ​ 728,926 Paycheck Protection Program Loan ​ 278,190 ​ — ​ 278,190 Non-current Operating Lease Liabilities ​ 35,625 ​ — ​ 35,625 Total Non-Current Liabilities ​ 6,385,691 ​ (2,795,876) ​ 3,589,815 Total liabilities ​ 8,158,018 ​ ​ (2,583,595) ​ 5,574,423 Stockholders’ equity ​ ​ ​ Preferred Stock, $0.01 par value ​ 41 ​ — ​ 41 Common Stock, $0.01 par value ​ 55,564 ​ — ​ 55,564 Additional paid-in-capital ​ 115,283,572 ​ 1,500,030 ​ 116,783,602 Accumulated deficit ​ (108,338,834) ​ 1,230,170 ​ (107,108,664) Accumulated Other Comprehensive Income ​ (802) ​ — ​ (802) Total stockholders’ equity ​ 6,999,541 ​ 2,730,200 ​ 9,729,741 Total liabilities and stockholders’ equity $ 15,157,559 ​ $ 146,605 $ 15,304,164 ​ Statement of Operations and Comprehensive Income for the year ended December 31, 2020 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the year ended December 31, 2020 ​ ​ As Previously ​ 2020 Restatement ​ ​ ​ Statement of Operations and Comprehensive Loss Reported Adjustment As restated Collaboration Revenue $ 12,059 ​ ​ — $ 12,059 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Research and Development ​ 3,566,045 ​ ​ — ​ 3,566,045 General and Administrative ​ 4,658,769 ​ ​ — ​ 4,658,769 Change in Fair Value of Contingent Consideration ​ — ​ $ (1,230,170) ​ (1,230,170) Gain on Disposal of Foreign Entity ​ — ​ ​ (113,717) ​ (113,717) Total Operating Expenses ​ 8,224,814 ​ (1,343,887) ​ 6,880,927 Operating Loss before Other Income ​ (8,212,755) ​ 1,343,887 ​ (6,868,868) Other Income, net: ​ ​ ​ Gain on Disposal of Foreign Entity ​ 113,717 ​ (113,717) ​ — Interest Income ​ 23,339 ​ — ​ 23,339 Interest Expense ​ (4,186) ​ — ​ (4,186) Total other (expense) income ​ 132,870 ​ (113,717) ​ 19,153 Loss before Income Tax Benefit (Expense) ​ (8,079,885) ​ 1,230,170 ​ (6,849,715) Income Tax Benefit (Expense) ​ (12,055) ​ — ​ (12,055) Net loss $ (8,091,940) $ 1,230,170 $ (6,861,770) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Average Shares Outstanding - Basic and Diluted ​ 4,576,058 ​ ​ 15,433 ​ 4,591,491 Basic and Diluted net loss per share ​ $ (1.77) ​ ​ ​ ​ $ (1.49) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Other comprehensive loss: ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss ​ ​ (8,091,940) ​ $ 1,230,170 ​ ​ (6,861,770) Dissolution of Foreign Entity ​ ​ (113,717) ​ ​ — ​ ​ (113,717) Foreign Currency Translate Adjustments ​ ​ (26,550) ​ ​ — ​ ​ (26,550) Comprehensive loss $ (8,232,207) ​ $ 1,230,170 $ (7,002,037) ​ Stockholders’ Equity as of December 31, 2020 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, 2020 ​ ​ ​ As Previously ​ 2020 Restatement ​ ​ ​ ​ Stockholders’ equity Reported Adjustment As restated ​ Preferred Stock, $0.01 par value $ 41 ​ — $ 41 ​ Common Stock, $0.01 par value ​ 55,564 ​ — ​ 55,564 ​ Additional paid-in-capital ​ 115,283,572 $ 1,500,030 ​ 116,783,602 ​ Accumulated deficit ​ (108,338,834) ​ 1,230,170 ​ (107,108,664) ​ Accumulated Other Comprehensive Income ​ (802) ​ — ​ (802) ​ Total stockholders’ equity $ 6,999,541 $ 2,730,200 $ 9,729,741 ​ ​ Statement of Cash flows for the year ended December 31, 2020 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the year ended December 31, 2020 ​ ​ As Previously ​ 2020 Restatement ​ ​ ​ Statement of Cash Flows Reported Adjustment As restated Operating Activities ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss $ (8,091,940) $ 1,230,170 $ (6,861,770) Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Depreciation and Amortization of Intangible Assets ​ 33,399 ​ — ​ 33,399 Reduction of Right-of-Use Assets ​ 166,822 ​ — ​ 166,822 Stock-Based Compensation ​ 723,856 ​ — ​ 723,856 Change in Fair Value of Contingent Consideration ​ — ​ (1,230,170) ​ (1,230,170) Expiration of a Prepaid Agreement ​ 159,848 ​ — ​ 159,848 Deferred Taxes ​ 12,055 ​ — ​ 12,055 Changes in Operating Assets and Liabilities, Net of Effects of Business Acquired: ​ ​ ​ ​ Prepaid Expenses and Other Current Assets ​ (146,971) ​ — ​ (146,971) Refundable Tax Credit Receivable ​ (18,957) ​ — ​ (18,957) Other Assets ​ 18,916 ​ — ​ 18,916 Accounts Payable ​ 136,697 ​ — ​ 136,697 Lease Liabilities ​ (166,822) ​ — ​ (166,822) Accrued Expenses ​ (144,072) ​ — ​ (144,072) Net cash used in operating activities ​ (7,317,169) ​ — ​ (7,317,169) Net cash used in investing activities ​ (244,438) ​ — ​ (244,438) Net cash provided by financing activities ​ 4,997,503 ​ — ​ 4,997,503 Effects of Exchange Rate Changes on Cash ​ (26,931) ​ — ​ (26,931) Net Cash Increase or decrease ​ (2,591,035) ​ — ​ (2,591,035) Cash, Including Restricted Cash, Beginning of Year ​ 3,821,712 ​ — ​ 3,821,712 Cash, Including Restricted Cash, End of Year $ 1,230,677 ​ — $ 1,230,677 ​ Balance Sheet as of December 31, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, 2021 ​ ​ As Previously ​ 2020 Restatement ​ 2021 Restatement ​ ​ ​ Balance Sheet Reported Adjustment Adjustment As Restated Total Current Assets $ 8,990,770 ​ — ​ — $ 8,990,770 ​ Property and Equipment, Net ​ 73,999 ​ — ​ — ​ 73,999 ​ Restricted cash ​ 45,000 ​ — ​ — ​ 45,000 ​ Goodwill ​ — $ 146,605 $ (146,605) ​ — ​ Intangible Assets and In-process R&D, Net ​ 8,695,850 ​ — ​ 2,072,314 ​ 10,768,164 ​ Operating Leases Assets with Right-of-Use ​ 209,411 ​ — ​ — ​ 209,411 ​ Other Assets ​ 42,964 ​ — ​ — ​ 42,964 ​ Total assets $ 18,057,994 $ 146,605 $ 1,925,709 $ 20,130,308 ​ Liabilities and stockholders’ equity ​ ​ ​ ​ ​ Total current liabilities ​ 1,609,608 ​ — ​ — ​ 1,609,608 ​ Contingent Consideration ​ 6,518,770 ​ (2,583,595) ​ (886,220) ​ 3,048,955 ​ Deferred Tax Liability ​ 614,436 ​ — ​ 187,695 ​ 802,131 ​ Non-current Operating Lease Liabilities ​ 90,566 ​ — ​ — ​ 90,566 ​ Total Non-Current Liabilities ​ 7,223,772 ​ (2,795,876) ​ (698,525) ​ 3,941,652 ​ Total liabilities ​ 8,833,380 ​ (2,583,595) ​ (698,525) ​ 5,551,260 ​ Stockholders’ equity ​ ​ ​ ​ ​ Preferred Stock, $0.01 par value ​ — ​ — ​ — ​ — ​ Common Stock, $0.01 par value ​ 126,640 ​ — ​ — ​ 126,640 ​ Additional paid-in-capital ​ 133,918,158 ​ 1,500,030 ​ — ​ 135,418,188 ​ Accumulated deficit ​ (124,733,753) ​ 1,230,170 ​ 2,624,234 ​ (120,879,349) ​ Accumulated Other Comprehensive Income ​ (86,431) ​ — ​ — ​ (86,431) ​ Total stockholders’ equity ​ 9,224,614 ​ 2,730,200 ​ 2,624,234 ​ 14,579,048 ​ Total liabilities and stockholders’ equity $ 18,057,994 $ 146,605 $ 1,925,709 $ 20,130,308 ​ ​ Statement of Operations and Comprehensive Loss for the year ended December 31, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the year ended December 31, 2021 ​ ​ As Previously ​ 2021 Restatement ​ ​ ​ Statement of Operations and Comprehensive Loss Reported Adjustment As restated Research and Development $ 5,350,264 ​ — $ 5,350,264 General and Administrative ​ 5,323,649 ​ — ​ 5,323,649 Goodwill Impairment ​ 4,498,234 $ (460,423) ​ 4,037,811 Intangible Asset Impairment ​ 1,770,314 ​ (1,770,314) ​ — Change in Fair Value of Contingent Consideration ​ ​ — ​ ​ (475,956) ​ ​ (475,956) Total Operating Expenses ​ 16,942,461 ​ (2,706,693) ​ 14,235,768 Operating Loss before Other Income ​ (16,942,461) ​ 2,706,693 ​ (14,235,768) Other income, net: ​ ​ ​ Gain on Forgiveness of Loan ​ 278,190 ​ — ​ 278,190 Change in Fair Value of Contingent Consideration ​ (29,719) ​ 29,719 ​ — Interest Expense ​ ​ (6,851) ​ ​ — ​ ​ (6,851) Interest Income ​ 1,141 ​ — ​ 1,141 Total other income ​ 242,761 ​ 29,719 ​ 272,480 Loss before Income Tax Benefit (Expense) ​ (16,699,700) ​ 2,736,412 ​ (13,963,288) Income Tax Benefit (Expense) ​ 304,781 ​ (112,178) ​ 192,603 Net loss $ (16,394,919) $ 2,624,234 $ (13,770,685) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Average Shares Outstanding - Basic and Diluted ​ 9,240,500 ​ 403,461 ​ 9,643,961 Basic and Diluted net loss per share $ (1.77) ​ — $ (1.43) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Other comprehensive loss: ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss ​ ​ (16,394,919) ​ $ 2,624,234 ​ ​ (13,770,685) Foreign Currency Translate Adjustments ​ ​ (85,629) ​ ​ — ​ ​ (85,629) Comprehensive loss ​ $ (16,480,548) ​ $ 2,624,234 ​ $ (13,856,314) ​ Stockholders’ Equity as of December 31, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, 2021 ​ ​ ​ ​ ​ 2020 ​ 2021 ​ ​ ​ ​ ​ As Previously ​ Restatement ​ Restatement ​ ​ ​ Stockholders’ equity Reported Adjustment Adjustment As restated Preferred Stock, $0.01 par value ​ — ​ — ​ — ​ — Common Stock, $0.01 par value $ 126,640 ​ — ​ — $ 126,640 Additional paid-in-capital ​ 133,918,158 $ 1,500,030 ​ — ​ 135,418,188 Accumulated deficit ​ (124,733,753) ​ 1,230,170 $ 2,624,234 ​ (120,879,349) Accumulated Other Comprehensive Income ​ (86,431) ​ — ​ — ​ (86,431) Total stockholders’ equity $ 9,224,614 $ 2,730,200 $ 2,624,234 $ 14,579,048 ​ Statement of Cash Flows for the year ended December 31, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the year ended December 31, 2021 ​ ​ As Previously ​ 2021 Restatement ​ ​ ​ Statement of Cash Flows Reported Adjustment As restated Operating Activities ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss $ (16,394,919) $ 2,624,234 $ (13,770,685) Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Depreciation and Amortization of Intangible Assets ​ 45,296 ​ — ​ 45,296 Reduction of Right-of-Use Assets ​ 181,977 ​ — ​ 181,977 Stock-Based Compensation ​ 842,475 ​ — ​ 842,475 Contingent Consideration ​ (212,281) ​ (293,394) ​ (505,675) Deferred Taxes ​ (304,782) ​ 112,179 ​ (192,603) Paycheck Protection Program Loan Forgiveness ​ (278,190) ​ — ​ (278,190) Goodwill Impairment Loss ​ 4,498,234 ​ (460,423) ​ 4,037,811 Intangible Asset Impairment Loss ​ 1,770,314 ​ (1,770,314) ​ — Changes in Operating Assets and Liabilities, Net of Effects of Business Acquired: ​ ​ ​ ​ Prepaid Expenses and Other Current Assets ​ (156,951) ​ — ​ (156,951) Refundable Tax Credit Receivable ​ (441,196) ​ — ​ (441,196) Other Assets ​ 14,111 ​ — ​ 14,111 Accounts Payable ​ (310,665) ​ — ​ (310,665) Lease Liabilities ​ (181,977) ​ — ​ (181,977) Accrued Expenses ​ 40,882 ​ — ​ 40,882 Net cash used in operating activities ​ (10,887,672) ​ 212,282 ​ (10,675,390) Net cash used in investing activities ​ (157,020) ​ — ​ (157,020) Financing Activities ​ ​ ​ ​ ​ ​ ​ ​ ​ Proceeds stock offerings ​ ​ 18,750,016 ​ ​ — ​ ​ 18,750,016 Stock Issuance costs ​ ​ (1,004,809) ​ ​ — ​ ​ (1,004,809) Exercise Warrants ​ ​ 50,001 ​ ​ — ​ ​ 50,001 Repayment of Loan Payable ​ ​ — ​ ​ (212,282) ​ ​ (212,282) Net cash provided by financing activities ​ 17,795,208 ​ (212,282) ​ 17,582,926 Effects of Exchange Rate Changes on Cash ​ (81,503) ​ — ​ (81,503) Net Cash Increase or decrease ​ 6,669,013 ​ — ​ 6,669,013 Cash, Including Restricted Cash, Beginning of Year ​ 1,230,677 ​ — ​ 1,230,677 Cash, Including Restricted Cash, End of Year $ 7,899,690 ​ — $ 7,899,690

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2021
Summary of Significant Accounting Policies
Schedule of unvested restricted common stock and potential common stock equivalents are not included in the calculation of diluted net loss per share	​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2021 2020 Common Stock Warrants ​ 6,757,180 ​ 2,726,700 Employee Stock Options ​ 515,922 ​ 246,893 Preferred Stock ​ 2,089 ​ 865,500 Total Shares of Common Stock Issuable ​ 7,275,191 ​ 3,839,093
Schedule of Business Acquisitions by Acquisition, Contingent Consideration	​ ​ ​ ​ ​ ​ ​ Acquisition Milestone Achievement Condition Contingent Consideration Payable Bayon ​ ​ ​ ​ ​ ​ Successful completion of Phase 1b ​ $ 0.495 million ​ ​ Successful completion of Phase 2 ​ $ 0.990 million ​ ​ Successful completion of Phase 3 ​ $ 4.000 million ​ ​ FDA approval ​ $ 1.650 million ​ ​ ​ ​ ​ ​ Panoptes ​ ​ ​ ​ ​ Beginning of Phase 3 ​ $ 4.750 million ​ ​ FDA approval ​ $ 4.750 million ​ ​ ​ ​ ​ ​ Jade: ​ ​ ​ ​ ​ FDA approval ​ $ 2.164 million

Fair Value (Tables)

Fair Value (Tables)	12 Months Ended
	Dec. 31, 2021
Fair Value
Schedule of fair value on a recurring basis using level 3 inputs	​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2021 December 31, 2020 Contingent Consideration: ​ ​ ​ ​ ​ ​ Current ​ — ​ — Noncurrent ​ 3,048,955 ​ 2,547,074 Total Contingent Consideration ​ $ 3,048,955 ​ $ 2,547,074
Schedule of fair value unobservable level 3 inputs	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Valuation Technique Unobservable Inputs 2021 Range 2020 Range ​ Discounted cash flow Payment discount rate ​ 13.1 % 12.6 % Bayon ​ ​ Payment period ​ 2023 - 2028 — ​ Panoptes ​ ​ Payment period ​ 2024 - 2028 2023 - 2025 ​ Jade ​ ​ ​ Payment period ​ 2026 ​ 2026 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Bayon ​ ​ ​ Probability of Success for payment ​ 12% - 72% ​ — ​ Panoptes ​ ​ ​ Probability of Success for payment ​ 17% - 36% ​ 20% - 45% ​ Jade ​ ​ Probability of Success for payment ​ 47 % 45 %

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2021
Property and Equipment
Schedule of property and equipment	Property and equipment at December 31, 2021 and 2020 consists of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Estimated Useful ​ ​ ​ ​ ​ ​ Life ​ ​ ​ ​ ​ ​ ​ (Years) 2021 2020 Laboratory Equipment 3 ​ $ 88,399 ​ $ 82,653 Office Equipment ​ 3 ​ ​ 3,614 ​ ​ 3,888 Office Furniture 5 ​ 72,549 ​ 14,430 Leasehold Improvements 2 ​ 22,569 ​ 22,569 Total Property and Equipment, Gross ​ 187,131 ​ 123,540 Less Accumulated Depreciation ​ 113,132 ​ 92,974 Total Property and Equipment, Net ​ $ 73,999 ​ $ 30,566

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2021
Accrued Expenses
Schedule of accrued expenses	​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2021 2020 Payroll and Benefits ​ $ 937,970 ​ $ 629,465 Professional Fees ​ 194,425 ​ 328,420 Clinical Trials ​ 168,785 ​ 203,646 Other ​ 28,961 ​ 127,730 Total Accrued Expenses ​ $ 1,330,141 ​ $ 1,289,261

Intangible Assets and In-Proc_2

Intangible Assets and In-Process R&D (Tables)	12 Months Ended
	Dec. 31, 2021
Intangible Assets and In-Process R&D
Schedule of intangible assets and in-process R&D	Intangible assets and in-process R&D at December 31, 2021 and 2020 consists of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Estimated Useful ​ ​ ​ ​ ​ Life (Years) 2021 2020 Trade Secrets 10 ​ $ 250,000 ​ $ 250,000 Less: Accumulated Amortization ​ (81,250) ​ (56,250) Intangible Assets, Net ​ 168,750 ​ 193,750 In-Process R&D ​ 10,599,414 ​ 9,536,414 Total Intangible Assets and In-Process R&D, Net ​ $ 10,768,164 ​ $ 9,730,164 ​

Warrants (Tables)

Warrants (Tables)	12 Months Ended
	Dec. 31, 2021
Warrants
Schedule of warrant activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ Weighted ​ ​ ​ ​ Average ​ Average ​ ​ Number of ​ Exercise ​ Remaining ​ Awards Price Term in Years ​ ​ ​ ​ ​ ​ ​ ​ Outstanding at December 31, 2019 2,875,006 ​ $ 14.14 ​ 3.37 Issued 25,000 ​ 12.50 ​ 4.01 Exercised (45,417) ​ 4.80 ​ 2.29 Expired ​ (127,889) ​ ​ 139.28 ​ — Outstanding at December 31, 2020 2,726,700 ​ $ 8.41 ​ 2.45 Issued 4,098,965 ​ 3.39 ​ 4.68 Exercised (10,417) ​ 4.80 ​ 1.29 Expired ​ (58,068) ​ ​ 52.50 ​ — Outstanding at December 31, 2021 6,757,180 ​ $ 4.99 ​ 3.42 ​

Equity Incentive Plan (Tables)

Equity Incentive Plan (Tables)	12 Months Ended
	Dec. 31, 2021
Equity Incentive Plan
Schedule of stock option activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted-Average ​ ​ Number of ​ Weighted-Average ​ Contractual Life ​ Options Exercise Price (In Years) Outstanding at December 31, 2019 ​ 174,175 ​ $ 27.42 6.22 Granted 93,165 ​ 6.31 ​ Expired (17,114) ​ 10.59 Forfeited (3,333) ​ 7.20 Outstanding at December 31, 2020 246,893 ​ $ 20.90 7.20 Exercisable at December 31, 2020 ​ 142,061 ​ $ 31.58 ​ 5.85 Vested and Expected to Vest at December 31, 2020 ​ 246,893 ​ $ 20.90 ​ 7.20 Granted 345,865 ​ 4.11 ​ Expired (32,544) ​ 25.86 ​ Forfeited (44,292) ​ 6.49 ​ Outstanding at December 31, 2021 515,922 ​ $ 10.43 8.30 Exercisable at December 31, 2021 201,653 ​ $ 22.00 6.37 Vested and Expected to Vest at December 31, 2021 515,922 ​ $ 10.43 8.30
Schedule of weighted average assumptions	​ ​ ​ ​ ​ ​ ​ ​ 2021 2020 Risk-Free Interest Rate 1.82 % 1.82 % Expected Life 10.0 years 10.0 years ​ Expected Average Volatility 140 % 153 % Expected Dividend Yield 0 % 0 %
Schedule of restricted stock activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted-Average ​ ​ Number of ​ Weighted-Average ​ Remaining ​ Shares Grant Date Fair Value Recognition Period Non-vested Outstanding at December 31, 2019 ​ 50,187 ​ $ 8.64 ​ 1.49 Awarded 49,000 ​ 6.55 Vested ​ (31,767) ​ ​ 8.69 ​ ​ Non-vested Outstanding at December 31, 2020 67,420 ​ $ 7.10 1.66 Vested (46,437) ​ 7.33 Forfeited (5,971) ​ 6.66 Non-vested Outstanding at December 31, 2021 15,012 ​ $ 6.55 1.09
Schedule of stock-based compensation expense	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2021 2020 ​ ​ ​ ​ ​ ​ ​ Research and Development ​ $ 246,386 ​ $ 197,806 General and Administrative ​ ​ 596,089 ​ ​ 526,050 Total Stock-Based Compensation Expense ​ $ 842,475 ​ $ 723,856

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Taxes
Schedule of components of loss before income taxes	​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2021 2020 Domestic ​ $ (10,639,818) ​ $ (6,766,157) Foreign ​ (3,323,470) ​ (83,558) Total Loss Before Income Taxes ​ $ (13,963,288) ​ $ (6,849,715)
Schedule of components of income tax expense	​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2021 2020 Deferred Taxes: ​ ​ ​ Federal ​ $ (24,086) ​ $ (529) State ​ (168,517) ​ 12,584 Total Deferred Taxes ​ $ (192,603) ​ $ 12,055 Income Tax (Benefit) Expense ​ $ (192,603) ​ $ 12,055
Schedule of effective income tax rate reconciliation	​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2021 2020 United States Federal Income Tax Rate ​ 21.00 % 21.00 % State Taxes, Net of Federal Benefit ​ 3.35 (1.59) ​ Permanent Differences ​ 0.72 (15.00) ​ Goodwill Impairment ​ (6.07) ​ — ​ Change in Valuation Allowance ​ (21.33) 17.53 ​ Research and Development Credits ​ 1.09 1.65 ​ Tax Rate Differential ​ 1.00 (2.12) ​ State Non-Income Based Tax ​ 0.01 ​ 0.01 ​ Stock-Based Compensation ​ — ​ (1.32) ​ Gain on Dissolution of Foreign Subsidiary ​ — (15.81) ​ Other ​ 1.61 (4.50) ​ Effective Tax Rate Expense ​ 1.38 % (0.15) %
Schedule of deferred tax assets and liabilities	​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2021 2020 Net Deferred Tax Liability: ​ ​ ​ ​ ​ ​ Net Operating Loss Carryforwards ​ $ 20,689,134 ​ $ 17,042,422 Research and Development Credit Carryforwards ​ 2,853,598 ​ 2,695,773 Capitalized Research and Development ​ 5,640,428 ​ 6,251,945 Stock-Based Compensation ​ ​ 835,432 ​ ​ 781,252 Cash Versus Accrual Adjustments ​ 128,188 ​ 223,674 Total Deferred Tax Assets ​ 30,146,780 ​ 26,995,066 Valuation Allowance ​ (28,298,339) ​ (25,320,159) Net Deferred Tax Asset ​ 1,848,441 ​ 1,674,907 Depreciation and Amortization ​ ​ (956) ​ ​ (1,083) In-Process Research and Development ​ (2,649,616) ​ (2,402,750) Net Deferred Tax Liability ​ $ (802,131) ​ $ (728,926)

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies
Schedule of maturities of lease Liabilities	Maturities of lease liabilities were as follows as of December 31, 2021: ​ ​ ​ ​ ​ ​ Operating Leases 2022 $ 133,339 2023 ​ ​ 95,086 Less: Imputed Interest ​ (19,014) Lease Liabilities ​ $ 209,411

Acquisitions (Tables)

Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2021
Acquisitions
Summary of preliminary purchase price allocation and estimated fair value	​ ​ ​ ​ ​ Bayon Current Assets (1) ​ $ 5,290 In-Process R&D ​ 1,063,000 Goodwill ​ 406,599 Accounts Payable ​ (36,525) Deferred Tax Liability ​ (265,808) Total Consideration ​ $ 1,172,556 (1) Current Assets include cash and receivables of $3,910 and $1,380, respectively. ​ ​ ​ ​ ​ ​ Panoptes Current Assets ​ $ 410,863 In-Process R&D ​ 5,624,100 Goodwill ​ 2,105,316 Property, Plant and Equipment ​ 2,042 Accounts Payable and Other Liabilities ​ (87,777) Deferred Tax Liability ​ ​ (351,507) Assumed Liabilities ​ (312,852) Total Consideration ​ $ 7,390,185 (1) Current Assets include cash, receivables, and prepaid expenses of $333,860, $73,368, and $3,635, respectively.
Summary of business acquisition fair value consideration	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Common ​ ​ ​ ​ ​ ​ Shares ​ Price per Share (a) ​ Amount Contingent consideration at fair value ​ — ​ — ​ $ 1,007,556 Cash Consideration — ​ — ​ 97,066 Kiora Common Stock 33,798 ​ $ 2.01 ​ 67,934 Total Fair Value of Consideration ​ ​ ​ ​ $ 1,172,556 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Common ​ ​ ​ ​ ​ ​ Shares ​ Price per Share (a) ​ Amount Contingent consideration at fair value ​ — ​ — ​ $ 2,279,525 Cash Consideration — ​ — ​ 441,552 Holdback shares 424,685 ​ $ 3.5321 ​ 1,500,030 Kiora Common Stock 897,222 ​ $ 3.5321 ​ 3,169,078 Total Fair Value of Consideration ​ ​ ​ ​ $ 7,390,185
Schedule of Proforma disclosure for Panoptes acquisition	The following table includes the pro forma results for Bayon the year ended December 31, 2021 of the combined companies as though the Bayon Acquisition had been completed as of January 1, 2020. ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended ​ Year Ended ​ ​ December 31, 2021 ​ December 31, 2020 ​ (unaudited) (unaudited) Operating Expenses ​ $ 14,257,347 ​ $ 7,082,768 Net Loss ​ $ (13,792,265) ​ $ (6,873,698) ​ The following table includes the pro forma results for Panoptes the year ended December 31, 2020 of the combined companies as though the Panoptes Acquisition had been completed as of the beginning of the period presented. ​ ​ ​ ​ ​ ​ ​ Year Ended ​ ​ December 31, 2020 ​ (unaudited) Revenues ​ $ 558,063 Operating Expenses ​ $ 8,498,798 Net Loss ​ $ (7,942,031) ​

Quarterly Financial Informati_2

Quarterly Financial Information (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2021
Quarterly Financial Information (Unaudited)
Schedule of quarterly financial information	Balance Sheet as of March 31, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of March 31, 2021 ​ ​ As Previously ​ 2020 ​ ​ 2021 ​ ​ ​ Balance Sheet Reported ​ restatements ​ restatements ​ As Restated Total Current Assets ​ $ 6,991,086 ​ ​ — ​ ​ — ​ $ 6,991,086 Property and Equipment, Net ​ 84,264 ​ — ​ — ​ 84,264 Restricted Cash ​ 45,000 ​ — ​ — ​ 45,000 Goodwill ​ 3,484,607 ​ $ 146,605 ​ — ​ 3,631,212 Intangible Assets and In-process R&D, Net ​ 9,723,914 ​ — ​ — ​ 9,723,914 Operating Leases Assets with Right-of-Use ​ 242,730 ​ — ​ — ​ 242,730 Other Assets ​ 49,001 ​ — ​ — ​ 49,001 Total assets ​ $ 20,620,602 ​ $ 146,605 ​ — ​ $ 20,767,207 Liabilities and stockholders’ equity ​ ​ ​ ​ Total current liabilities ​ $ 1,425,598 ​ 212,281 ​ ​ $ 1,637,879 Contingent Consideration ​ 5,342,950 ​ (2,795,876) ​ $ (570,203) ​ 1,976,871 Deferred Tax Liability ​ 728,926 ​ — ​ — ​ 728,926 Paycheck Protection Program Loan ​ 278,190 ​ — ​ — ​ 278,190 Non-current Operating Lease Liabilities ​ 159,938 ​ — ​ — ​ 159,938 Total liabilities ​ 7,935,602 ​ (2,583,595) ​ (570,203) ​ 4,781,804 Stockholders’ equity ​ ​ ​ ​ Preferred Stock, $0.01 par value ​ 41 ​ — ​ — ​ 41 Common Stock, $0.01 par value ​ 70,979 ​ — ​ — ​ 70,979 Additional paid-in-capital ​ 123,523,964 ​ 1,500,030 ​ — ​ 125,023,994 Accumulated deficit ​ (110,919,655) ​ 1,230,170 ​ 570,203 ​ (109,119,282) Accumulated Other Comprehensive Income ​ 9,671 ​ — ​ — ​ 9,671 Total stockholders’ equity ​ 12,685,000 ​ 2,730,200 ​ 570,203 ​ 15,985,403 Total liabilities and stockholders’ equity ​ $ 20,620,602 ​ $ 146,605 ​ — ​ $ 20,767,207 ​ Statement of Operations and Comprehensive Loss for the 3 months ended March 31, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the 3 months ended March 31, 2021 ​ ​ As Previously ​ 2021 ​ ​ Statement of Operations and Comprehensive Loss ​ Reported ​ restatements ​ As restated Research and Development ​ $ 1,280,242 ​ — ​ $ 1,280,242 General and Administrative ​ 1,300,143 ​ — ​ 1,300,143 Change in Fair Value of Contingent Consideration ​ — ​ $ (570,203) ​ (570,203) Total Operating Expenses ​ 2,580,385 ​ (570,203) ​ 2,010,182 Operating Loss before Other Income ​ (2,580,385) ​ 570,203 ​ (2,010,182) Interest Income ​ ​ 250 ​ ​ — ​ ​ 250 Interest Expense ​ (686) ​ — ​ (686) Total other (expense) income ​ (436) ​ — ​ (436) Loss before Income Tax Benefit (Expense) ​ ​ (2,580,821) ​ ​ 570,203 ​ ​ (2,010,618) Income Tax Benefit (Expense) ​ ​ — ​ ​ — ​ ​ — Net loss ​ $ (2,580,821) ​ $ 570,203 ​ $ (2,010,618) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Average Shares Outstanding - Basic and Diluted ​ 6,954,438 ​ 403,461 ​ 7,357,899 Basic and Diluted net loss ​ $ (0.37) ​ ​ $ (0.27) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Other comprehensive loss: ​ ​ ​ ​ ​ ​ ​ ​ ​ Net Loss ​ $ (2,580,821) ​ $ 570,203 ​ $ (2,010,618) Foreign Currency Translation Adjustments ​ ​ 10,473 ​ ​ — ​ ​ 10,473 Comprehensive Loss ​ $ (2,570,348) ​ $ 570,203 ​ $ (2,000,145) ​ Stockholders’ Equity as of March 31, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of March 31, 2021 ​ ​ As Previously ​ 2020 ​ 2021 ​ ​ ​ Stockholders’ equity Reported restatements restatements As restated Preferred Stock, $0.01 par value ​ $ 41 ​ — ​ — ​ $ 41 Common Stock, $0.01 par value ​ 70,979 ​ — ​ — ​ 70,979 Additional paid-in-capital ​ 123,523,964 ​ $ 1,500,030 ​ — ​ 125,023,994 Accumulated deficit ​ (110,919,655) ​ 1,230,170 ​ $ 570,203 ​ (109,119,282) Accumulated Other Comprehensive Income ​ 9,671 ​ — ​ — ​ 9,671 Total stockholders’ equity ​ $ 12,685,000 ​ $ 2,730,200 ​ $ 570,203 ​ $ 15,985,403 ​ Statement of Cash Flows for the 3 months ended March 31, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of March 31, 2021 ​ ​ 2021 ​ ​ ​ As Previously ​ Restatement ​ ​ Statement of Cash Flows ​ Reported ​ Adjustment ​ As restated Operating Activities ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss ​ $ (2,580,821) ​ $ 570,203 ​ $ (2,010,618) Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Depreciation and Amortization of Intangible Assets ​ 10,599 ​ — ​ 10,599 Reduction of Right-of-Use Assets ​ 39,490 ​ — ​ 39,490 Stock-Based Compensation ​ 216,945 ​ — ​ 216,945 Change in Fair Value of Contingent Consideration ​ — ​ (570,203) ​ (570,203) Deferred Taxes ​ — ​ — ​ — Paycheck Protection Program Loan Forgiveness ​ — ​ — ​ — Goodwill Impairment Loss ​ — ​ — ​ — Intangible Asset Impairment Loss ​ — ​ — ​ — Changes in Operating Assets and Liabilities, Net of Effects of Business Acquired: ​ — ​ — ​ Prepaid Expenses and Other Current Assets ​ 216,078 ​ — ​ 216,078 Refundable Tax Credit Receivable ​ (59,706) ​ — ​ (59,706) Other Assets ​ 8,073 ​ — ​ 8,073 Accounts Payable ​ 22,583 ​ — ​ 22,583 Lease Liabilities ​ (39,490) ​ — ​ (39,490) Accrued Expenses ​ (403,802) ​ — ​ (403,802) Net cash used in operating activities ​ (2,570,051) ​ — ​ (2,570,051) Net cash used in investing activities ​ (58,119) ​ — ​ (58,119) Financing Activities ​ ​ ​ ​ ​ ​ ​ ​ ​ Proceeds from stock offerings ​ 7,988,861 ​ — ​ 7,988,861 Stock issuance costs ​ — ​ — ​ — Exercise warrants ​ 50,001 ​ — ​ 50,001 Repayment of Loan Payable ​ — ​ — ​ — Net cash provided by financing activities ​ 8,038,862 ​ — ​ 8,038,862 Effects of Exchange Rate Changes on Cash ​ 14,123 ​ — ​ 14,123 Net Cash Increase or decrease ​ 5,424,815 ​ — ​ 5,424,815 Cash, Including Restricted Cash, Beginning of Year ​ 1,230,677 ​ ​ ​ 1,230,677 Cash, Including Restricted Cash, End of Year ​ $ 6,655,492 ​ — ​ $ 6,655,492 ​ Balance Sheet as of June 30, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of June 30, 2021 ​ ​ As Previously ​ 2020 ​ ​ 2021 ​ ​ ​ Balance Sheet Reported restatements ​ restatements As Restated Total Current Assets ​ $ 4,415,173 ​ — ​ — ​ $ 4,415,173 Property and Equipment, Net ​ 83,682 ​ — ​ — ​ 83,682 Restricted cash ​ 45,000 ​ — ​ — ​ 45,000 Goodwill ​ 3,484,607 ​ $ 146,605 ​ — ​ 3,631,212 Intangible Assets and In-process R&D, Net ​ 9,717,664 ​ — ​ — ​ 9,717,664 Operating Leases Assets with Right-of-Use ​ 308,013 ​ — ​ — ​ 308,013 Other Assets ​ 45,921 ​ — ​ — ​ 45,921 Total assets ​ $ 18,100,060 ​ $ 146,605 ​ — ​ $ 18,246,665 Liabilities and stockholders’ equity ​ ​ ​ ​ Total current liabilities ​ $ 1,436,440 ​ 212,281 ​ — ​ $ 1,648,721 Contingent Consideration ​ 5,342,950 ​ (2,795,876) ​ $ (496,486) ​ 2,050,588 Deferred Tax Liability ​ 728,926 ​ — ​ — ​ 728,926 Non-current Operating Lease Liabilities ​ 137,957 ​ — ​ — ​ 137,957 Total liabilities ​ 7,646,273 ​ (2,583,595) ​ (496,486) ​ 4,566,192 Stockholders’ equity ​ ​ ​ ​ Preferred Stock, $0.01 par value ​ 41 ​ — ​ — ​ 41 Common Stock, $0.01 par value ​ 70,979 ​ — ​ — ​ 70,979 Additional paid-in-capital ​ 123,786,856 ​ 1,500,030 ​ — ​ 125,286,886 Accumulated deficit ​ (113,388,953) ​ 1,230,170 ​ 496,486 ​ (111,662,297) Accumulated Other Comprehensive Income ​ (15,136) ​ — ​ — ​ (15,136) Total stockholders’ equity ​ 10,453,787 ​ 2,730,200 ​ 496,486 ​ 13,680,473 Total liabilities and stockholders’ equity ​ $ 18,100,060 ​ $ 146,605 ​ — ​ $ 18,246,665 ​ Statement of Operations and Comprehensive Loss for the 3 months ended June 30, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the 3 months ended June 30, 2021 ​ ​ As Previously ​ 2021 ​ ​ ​ Statement of Operations and Comprehensive Loss Reported Restatement As restated Research and Development ​ $ 1,439,922 ​ — ​ $ 1,439,922 General and Administrative ​ 1,305,865 ​ — ​ 1,305,865 Change in Fair Value of Contingent Consideration Expense ​ — ​ $ 73,717 ​ 73,717 Total Operating Expenses ​ 2,745,787 ​ 73,717 ​ 2,819,504 Operating Loss before Other Income ​ (2,745,787) ​ (73,717) ​ (2,819,504) Other (expense) income: ​ ​ ​ Gain on Forgiveness of Loan ​ 278,190 ​ — ​ 278,190 Interest Income ​ 332 ​ — ​ 332 Interest Expense ​ (2,033) ​ — ​ (2,033) Total other (expense) income ​ 276,489 ​ ​ 276,489 Loss before Income Tax Benefit (Expense) ​ ​ (2,469,298) ​ ​ (73,717) ​ ​ (2,543,015) Income Tax Benefit (Expense) ​ ​ — ​ ​ — ​ ​ — Net Loss ​ $ (2,469,298) ​ $ (73,717) ​ $ (2,543,015) Weighted Average Shares Outstanding - Basic and Diluted ​ 7,062,750 ​ 403,461 ​ 7,466,211 Basic and Diluted net loss ​ $ (0.35) ​ ​ $ (0.34) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Other comprehensive loss: ​ ​ ​ ​ ​ ​ ​ ​ ​ Net Loss ​ $ (2,469,298) ​ $ (73,317) ​ $ (2,543,015) Foreign Currency Translation Adjustments ​ ​ (24,807) ​ ​ — ​ ​ (24,807) Comprehensive Loss ​ $ (2,494,105) ​ $ (73,317) ​ $ (2,567,822) ​ Statement of Operations and Comprehensive Loss for the 6 months ended June 30, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the 6 months ended June 30, 2021 ​ As ​ ​ ​ ​ Previously ​ 2021 ​ ​ Statement of Operations and Comprehensive Loss ​ Reported ​ restatements ​ As restated Research and Development ​ $ 2,720,164 ​ ​ — $ 2,720,164 General and Administrative ​ 2,606,008 ​ — ​ 2,606,008 Change in Fair Value of Contingent Consideration ​ — ​ $ (496,486) ​ (496,486) Total Operating Expenses ​ 5,326,172 ​ (496,486) ​ 4,829,686 Operating Loss before Other Income ​ (5,326,172) ​ 496,486 ​ (4,829,686) Other (expense) income: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Gain on Forgiveness of Loan ​ 278,190 ​ — ​ 278,190 Interest Income ​ 582 ​ — ​ 582 Interest Expense ​ (2,719) ​ — ​ (2,719) Total other (expense) income ​ 276,053 ​ — ​ 276,053 Loss before Income Tax Benefit (Expense) ​ ​ (5,050,119) ​ ​ 496,486 ​ ​ (4,553,633) Income Tax Benefit (Expense) ​ ​ — ​ ​ — ​ ​ — Net Loss ​ $ (5,050,119) ​ $ 496,486 ​ $ (4,553,633) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Average Shares Outstanding - Basic and Diluted ​ 7,005,902 ​ ​ 403,461 ​ 7,409,363 Basic and Diluted net loss ​ $ (0.72) ​ ​ ​ ​ $ (0.61) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Other comprehensive loss: ​ ​ ​ ​ ​ ​ ​ ​ ​ Net Loss ​ $ (5,050,119) ​ $ 496,486 ​ $ (4,553,633) Foreign Currency Translation Adjustments ​ (14,334) ​ — ​ (14,334) Comprehensive Loss ​ $ (5,064,453) ​ $ 496,486 ​ $ (4,567,967) ​ Stockholders’ Equity as of June 30, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of June 30, 2021 ​ ​ As Previously ​ 2020 ​ 2021 ​ ​ ​ Stockholders’ equity Reported restatements restatements As restated Preferred Stock, $0.01 par value ​ $ 41 ​ — ​ — ​ $ 41 Common Stock, $0.01 par value ​ 70,979 ​ — ​ — ​ 70,979 Additional paid-in-capital ​ 123,786,856 ​ $ 1,500,030 ​ — ​ 125,286,886 Accumulated deficit ​ (113,388,953) ​ 1,230,170 ​ $ 496,486 ​ (111,662,297) Accumulated Other Comprehensive Income ​ (15,136) ​ — ​ — ​ (15,136) Total stockholders’ equity ​ $ 10,453,787 ​ $ 2,730,200 ​ $ 496,486 ​ $ 13,680,473 ​ Statement of Cash Flows for the 6 months ended June 30, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of June 30, 2021 ​ ​ ​ 2021 ​ ​ ​ ​ As Previously ​ Restatement ​ ​ ​ Statement of Cash Flows ​ Reported ​ Adjustment ​ As restated Operating Activities ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss ​ $ (5,050,119) ​ $ 496,486 ​ $ (4,553,633) Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Depreciation and Amortization of Intangible Assets ​ 23,203 ​ — ​ 23,203 Reduction of Right-of-Use Assets ​ 86,387 ​ — ​ 86,387 Stock-Based Compensation ​ 479,837 ​ — ​ 479,837 Change in Fair Value of Contingent Consideration ​ — ​ (496,486) ​ (496,486) Deferred Taxes ​ — ​ — ​ Paycheck Protection Program Loan Forgiveness ​ ​ ​ ​ (278,190) ​ (278,190) Goodwill Impairment Loss ​ — ​ — ​ — Intangible Asset Impairment Loss ​ — ​ — ​ — Changes in Operating Assets and Liabilities, Net of Effects of Business Acquired: ​ — ​ — ​ Prepaid Expenses and Other Current Assets ​ 8,786 ​ — ​ 8,786 Refundable Tax Credit Receivable ​ (222,645) ​ — ​ (222,645) Other Assets ​ 11,153 ​ — ​ 11,153 Accounts Payable ​ (142,444) ​ — ​ (142,444) Lease Liabilities ​ (86,387) ​ — ​ (86,387) Accrued Expenses ​ (315,196) ​ — ​ (315,196) Net cash used in operating activities ​ (5,207,425) ​ (278,190) ​ (5,485,615) Net cash used in investing activities ​ (63,865) ​ — ​ (63,865) Financing Activities ​ ​ ​ ​ ​ ​ ​ ​ ​ Proceeds from stock offerings ​ 7,988,861 ​ — ​ 7,988,861 Stock Issuance Costs ​ — ​ ​ ​ — PPP Loan Forgiveness ​ (278,190) ​ 278,190 ​ Exercise of Warrants ​ 50,001 ​ — ​ 50,001 Repayment of Loan Payable ​ — ​ — ​ — Net cash provided by financing activities ​ 7,760,672 ​ 278,190 ​ 8,038,862 Effects of Exchange Rate Changes on Cash ​ (11,835) ​ — ​ (11,835) Net Cash Increase or decrease ​ 2,477,547 ​ — ​ 2,477,547 Cash, Including Restricted Cash, Beginning of Year ​ 1,230,677 ​ ​ ​ 1,230,677 Cash, Including Restricted Cash, End of Year ​ $ 3,708,224 ​ $ — ​ $ 3,708,224 ​ Balance Sheet as of September 30, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of September 30, 2021 ​ ​ As Previously ​ 2020 ​ ​ 2021 ​ ​ ​ Balance Sheet Reported restatements ​ Restatement As Restated Total Current Assets $ 11,870,019 ​ — ​ — $ 11,870,019 Property and Equipment, Net ​ 78,833 ​ — ​ — ​ 78,833 Restricted cash ​ 45,000 ​ — ​ — ​ 45,000 Goodwill ​ 3,484,607 $ 146,605 ​ — ​ 3,631,212 Intangible Assets and In-process R&D, Net ​ 9,711,414 ​ — ​ — ​ 9,711,414 Operating Leases Assets with Right-of-Use ​ 259,217 ​ — ​ — ​ 259,217 Other Assets ​ 44,249 ​ — ​ — ​ 44,249 Total assets $ 25,493,339 $ 146,605 ​ — $ 25,639,944 Liabilities and stockholders’ equity ​ ​ ​ ​ Total current liabilities $ 1,958,942 ​ 212,281 ​ — $ 2,171,223 Contingent Consideration ​ 5,342,950 ​ (2,795,876) $ (428,480) ​ 2,118,594 Deferred Tax Liability ​ 728,926 ​ — ​ — ​ 728,926 Non-current Operating Lease Liabilities ​ 114,475 ​ — ​ — ​ 114,475 Total liabilities ​ 8,145,293 ​ (2,583,595) ​ (428,480) ​ 5,133,218 Stockholders’ equity ​ ​ ​ ​ Preferred Stock, $0.01 par value ​ — ​ — ​ — ​ — Common Stock, $0.01 par value ​ 126,193 ​ — ​ — ​ 126,193 Additional paid-in-capital ​ 133,637,500 ​ 1,500,030 ​ — ​ 135,137,530 Accumulated deficit ​ (116,355,777) ​ 1,230,170 ​ 428,480 ​ (114,697,127) Accumulated Other Comprehensive Income ​ (59,870) ​ — ​ — ​ (59,870) Total stockholders’ equity ​ 17,348,046 ​ 2,730,200 ​ 428,480 ​ 20,506,726 Total liabilities and stockholders’ equity $ 25,493,339 $ 146,605 ​ — $ 25,639,944 ​ Statement of Operations and Comprehensive Loss for the 3 months ended September 30, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the 3 months ended September 30, 2021 ​ ​ As Previously ​ Restatement ​ ​ ​ Statement of Operations and Comprehensive Loss ​ Reported ​ Adjustment ​ As restated Research and Development $ 1,628,467 ​ — $ 1,628,467 General and Administrative ​ 1,338,616 ​ — ​ 1,338,616 Change in Fair Value of Contingent Consideration ​ — $ 68,006 ​ 68,006 Total Operating Expenses ​ 2,967,083 ​ 68,006 ​ 3,035,089 Operating Loss before Other Income ​ (2,967,083) ​ (68,006) ​ (3,035,089) Other (expense) income: ​ ​ ​ Interest Income ​ 259 ​ — ​ 259 Total other (expense) income ​ 259 ​ — ​ 259 Loss before Income Tax Benefit (Expense) ​ ​ (2,966,824) ​ ​ (68,006) ​ ​ (3,034,830) Income Tax Benefit (Expense) ​ ​ — ​ ​ — ​ ​ — Net Loss $ (2,966,824) $ (68,006) $ (3,034,830) Weighted Average Shares Outstanding – Basic and Diluted ​ 10,265,108 ​ 403,461 ​ 10,668,569 Basic and Diluted net loss $ (0.29) ​ ​ $ (0.28) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Other comprehensive loss: ​ ​ ​ ​ ​ ​ ​ ​ ​ Net Loss ​ $ (2,966,824) ​ $ (68,006) ​ $ (3,034,830) Foreign Currency Translation Adjustments ​ ​ (44,734) ​ ​ — ​ ​ (44,734) Comprehensive Loss ​ $ (3,011,558) ​ $ (68,006) ​ $ (3,079,564) ​ Statement of Operations and Comprehensive Loss for the 9 months ended September 30, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the 9 months ended September 30, 2021 ​ As Previously 2021 ​ Statement of Operations and Comprehensive Loss ​ Reported ​ restatements ​ As restated Research and Development ​ $ 4,348,631 ​ ​ — ​ $ 4,348,631 General and Administrative ​ ​ 3,944,624 ​ ​ — ​ ​ 3,944,624 Change in Fair Value of Contingent Consideration ​ ​ — ​ $ (428,480) ​ ​ (428,480) Total Operating Expenses ​ ​ 8,293,255 ​ ​ (428,480) ​ ​ 7,864,775 Operating Loss before Other Income ​ ​ (8,293,255) ​ ​ 428,480 ​ ​ (7,864,775) Other (expense) income: ​ ​ ​ ​ ​ ​ Gain on Forgiveness of Loan ​ ​ 278,190 ​ ​ — ​ ​ 278,190 Interest Income ​ ​ 841 ​ ​ — ​ ​ 841 Interest Expense ​ ​ (2,719) ​ ​ — ​ ​ (2,719) Total other (expense) income ​ ​ 276,312 ​ ​ — ​ ​ 276,312 Loss before Income Tax Benefit (Expense) ​ ​ (8,016,943) ​ ​ 428,480 ​ ​ (7,588,463) Income Tax Benefit (Expense) ​ ​ — ​ ​ — ​ ​ — Loss before Income Tax Benefit (Expense) ​ $ (8,016,943) ​ $ 428,480 ​ $ (7,588,463) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Average Shares Outstanding - Basic and Diluted ​ 8,101,004 ​ ​ 403,461 ​ 8,504,465 Basic and Diluted net loss ​ $ (0.99) ​ ​ ​ ​ $ (0.89) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Other comprehensive loss: ​ ​ ​ ​ ​ ​ ​ ​ ​ Net Loss ​ $ (8,016,943) ​ $ 428,480 ​ $ (7,588,463) Foreign Currency Translation Adjustments ​ (59,068) ​ — ​ (59,068) Comprehensive Loss ​ $ (8,076,011) ​ 428,480 ​ $ (7,647,531) ​ Stockholders’ Equity as of September 30, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of September 30, 2021 ​ ​ As Previously ​ 2020 ​ 2021 Restatements ​ ​ ​ Stockholders’ equity Reported Restatements ​ As restated Preferred Stock, $0.01 par value ​ — ​ — ​ — ​ — Common Stock, $0.01 par value $ 126,193 ​ — ​ — $ 126,193 Additional paid-in-capital ​ 133,637,500 $ 1,500,030 ​ — ​ 135,137,530 Accumulated deficit ​ (116,355,777) ​ 1,230,170 $ 428,480 ​ (114,697,127) Accumulated Other Comprehensive Income ​ (59,870) ​ — ​ — ​ (59,870) Total stockholders’ equity $ 17,348,046 $ 2,730,200 $ 428,480 $ 20,506,726 ​ ​ Statement of Cash Flows for the 9 months ended September 30, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of September 30, 2021 ​ ​ 2021 ​ ​ ​ As Previously ​ Restatement ​ ​ Statement of Cash Flows ​ Reported ​ Adjustment ​ As restated Operating Activities ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss ​ $ (8,016,943) ​ $ 428,480 ​ $ (7,588,463) Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Depreciation and Amortization of Intangible Assets ​ ​ 34,260 ​ ​ — ​ 34,260 Reduction of Right-of-Use Assets ​ ​ 133,514 ​ ​ — ​ 133,514 Stock-Based Compensation ​ ​ 629,306 ​ ​ — ​ 629,306 Change in Fair Value of Contingent Consideration ​ ​ — ​ (428,480) ​ (428,480) Deferred Taxes ​ ​ — ​ — ​ — Paycheck Protection Program Loan Forgiveness ​ ​ — ​ (278,190) ​ (278,190) Goodwill Impairment Loss ​ ​ — ​ — ​ — Intangible Asset Impairment Loss ​ ​ — ​ — ​ — Changes in Operating Assets and Liabilities, Net of Effects of Business Acquired: ​ ​ — ​ — ​ — Prepaid Expenses and Other Current Assets ​ ​ 107,940 ​ — ​ 107,940 Refundable Tax Credit Receivable ​ ​ (335,096) ​ — ​ (335,096) Other Assets ​ ​ 12,826 ​ — ​ 12,826 Accounts Payable ​ ​ (9,875) ​ — ​ (9,875) Lease Liabilities ​ ​ (133,514) ​ — ​ (133,514) Accrued Expenses ​ ​ 100,050 ​ — ​ 100,050 Net cash used in operating activities ​ ​ (7,477,532) ​ (278,190) ​ (7,755,722) Net cash used in investing activities ​ ​ (63,865) ​ — ​ (63,865) Financing Activities ​ ​ ​ ​ ​ ​ ​ ​ ​ Proceeds from stock offerings ​ ​ 17,745,207 ​ — ​ 17,745,207 Stock Issuance Costs ​ ​ — ​ — ​ — Exercise of Warrants ​ ​ 50,001 ​ — ​ 50,001 PPP loan forgiveness ​ ​ (278,190) ​ 278,190 ​ — Repayment of Loan Payable ​ ​ — ​ — ​ — Net cash provided by financing activities ​ ​ 17,517,018 ​ 278,190 ​ 17,795,208 Effects of Exchange Rate Changes on Cash ​ ​ (54,371) ​ — ​ (54,371) Net Cash Increase or decrease ​ ​ 9,921,250 ​ — ​ 9,921,250 Cash, Including Restricted Cash, Beginning of Year ​ ​ 1,230,677 ​ — ​ 1,230,677 Cash, Including Restricted Cash, End of Year ​ $ 11,151,927 ​ $ — ​ $ 11,151,927

Organization, Business (Details

Organization, Business (Details) - USD ($)	Aug. 11, 2021	Jan. 06, 2021	Dec. 31, 2021	Dec. 31, 2020
Subsidiary, Sale of Stock [Line Items]
Cash and Cash Equivalents, at Carrying Value			$ 7,854,690	$ 1,185,677
Accumulated Deficit			$ (120,879,349)	$ (107,108,664)
Proceeds from Issuance of Private Placement		$ 8,000,000
Registered direct offering
Subsidiary, Sale of Stock [Line Items]
Proceeds from Issuance of Private Placement	$ 9,800,000

Restatement of Financial Stat_3

Restatement of Financial Statements - Balance sheet (Details) - USD ($)	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
CONSOLIDATED BALANCE SHEETS
Total Current Assets	$ 8,990,770				$ 1,726,221
Property and Equipment, Net	73,999				30,566
Restricted cash	45,000				45,000
Goodwill	0				3,631,212
Intangible Assets and In-Process R&D, Net	10,768,164				9,730,164
Operating Lease Assets with Right-of-Use	209,411				83,928
Other Assets	42,964				57,073
Total Assets	20,130,308				15,304,164
LIABILITIES AND STOCKHOLDERS' EQUITY
Total current liabilities	1,609,608				1,984,608
Contingent Consideration	3,048,955				2,547,074
Deferred Tax Liability	802,131				728,926
Paycheck Protection Program Loan					278,190
Non-Current Operating Lease Liabilities	90,566				35,625
Total Non-Current Liabilities	3,941,652				3,589,815
Total Liabilities	5,551,260				5,574,423
Stockholders' Equity:
Preferred Stock, $0.01 par value					41
Common Stock, $0.01 par value	126,640				55,564
Additional paid-in-capital	135,418,188				116,783,602
Accumulated Deficit	(120,879,349)				(107,108,664)
Accumulated Other Comprehensive Income	(86,431)				(802)
Total Stockholders' Equity	14,579,048				9,729,741	$ 6,622,455
Total Liabilities and Stockholders' Equity	$ 20,130,308				$ 15,304,164
Preferred Stock, Par or Stated Value Per Share	$ 0.01				$ 0.01
Common Stock, Par or Stated Value Per Share	$ 0.01				$ 0.01
Correction in Accounting For Acquisitions And Subsequent Intangible Asset Impairment [Member]
CONSOLIDATED BALANCE SHEETS
Total Current Assets	$ 8,990,770	$ 11,870,019	$ 4,415,173	$ 6,991,086
Property and Equipment, Net	73,999	78,833	83,682	84,264
Restricted cash	45,000	45,000	45,000	45,000
Goodwill		3,631,212	3,631,212	3,631,212
Intangible Assets and In-Process R&D, Net	10,768,164	9,711,414	9,717,664	9,723,914
Operating Lease Assets with Right-of-Use	209,411	259,217	308,013	242,730
Other Assets	42,964	44,249	45,921	49,001
Total Assets	20,130,308	25,639,944	18,246,665	20,767,207
LIABILITIES AND STOCKHOLDERS' EQUITY
Total current liabilities	1,609,608	2,171,223	1,648,721	1,637,879
Contingent Consideration	3,048,955	2,118,594	2,050,588	1,976,871
Deferred Tax Liability	802,131	728,926	728,926	728,926
Paycheck Protection Program Loan				278,190
Non-Current Operating Lease Liabilities	90,566	114,475	137,957	159,938
Total Non-Current Liabilities	3,941,652
Total Liabilities	5,551,260	5,133,218	4,566,192	4,781,804
Stockholders' Equity:
Preferred Stock, $0.01 par value			41	41
Common Stock, $0.01 par value	126,640	126,193	70,979	70,979
Additional paid-in-capital	135,418,188	135,137,530	125,286,886	125,023,994
Accumulated Deficit	(120,879,349)	(114,697,127)	(111,662,297)	(109,119,282)
Accumulated Other Comprehensive Income	(86,431)	(59,870)	(15,136)	9,671
Total Stockholders' Equity	14,579,048	20,506,726	13,680,473	15,985,403	$ 9,729,741
Total Liabilities and Stockholders' Equity	$ 20,130,308	$ 25,639,944	$ 18,246,665	$ 20,767,207
Preferred Stock, Par or Stated Value Per Share	$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01
Common Stock, Par or Stated Value Per Share	$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01
Correction in Accounting For Acquisitions And Subsequent Intangible Asset Impairment [Member] | As reported
CONSOLIDATED BALANCE SHEETS
Total Current Assets	$ 8,990,770	$ 11,870,019	$ 4,415,173	$ 6,991,086	$ 1,726,221
Property and Equipment, Net	73,999	78,833	83,682	84,264	30,566
Restricted cash	45,000	45,000	45,000	45,000	45,000
Goodwill		3,484,607	3,484,607	3,484,607	3,484,607
Intangible Assets and In-Process R&D, Net	8,695,850	9,711,414	9,717,664	9,723,914	9,730,164
Operating Lease Assets with Right-of-Use	209,411	259,217	308,013	242,730	83,928
Other Assets	42,964	44,249	45,921	49,001	57,073
Total Assets	18,057,994	25,493,339	18,100,060	20,620,602	15,157,559
LIABILITIES AND STOCKHOLDERS' EQUITY
Total current liabilities	1,609,608	1,958,942	1,436,440	1,425,598	1,772,327
Contingent Consideration	6,518,770	5,342,950	5,342,950	5,342,950	5,342,950
Deferred Tax Liability	614,436	728,926	728,926	728,926	728,926
Paycheck Protection Program Loan				278,190	278,190
Non-Current Operating Lease Liabilities	90,566	114,475	137,957	159,938	35,625
Total Non-Current Liabilities	7,223,772				6,385,691
Total Liabilities	8,833,380	8,145,293	7,646,273	7,935,602	8,158,018
Stockholders' Equity:
Preferred Stock, $0.01 par value			41	41	41
Common Stock, $0.01 par value	126,640	126,193	70,979	70,979	55,564
Additional paid-in-capital	133,918,158	133,637,500	123,786,856	123,523,964	115,283,572
Accumulated Deficit	(124,733,753)	(116,355,777)	(113,388,953)	(110,919,655)	(108,338,834)
Accumulated Other Comprehensive Income	(86,431)	(59,870)	(15,136)	9,671	(802)
Total Stockholders' Equity	9,224,614	17,348,046	10,453,787	12,685,000	6,999,541
Total Liabilities and Stockholders' Equity	18,057,994	25,493,339	18,100,060	20,620,602	15,157,559
Correction in Accounting For Acquisitions And Subsequent Intangible Asset Impairment [Member] | 2020 Restatement Adjustment
CONSOLIDATED BALANCE SHEETS
Goodwill	146,605				146,605
Total Assets	146,605				146,605
LIABILITIES AND STOCKHOLDERS' EQUITY
Total current liabilities					212,281
Contingent Consideration	(2,583,595)				(2,795,876)
Total Non-Current Liabilities	(2,795,876)				(2,795,876)
Total Liabilities	(2,583,595)				(2,583,595)
Stockholders' Equity:
Additional paid-in-capital	1,500,030				1,500,030
Accumulated Deficit	1,230,170				1,230,170
Total Stockholders' Equity	2,730,200				2,730,200
Total Liabilities and Stockholders' Equity	146,605				$ 146,605
Common Stock, Par or Stated Value Per Share					$ 0.01
Correction in Accounting For Acquisitions And Subsequent Intangible Asset Impairment [Member] | 2021 Restatement Adjustment
CONSOLIDATED BALANCE SHEETS
Goodwill	(146,605)
Intangible Assets and In-Process R&D, Net	2,072,314
Total Assets	1,925,709
LIABILITIES AND STOCKHOLDERS' EQUITY
Contingent Consideration	(886,220)	(428,480)	(496,486)	(570,203)
Deferred Tax Liability	187,695
Total Non-Current Liabilities	(698,525)
Total Liabilities	(698,525)	(428,480)	(496,486)	(570,203)
Stockholders' Equity:
Accumulated Deficit	2,624,234	428,480	496,486	570,203
Total Stockholders' Equity	2,624,234	$ 428,480	$ 496,486	$ 570,203
Total Liabilities and Stockholders' Equity	$ 1,925,709

Restatement of Financial Stat_4

Restatement of Financial Statements - Statement of Operations and Comprehensive Loss (Details) - USD ($)		1 Months Ended		3 Months Ended			6 Months Ended	9 Months Ended	12 Months Ended
	Dec. 18, 2020	Oct. 31, 2021	Mar. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2021	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
Collaboration Revenue									$ 0	$ 12,059
Research and Development									5,350,264	3,566,045
General and Administrative									5,323,649	4,658,769
Change in fair value of contingent consideration									(475,956)	(1,230,170)
Contingent Consideration Recovery									475,956	1,230,170
Gain on Disposal of Foreign Entity									0	113,717
Goodwill Impairment									4,037,811	0
Total Operating Expenses									14,235,768	6,880,927
Operating Loss before Other Income									(14,235,768)	(6,868,868)
Other Income, net:
Gain on Forgiveness of Loan									278,190	0
Interest Expense									6,851	4,186
Interest Income									1,141	23,339
Total other (expense) income									272,480	19,153
Loss Before Income Tax Benefit (Expense)									(13,963,288)	(6,849,715)
Income Tax Benefit (Expense)									(192,603)	12,055
Net Loss									$ (13,770,685)	$ (6,861,770)
Weighted-Average Shares Outstanding- Basic									9,643,961	4,591,491
Weighted-Average Shares Outstanding- Diluted								8,504,465	9,643,961	4,591,491
Basic net loss per share									$ (1.43)	$ (1.49)
Diluted net loss per share								$ (0.89)	$ (1.43)	$ (1.49)
Other comprehensive loss:
Net Loss									$ (13,770,685)	$ (6,861,770)
Dissolution of Foreign Entity									0	113,717
Foreign Currency Translation Adjustments									(85,629)	(26,550)
Comprehensive Loss									(13,856,314)	(7,002,037)
Panoptes
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
Change in fair value of contingent consideration	$ 1,353,000		$ 474,000
Contingent Consideration Recovery	$ (1,353,000)		$ (474,000)
Jade acquisition
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
Change in fair value of contingent consideration									100,000
Contingent Consideration Recovery									(100,000)
Bayon acquisition
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
Change in fair value of contingent consideration		$ 381,000
Contingent Consideration Recovery		(381,000)
Goodwill Impairment		$ 407,000
2020 Restatement Adjustment | Jade acquisition
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
Change in fair value of contingent consideration										100,000
Contingent Consideration Recovery										(100,000)
2021 Restatement Adjustment | Jade acquisition
Other Income, net:
Contingent Consideration Expense / (Recovery)									1,230,000
Change in Fair Value of Contingent Consideration									3,912,000
Correction in Accounting For Acquisitions And Subsequent Intangible Asset Impairment [Member]
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
Collaboration Revenue										12,059
Research and Development				$ 1,628,467	$ 1,439,922	$ 1,280,242	$ 2,720,164	$ 4,348,631	5,350,264	3,566,045
General and Administrative				1,338,616	1,305,865	1,300,143	2,606,008	3,944,624	5,323,649	4,658,769
Change in fair value of contingent consideration							(496,486)	(428,480)	475,956	(1,230,170)
Contingent Consideration Recovery							496,486	428,480	(475,956)	1,230,170
Goodwill Impairment									4,037,811
Intangible Asset Impairment										(113,717)
Total Operating Expenses				3,035,089	2,819,504	2,010,182	4,829,686	7,864,775	14,235,768	6,880,927
Operating Loss before Other Income				(3,035,089)	(2,819,504)	(2,010,182)	(4,829,686)	(7,864,775)	(14,235,768)	(6,868,868)
Other Income, net:
Gain on Forgiveness of Loan					278,190		278,190	278,190	278,190
Contingent Consideration Expense / (Recovery)				68,006	73,717
Interest Expense					2,033	686	2,719	2,719	(6,851)	(4,186)
Interest Income				259	332	250	582	841	1,141	23,339
Total other (expense) income				259	276,489	(436)	276,053	276,312	272,480	19,153
Loss Before Income Tax Benefit (Expense)				$ (3,034,830)	$ (2,543,015)	(2,010,618)	(4,553,633)	(7,588,463)	(13,963,288)	(6,849,715)
Income Tax Benefit (Expense)									192,603	(12,055)
Net Loss						$ (2,010,618)	$ (4,553,633)	$ (7,588,463)	$ (13,770,685)	$ (6,861,770)
Weighted-Average Shares Outstanding- Basic				10,668,569	7,466,211	7,357,899	7,409,363	8,504,465	9,643,961	4,591,491
Weighted-Average Shares Outstanding- Diluted				10,668,569	7,466,211	7,357,899	7,409,363		9,643,961	4,591,491
Basic net loss per share				$ (0.28)	$ (0.34)	$ (0.27)	$ (0.61)	$ (0.89)	$ (1.43)	$ (1.49)
Diluted net loss per share				$ (0.28)	$ (0.34)	$ (0.27)	$ (0.61)		$ (1.43)	$ (1.49)
Other comprehensive loss:
Net Loss						$ (2,010,618)	$ (4,553,633)	$ (7,588,463)	$ (13,770,685)	$ (6,861,770)
Dissolution of Foreign Entity										(113,717)
Foreign Currency Translation Adjustments				$ (44,734)	$ (24,807)	10,473	(14,334)	(59,068)	(85,629)	(26,550)
Comprehensive Loss									(13,856,314)	(7,002,037)
Correction in Accounting For Acquisitions And Subsequent Intangible Asset Impairment [Member] | As reported
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
Collaboration Revenue										12,059
Research and Development				1,628,467	1,439,922	1,280,242	2,720,164	4,348,631	5,350,264	3,566,045
General and Administrative				1,338,616	1,305,865	1,300,143	2,606,008	3,944,624	5,323,649	4,658,769
Gain on Disposal of Foreign Entity										113,717
Goodwill Impairment									4,498,234
Intangible Asset Impairment									1,770,314
Total Operating Expenses				2,967,083	2,745,787	2,580,385	5,326,172	8,293,255	16,942,461	8,224,814
Operating Loss before Other Income				(2,967,083)	(2,745,787)	(2,580,385)	(5,326,172)	(8,293,255)	(16,942,461)	(8,212,755)
Other Income, net:
Gain on Forgiveness of Loan					278,190		278,190	278,190	278,190
Change in Fair Value of Contingent Consideration									(29,719)
Interest Expense					2,033	686	2,719	2,719	(6,851)	(4,186)
Interest Income				259	332	250	582	841	1,141	23,339
Total other (expense) income				259	276,489	(436)	276,053	276,312	242,761	132,870
Loss Before Income Tax Benefit (Expense)				$ (2,966,824)	$ (2,469,298)	(2,580,821)	(5,050,119)	(8,016,943)	(16,699,700)	(8,079,885)
Income Tax Benefit (Expense)									304,781	(12,055)
Net Loss						$ (2,580,821)	$ (5,050,119)	$ (8,016,943)	$ (16,394,919)	$ (8,091,940)
Weighted-Average Shares Outstanding- Basic				10,265,108	7,062,750	6,954,438	7,005,902	8,101,004	9,240,500	4,576,058
Weighted-Average Shares Outstanding- Diluted				10,265,108	7,062,750	6,954,438	7,005,902	8,101,004	9,240,500	4,576,058
Basic net loss per share				$ (0.29)	$ (0.35)	$ (0.37)	$ (0.72)	$ (0.99)	$ (1.77)	$ (1.77)
Diluted net loss per share				$ (0.29)	$ (0.35)	$ (0.37)	$ (0.72)	$ (0.99)	$ (1.77)	$ (1.77)
Other comprehensive loss:
Net Loss						$ (2,580,821)	$ (5,050,119)	$ (8,016,943)	$ (16,394,919)	$ (8,091,940)
Dissolution of Foreign Entity										(113,717)
Foreign Currency Translation Adjustments				$ (44,734)	$ (24,807)	10,473	(14,334)	(59,068)	(85,629)	(26,550)
Comprehensive Loss									(16,480,548)	(8,232,207)
Correction in Accounting For Acquisitions And Subsequent Intangible Asset Impairment [Member] | 2020 Restatement Adjustment
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
Change in fair value of contingent consideration										(1,230,170)
Contingent Consideration Recovery										1,230,170
Gain on Disposal of Foreign Entity										(113,717)
Intangible Asset Impairment										(113,717)
Total Operating Expenses										(1,343,887)
Operating Loss before Other Income										1,343,887
Other Income, net:
Total other (expense) income										(113,717)
Loss Before Income Tax Benefit (Expense)										1,230,170
Net Loss										$ 1,230,170
Weighted-Average Shares Outstanding- Basic										15,433
Weighted-Average Shares Outstanding- Diluted										15,433
Other comprehensive loss:
Net Loss										$ 1,230,170
Comprehensive Loss										1,230,170
Correction in Accounting For Acquisitions And Subsequent Intangible Asset Impairment [Member] | 2021 Restatement Adjustment
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
Change in fair value of contingent consideration							(496,486)	(428,480)	475,956
Contingent Consideration Recovery							496,486	428,480	(475,956)
Goodwill Impairment									(460,423)
Intangible Asset Impairment									(1,770,314)
Total Operating Expenses				68,006	73,717	(570,203)	(496,486)	(428,480)	(2,706,693)
Operating Loss before Other Income				(68,006)	(73,717)	570,203	496,486	428,480	2,706,693
Other Income, net:
Contingent Consideration Expense / (Recovery)				68,006	73,717
Change in Fair Value of Contingent Consideration									29,719
Total other (expense) income									29,719
Loss Before Income Tax Benefit (Expense)				$ (68,006)	$ (73,717)	570,203	496,486	428,480	2,736,412
Income Tax Benefit (Expense)									(112,178)
Net Loss						$ 570,203	$ 496,486	$ 428,480	$ 2,624,234	1,230,170
Weighted-Average Shares Outstanding- Basic				403,461	403,461	403,461	403,461	403,461	403,461
Weighted-Average Shares Outstanding- Diluted				403,461	403,461	403,461	403,461	403,461	403,461
Other comprehensive loss:
Net Loss						$ 570,203	$ 496,486	$ 428,480	$ 2,624,234	$ 1,230,170
Comprehensive Loss									$ 2,624,234

Restatement of Financial Stat_5

Restatement of Financial Statements - Shareholders' equity (Details) - USD ($)	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
Cumulative Effect of Change in Accounting Principle (Note 2)	$ 14,579,048				$ 9,729,741	$ 6,622,455
Preferred Stock, Par or Stated Value Per Share	$ 0.01				$ 0.01
Common Stock, Par or Stated Value Per Share	$ 0.01				$ 0.01
Preferred Stock
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
Cumulative Effect of Change in Accounting Principle (Note 2)	$ 0				$ 41	41
Common Stock
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
Cumulative Effect of Change in Accounting Principle (Note 2)	126,640				55,564	40,778
Additional Paid-In Capital
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
Cumulative Effect of Change in Accounting Principle (Note 2)	135,418,188				116,783,602	106,689,065
Accumulated Deficit
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
Cumulative Effect of Change in Accounting Principle (Note 2)	(120,879,349)				(107,108,664)	(100,246,894)
Accumulated Other Comprehensive Loss
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
Cumulative Effect of Change in Accounting Principle (Note 2)	(86,431)				(802)	$ 139,465
Correction in Accounting For Acquisitions And Subsequent Intangible Asset Impairment [Member]
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
Cumulative Effect of Change in Accounting Principle (Note 2)	$ 14,579,048	$ 20,506,726	$ 13,680,473	$ 15,985,403	$ 9,729,741
Preferred Stock, Par or Stated Value Per Share	$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01
Common Stock, Par or Stated Value Per Share	$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01
Correction in Accounting For Acquisitions And Subsequent Intangible Asset Impairment [Member] | Preferred Stock
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
Cumulative Effect of Change in Accounting Principle (Note 2)			$ 41	$ 41	$ 41
Correction in Accounting For Acquisitions And Subsequent Intangible Asset Impairment [Member] | Common Stock
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
Cumulative Effect of Change in Accounting Principle (Note 2)	$ 126,640	$ 126,193	70,979	70,979	55,564
Correction in Accounting For Acquisitions And Subsequent Intangible Asset Impairment [Member] | Additional Paid-In Capital
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
Cumulative Effect of Change in Accounting Principle (Note 2)	135,418,188	135,137,530	125,286,886	125,023,994	116,783,602
Correction in Accounting For Acquisitions And Subsequent Intangible Asset Impairment [Member] | Accumulated Deficit
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
Cumulative Effect of Change in Accounting Principle (Note 2)	(120,879,349)	(114,697,127)	(111,662,297)	(109,119,282)	(107,108,664)
Correction in Accounting For Acquisitions And Subsequent Intangible Asset Impairment [Member] | Accumulated Other Comprehensive Loss
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
Cumulative Effect of Change in Accounting Principle (Note 2)	(86,431)	(59,870)	(15,136)	9,671	(802)
Correction in Accounting For Acquisitions And Subsequent Intangible Asset Impairment [Member] | As reported
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
Cumulative Effect of Change in Accounting Principle (Note 2)	9,224,614	17,348,046	10,453,787	12,685,000	6,999,541
Correction in Accounting For Acquisitions And Subsequent Intangible Asset Impairment [Member] | As reported | Preferred Stock
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
Cumulative Effect of Change in Accounting Principle (Note 2)			41	41	41
Correction in Accounting For Acquisitions And Subsequent Intangible Asset Impairment [Member] | As reported | Common Stock
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
Cumulative Effect of Change in Accounting Principle (Note 2)	126,640	126,193	70,979	70,979	55,564
Correction in Accounting For Acquisitions And Subsequent Intangible Asset Impairment [Member] | As reported | Additional Paid-In Capital
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
Cumulative Effect of Change in Accounting Principle (Note 2)	133,918,158	133,637,500	123,786,856	123,523,964	115,283,572
Correction in Accounting For Acquisitions And Subsequent Intangible Asset Impairment [Member] | As reported | Accumulated Deficit
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
Cumulative Effect of Change in Accounting Principle (Note 2)	(124,733,753)	(116,355,777)	(113,388,953)	(110,919,655)	(108,338,834)
Correction in Accounting For Acquisitions And Subsequent Intangible Asset Impairment [Member] | As reported | Accumulated Other Comprehensive Loss
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
Cumulative Effect of Change in Accounting Principle (Note 2)	(86,431)	(59,870)	(15,136)	9,671	(802)
Correction in Accounting For Acquisitions And Subsequent Intangible Asset Impairment [Member] | 2020 Restatement Adjustment
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
Cumulative Effect of Change in Accounting Principle (Note 2)	2,730,200				$ 2,730,200
Common Stock, Par or Stated Value Per Share					$ 0.01
Correction in Accounting For Acquisitions And Subsequent Intangible Asset Impairment [Member] | 2020 Restatement Adjustment | Additional Paid-In Capital
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
Cumulative Effect of Change in Accounting Principle (Note 2)	1,500,030				$ 1,500,030
Correction in Accounting For Acquisitions And Subsequent Intangible Asset Impairment [Member] | 2020 Restatement Adjustment | Accumulated Deficit
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
Cumulative Effect of Change in Accounting Principle (Note 2)	1,230,170				$ 1,230,170
Correction in Accounting For Acquisitions And Subsequent Intangible Asset Impairment [Member] | 2021 Restatement Adjustment
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
Cumulative Effect of Change in Accounting Principle (Note 2)	2,624,234	428,480	496,486	570,203
Correction in Accounting For Acquisitions And Subsequent Intangible Asset Impairment [Member] | 2021 Restatement Adjustment | Accumulated Deficit
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
Cumulative Effect of Change in Accounting Principle (Note 2)	$ 2,624,234	$ 428,480	$ 496,486	$ 570,203

Restatement of Financial Stat_6

Restatement of Financial Statements - Statement of Cash Flows (Details) - USD ($)			3 Months Ended	6 Months Ended	9 Months Ended	12 Months Ended
	Aug. 11, 2021	Jan. 03, 2020	Mar. 31, 2021	Jun. 30, 2021	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Operating Activities
Net Loss						$ (13,770,685)	$ (6,861,770)
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:
Depreciation and Amortization of Intangible Assets						45,296	33,399
Reduction of Right-of-Use Assets						181,977	166,822
Stock-Based Compensation						842,475	723,856
Expiration of Prepaid Agreement						0	159,848
Deferred Taxes						(192,603)	12,055
Paycheck Protection Program Loan Forgiveness						(278,190)	0
Goodwill Impairment						4,037,811	0
Increase (Decrease) in Operating Capital [Abstract]
Increase (Decrease) in Prepaid Expense and Other Assets						156,951	146,971
Increase (Decrease) in Income Taxes Receivable						441,196	18,957
Increase (Decrease) in Other Operating Assets						(14,111)	(18,916)
Accounts Payable						(310,665)	136,697
Lease Liabilities						(181,977)	(166,822)
Accrued Expenses						40,882	(144,072)
Net Cash Used in Operating Activities						(10,675,390)	(7,317,169)
Net cash used in investing activities						(157,020)	(244,438)
Financing Activities
Proceeds from Stock Offerings	$ 9,800,000	$ 4,500,000				18,750,016	5,000,000
Stock Issuance Costs						(1,004,809)	(498,687)
Exercise of Warrants						50,001	218,000
Net cash provided by financing activities						17,582,926	4,997,503
Effect of Exchange Rate Changes on Cash						(81,503)	(26,931)
Net Cash Increase or decrease						6,669,013	(2,591,035)
Cash, Including Restricted Cash, Beginning of Year			$ 1,230,677	$ 1,230,677	$ 1,230,677	1,230,677	3,821,712
Cash, Including Restricted Cash, End of Year						7,899,690	1,230,677
Correction in Accounting For Acquisitions And Subsequent Intangible Asset Impairment [Member]
Operating Activities
Net Loss			(2,010,618)	(4,553,633)	(7,588,463)	(13,770,685)	(6,861,770)
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:
Depreciation and Amortization of Intangible Assets			10,599	23,203	34,260	45,296	33,399
Reduction of Right-of-Use Assets			39,490	86,387	133,514	181,977	166,822
Stock-Based Compensation			216,945	479,837	629,306	842,475	723,856
Change in Fair Value of Contingent Consideration			570,203		428,480	505,675	(1,230,170)
Expiration of Prepaid Agreement							159,848
Deferred Taxes						(192,603)	12,055
Paycheck Protection Program Loan Forgiveness				(278,190)	(278,190)	(278,190)
Goodwill Impairment						4,037,811
Intangible Asset Impairment							(113,717)
Increase (Decrease) in Operating Capital [Abstract]
Increase (Decrease) in Prepaid Expense and Other Assets			216,078	8,786	107,940	(156,951)	(146,971)
Increase (Decrease) in Income Taxes Receivable			(59,706)	(222,645)	(335,096)	(441,196)	(18,957)
Increase (Decrease) in Other Operating Assets			8,073	11,153	12,826	14,111	18,916
Accounts Payable			22,583	(142,444)	(9,875)	(310,665)	136,697
Lease Liabilities			(39,490)	(86,387)	(133,514)	(181,977)	(166,822)
Accrued Expenses			(403,802)	(315,196)	100,050	40,882	(144,072)
Net Cash Used in Operating Activities			(2,570,051)	(5,485,615)	(7,755,722)	(10,675,390)	(7,317,169)
Net cash used in investing activities			(58,119)	(63,865)	(63,865)	(157,020)	(244,438)
Financing Activities
Proceeds from Stock Offerings			7,988,861	7,988,861	17,745,207	18,750,016
Stock Issuance Costs						(1,004,809)
Exercise of Warrants			50,001	50,001	50,001	50,001
Net cash provided by financing activities			8,038,862	8,038,862	17,795,208	17,582,926	4,997,503
Effect of Exchange Rate Changes on Cash			14,123	(11,835)	(54,371)	(81,503)	(26,931)
Net Cash Increase or decrease			5,424,815	2,477,547	9,921,250	6,669,013	(2,591,035)
Cash, Including Restricted Cash, Beginning of Year			1,230,677	1,230,677	1,230,677	1,230,677	3,821,712
Cash, Including Restricted Cash, End of Year			6,655,492	3,708,224	11,151,927	7,899,690	1,230,677
Correction in Accounting For Acquisitions And Subsequent Intangible Asset Impairment [Member] | As reported
Operating Activities
Net Loss			(2,580,821)	(5,050,119)	(8,016,943)	(16,394,919)	(8,091,940)
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:
Depreciation and Amortization of Intangible Assets			10,599	23,203	34,260	45,296	33,399
Reduction of Right-of-Use Assets			39,490	86,387	133,514	181,977	166,822
Stock-Based Compensation			216,945	479,837	629,306	842,475	723,856
Change in Fair Value of Contingent Consideration						212,281
Expiration of Prepaid Agreement							159,848
Deferred Taxes						(304,782)	12,055
Paycheck Protection Program Loan Forgiveness						(278,190)
Goodwill Impairment						4,498,234
Intangible Asset Impairment						1,770,314
Increase (Decrease) in Operating Capital [Abstract]
Increase (Decrease) in Prepaid Expense and Other Assets			216,078	8,786	107,940	(156,951)	(146,971)
Increase (Decrease) in Income Taxes Receivable			(59,706)	(222,645)	(335,096)	(441,196)	(18,957)
Increase (Decrease) in Other Operating Assets			8,073	11,153	12,826	14,111	18,916
Accounts Payable			22,583	(142,444)	(9,875)	(310,665)	136,697
Lease Liabilities			(39,490)	(86,387)	(133,514)	(181,977)	(166,822)
Accrued Expenses			(403,802)	(315,196)	100,050	40,882	(144,072)
Net Cash Used in Operating Activities			(2,570,051)	(5,207,425)	(7,477,532)	(10,887,672)	(7,317,169)
Net cash used in investing activities			(58,119)	(63,865)	(63,865)	(157,020)	(244,438)
Financing Activities
Proceeds from Stock Offerings			7,988,861	7,988,861	17,745,207	18,750,016
Stock Issuance Costs						(1,004,809)
Exercise of Warrants			50,001	50,001	50,001	50,001
Net cash provided by financing activities			8,038,862	7,760,672	17,517,018	17,795,208	4,997,503
Effect of Exchange Rate Changes on Cash			14,123	(11,835)	(54,371)	(81,503)	(26,931)
Net Cash Increase or decrease			5,424,815	2,477,547	9,921,250	6,669,013	(2,591,035)
Cash, Including Restricted Cash, Beginning of Year			1,230,677	1,230,677	1,230,677	1,230,677	3,821,712
Cash, Including Restricted Cash, End of Year			6,655,492	3,708,224	11,151,927	7,899,690	1,230,677
Correction in Accounting For Acquisitions And Subsequent Intangible Asset Impairment [Member] | 2020 Restatement Adjustment
Operating Activities
Net Loss							1,230,170
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:
Intangible Asset Impairment							(113,717)
Correction in Accounting For Acquisitions And Subsequent Intangible Asset Impairment [Member] | 2021 Restatement Adjustment
Operating Activities
Net Loss			570,203	496,486	428,480	2,624,234	1,230,170
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:
Change in Fair Value of Contingent Consideration			$ 570,203		428,480	293,394	$ (1,230,170)
Deferred Taxes						112,179
Paycheck Protection Program Loan Forgiveness				(278,190)	(278,190)
Goodwill Impairment						(460,423)
Intangible Asset Impairment						(1,770,314)
Increase (Decrease) in Operating Capital [Abstract]
Net Cash Used in Operating Activities				(278,190)	(278,190)	212,282
Financing Activities
Net cash provided by financing activities				$ 278,190	$ 278,190	$ (212,282)

Restatement of Financial Stat_7

Restatement of Financial Statements - Additional information (Details) - USD ($)		1 Months Ended		12 Months Ended
	Dec. 18, 2020	Oct. 31, 2021	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Error Corrections and Prior Period Adjustments Restatement [Line Items]
In-process R&D				$ 10,599,000	$ 9,536,000
Goodwill				0	3,631,212
Decrease in contingent consideration				(475,956)	(1,230,170)
Goodwill Impairment				4,037,811	0
Panoptes
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Contingent consideration liability					1,353,000
Contingent consideration current liability payable					212,000
Increase in additional paid-in capital	$ 1,500,000
Increase decrease in goodwill	147,000
Decrease in contingent consideration	$ 1,353,000		$ 474,000
Jade acquisition
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Contingent consideration liability				580,000	480,000
Decrease in contingent consideration				100,000
Jade acquisition | 2020 Restatement Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Decrease in contingent consideration					$ 100,000
Jade acquisition | 2021 Restatement Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Contingent Consideration Expense / (Recovery)				$ 1,230,000
Bayon acquisition
Error Corrections and Prior Period Adjustments Restatement [Line Items]
In-process R&D		$ 302,000
Deferred tax liability		76,000
Increase decrease in goodwill		607,000
Decrease in contingent consideration		381,000
Goodwill Impairment		$ 407,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Net Loss per Share - Basic and Diluted (Details) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total Shares of Common Stock Issuable	7,275,191	3,839,093
Common Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total Shares of Common Stock Issuable	6,757,180	2,726,700
Preferred Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total Shares of Common Stock Issuable	2,089	865,500
Employee Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total Shares of Common Stock Issuable	515,922	246,893

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Obligations for Each Relevant Transaction (Details) $ in Thousands	Dec. 31, 2021 USD ($)
Bayon acquisition | Successful completion of Phase 1b $0.495 million
Business Acquisition [Line Items]
Fair value of contingent consideration	$ 495
Bayon acquisition | Successful completion of Phase 2 $0.990 million
Business Acquisition [Line Items]
Fair value of contingent consideration	990
Bayon acquisition | Successful completion of Phase 3 $4 million
Business Acquisition [Line Items]
Fair value of contingent consideration	4,000
Bayon acquisition | FDA approval
Business Acquisition [Line Items]
Fair value of contingent consideration	1,650
Panoptes acquisition | Beginning of Phase 3
Business Acquisition [Line Items]
Fair value of contingent consideration	4,750
Panoptes acquisition | FDA approval
Business Acquisition [Line Items]
Fair value of contingent consideration	4,750
Jade acquisition | FDA approval
Business Acquisition [Line Items]
Fair value of contingent consideration	$ 2,164

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Additional Information (Details)					1 Months Ended	12 Months Ended
	Sep. 17, 2021 shares	Aug. 11, 2021 $ / shares shares	Jan. 06, 2021 USD ($) $ / shares shares	Jan. 03, 2020 shares	Oct. 31, 2021 USD ($)	Dec. 31, 2021 USD ($) item shares	Dec. 31, 2020 USD ($) item shares
Goodwill						$ 0	$ 3,631,212
Impairment loss on goodwill						4,037,811	0
In-process R&D						10,599,000	9,536,000
Accrued clinical expenses						168,785	203,646
Deferred Tax Liabilities, Net						802,131	728,926
Unrecognized uncertain income tax						$ 0	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number | shares						41,216	77,262
Other assets or liabilities that are subject to fair value methodology and estimation						$ 0	$ 0
Number of vendors with whom the company has entered into related party transactions | item						1	2
Number of consultants with whom the company has entered into related party transactions | item						6	7
Shares issued | shares	10,911	4,668,844	1,531,101	500,000
Warrants to purchase common stock | shares		233,442
Purchase price | $ / shares		$ 2.3025
Net proceeds from the private placement			$ 8,000,000
Related party transactions payments related to services provided							$ 502,000
Decrease in contingent consideration						$ (475,956)	(1,230,170)
Common Stock | Private Placement
Shares issued | shares			1,531,101
Warrants to purchase common stock | shares			1,531,101
Purchase price | $ / shares			$ 5.225
Net proceeds from the private placement						$ 8,000,000
Maximum
Estimated useful life (in years)						5 years
Minimum
Estimated useful life (in years)						2 years
Jade acquisition
Fair value of contingent consideration						$ 580,000	480,000
Decrease in contingent consideration						100,000
Panoptes acquisition
Money Market Funds Fair Value							$ 2,067,000
Fair value of contingent consideration						1,593,000
Decrease in contingent consideration						474,000
Bayon acquisition
Impairment loss on goodwill					$ 407,000
In-process R&D					302,000
Decrease in contingent consideration					$ 381,000
Contingent consideration						$ 876,000

Fair Value - Liabilities Measur

Fair Value - Liabilities Measured At Fair Value Recurring Basis Using Level 3 (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Contingent Consideration:
Noncurrent	$ 3,048,955	$ 2,547,074
Fair Value, Recurring | Level 3
Contingent Consideration:
Noncurrent	3,048,955	2,547,074
Business Combination, Contingent Consideration, Liability, Total	$ 3,048,955	$ 2,547,074

Fair Value - Estimate to Measur

Fair Value - Estimate to Measure Contingent Consideration Unobservable Level 3 (Details) $ in Thousands	Dec. 31, 2021 USD ($)	Dec. 31, 2020
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Changes in contingent consideration	$ 502
Payment discount rate | Discounted cash flow
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value contingent consideration measurement input		12.6
Probability of Success for payment | Discounted cash flow | Bayon | Minimum
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value contingent consideration measurement input	12
Probability of Success for payment | Discounted cash flow | Bayon | Maximum
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value contingent consideration measurement input	72
Probability of Success for payment | Discounted cash flow | Panoptes | Minimum
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value contingent consideration measurement input	17	20
Probability of Success for payment | Discounted cash flow | Panoptes | Maximum
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value contingent consideration measurement input	36	45
Probability of Success for payment | Discounted cash flow | Jade
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value contingent consideration measurement input		45

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Total Property and Equipment, Gross	$ 187,131	$ 123,540
Less: Accumulated Depreciation	113,132	92,974
Total Property and Equipment, Net	73,999	30,566
Laboratory Equipment
Property, Plant and Equipment [Line Items]
Total Property and Equipment, Gross	$ 88,399	82,653
Property, Plant and Equipment, Useful Life	3 years
Office Equipment
Property, Plant and Equipment [Line Items]
Total Property and Equipment, Gross	$ 3,614	3,888
Property, Plant and Equipment, Useful Life	3 years
Office Furniture
Property, Plant and Equipment [Line Items]
Total Property and Equipment, Gross	$ 72,549	14,430
Property, Plant and Equipment, Useful Life	5 years
Leasehold Improvements
Property, Plant and Equipment [Line Items]
Total Property and Equipment, Gross	$ 22,569	$ 22,569
Property, Plant and Equipment, Useful Life	2 years

Property and Equipment - Additi

Property and Equipment - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Property and Equipment
Depreciation	$ 20,296	$ 8,399

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Accrued Expenses
Payroll and Benefits	$ 937,970	$ 629,465
Professional Fees	194,425	328,420
Clinical Trials	168,785	203,646
Other	28,961	127,730
Total Accrued Expenses	$ 1,330,141	$ 1,289,261

Debt (Details)

Debt (Details) - USD ($)	1 Months Ended	12 Months Ended
	May 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Debt
Proceeds from Paycheck Protection Program Loan	$ 278,000	$ 0	$ 278,190

Intangible Assets and In-Proc_3

Intangible Assets and In-Process R&D (Details) - Trade Secrets - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Trade Secrets	$ 250,000	$ 250,000
Less: Accumulated Amortization	(81,250)	(56,250)
Intangible Assets, Net	168,750	193,750
In-Process R&D	10,599,414	9,536,414
Total Intangible Assets and In-Process R&D, Net	$ 10,768,164	$ 9,730,164
Estimated Useful Life (Years)	10 years

Intangible Assets and In-Proc_4

Intangible Assets and In-Process R&D - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Sep. 26, 2018
Intangible Assets and In-Process R&D, Net	$ 10,768,164	$ 9,730,164
Amortization of Intangible Assets, Total	25,000	$ 25,000
SentrX Animal Care Inc
Intangible Assets and In-Process R&D, Net	250,000
Intangible Assets Expected Milestone Payable	$ 4,750,000		$ 4,750,000

Capital Stock (Details)

Capital Stock (Details) - USD ($)							12 Months Ended
	Sep. 17, 2021	Aug. 11, 2021	Jul. 27, 2021	Jan. 06, 2021	Dec. 18, 2020	Jan. 03, 2020	Dec. 31, 2021	Dec. 31, 2020	Jun. 25, 2020
Class of Stock [Line Items]
Shares issued	10,911	4,668,844		1,531,101		500,000
Share Price						$ 10
Warrant Term				5 years
Common Stock, Shares Authorized							50,000,000	50,000,000	120,000,000
Class Of Warrant Or Right Number Of Warrant Issued				1,531,101
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		233,442
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 2.8781
Share Purchase Price Of Common Stock And Warrant				$ 5.225
Warrants, exercise price, per share, subject to adjustments				$ 5.225
Proceeds from Issuance of Private Placement				$ 8,000,000
Total net proceeds from offerings		$ 9,800,000				$ 4,500,000	$ 18,750,016	$ 5,000,000
Purchase price		$ 2.3025
Number of warrants issued to purchase the shares		233,442
Exercise price		$ 2.8781
Expiry term		5 years
Preferred Stock, Par or Stated Value Per Share							$ 0.01	$ 0.01
Issuance of Common Stock in Offerings, Net of Offering Costs								$ 4,501,313
Warrant
Class of Stock [Line Items]
Warrant Term				6 months
Private Placement Warrants
Class of Stock [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		2,334,422
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 2.24
Number of warrants issued to purchase the shares		2,334,422
Exercise price		$ 2.24
Expiry term		5 years
Common Stock
Class of Stock [Line Items]
Conversion of Series C Preferred Stock into Common Stock (in shares)			852,500
Preferred Stock
Class of Stock [Line Items]
Conversion of Series C Preferred Stock into Common Stock (in shares)			4,092
SeriesD Convertible Preferred Stock
Class of Stock [Line Items]
Shares issued	39
Convertible Preferred Stock, Shares Issued upon Conversion					20,000
Convertible Preferred Stock, Conversion Price					$ 3.5321
Preferred Stock, Par or Stated Value Per Share					$ 1,000

Warrants (Details)

Warrants (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding at beginning of year	77,262
Outstanding at end of year	41,216	77,262
Weighted Average Remaining Term in Years, Outstanding			1 year 5 months 26 days
Warrant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding at beginning of year	2,726,700	2,875,006
Issued	4,098,965	25,000
Exercised	(10,417)	(45,417)
Expired	(58,068)
Expired		(127,889)
Outstanding at end of year	6,757,180	2,726,700	2,875,006
Weighted Average Exercise Price, Outstanding at beginning of year	$ 8.41	$ 14.14
Weighted Average Exercise Price, Issued	3.39	12.50
Weighted Average Exercise Price, Exercised	4.80	4.80
Weighted Average Exercise Price, Expired	52.50	139.28
Weighted Average Exercise Price, Outstanding at end of year	$ 4.99	$ 8.41	$ 14.14
Weighted Average Remaining Term in Years, Outstanding	3 years 5 months 1 day	2 years 5 months 12 days	3 years 4 months 13 days
Weighted Average Remaining Term in Years, Issued	4 years 8 months 4 days	4 years 3 days
Weighted Average Remaining Term in Years, Exercised	1 year 3 months 14 days	2 years 3 months 14 days
Weighted Average Remaining Term in Years, Expired	0 years	0 years

Panoptes Holdback shares (Detai

Panoptes Holdback shares (Details) - Panoptes	1 Months Ended
	Dec. 31, 2020 shares
Number of common stock shares held back	424,685
Held back shares issuing period	18 months
Series D Convertible Preferred Stock
Number of shares convertible	1,500

Equity Incentive Plan (Details)

Equity Incentive Plan (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Equity Incentive Plan
Number of Options, Outstanding at beginning of year	246,893	174,175
Number of Options, Granted	345,865	93,165
Number of Options, Expired	(32,544)	(17,114)
Number of Options, Forfeited	(44,292)	(3,333)
Number of Options, Outstanding at end of year	515,922	246,893	174,175
Number of Options, Exercisable at end of year	201,653	142,061
Number of Options, Vested and expected to vest at end of year	515,922	246,893
Weighted- Average Exercise Price, Outstanding at beginning of year	$ 20.90	$ 27.42
Weighted- Average Exercise Price, Granted	4.11	6.31
Weighted- Average Exercise Price, Expired	25.86	10.59
Weighted- Average Exercise Price, Forfeited	6.49	7.20
Weighted- Average Exercise Price, Outstanding at end of year	10.43	20.90	$ 27.42
Weighted- Average Exercise Price, Exercisable at end of year	22	31.58
Weighted- Average Exercise Price, Vested and expected to vest at end of year	$ 10.43	$ 20.90
Weighted-Average Remaining Contractual Life (In Years), Outstanding	8 years 3 months 18 days	7 years 2 months 12 days	6 years 2 months 19 days
Weighted-Average Remaining Contractual Life (In Years), Exercisable at end of year	6 years 4 months 13 days	5 years 10 months 6 days
Weighted-Average Remaining Contractual Life (In Years), Vested and expected to vest at end of year	8 years 3 months 18 days	7 years 2 months 12 days

Equity Incentive Plan - Weighte

Equity Incentive Plan - Weighted-Average Assumptions (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Risk-Free Interest Rate	1.82%	1.82%
Expected Life	10 years	10 years
Expected Average Volatility	140%	153%
Expected Dividend Yield	0%	0%

Equity Incentive Plan - Restric

Equity Incentive Plan - Restricted Stock Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Outstanding at beginning of year	77,262
Outstanding at end of year	41,216	77,262
Weighted- Average Remaining Recognition Period Nonvested Outstanding			1 year 5 months 26 days
Restricted Stock
Outstanding at beginning of year	67,420	50,187
Number of Shares Awarded	0	49,000
Number of Shares Vested	(46,437)	(31,767)
Number of Shares Forfeited	(5,971)
Outstanding at end of year	15,012	67,420	50,187
Weighted- Average Grant Date Fair Value Outstanding at beginning of year	$ 7.10	$ 8.64
Weighted- Average Grant Date Fair Value Awarded	7.33	6.55
Weighted- Average Grant Date Fair Value Vested		8.69
Weighted- Average Grant Date Fair Value Forfeited	6.66
Weighted- Average Grant Date Fair Value Outstanding at end of year	$ 6.55	$ 7.10	$ 8.64
Weighted- Average Remaining Recognition Period Nonvested Outstanding	1 year 1 month 2 days	1 year 7 months 28 days

Equity Incentive Plan - Stock-b

Equity Incentive Plan - Stock-based Compensation (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total Stock-Based Compensation Expense	$ 842,475	$ 723,856
Research and Development
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total Stock-Based Compensation Expense	246,386	197,806
General and Administrative
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total Stock-Based Compensation Expense	$ 596,089	$ 526,050

Equity Incentive Plan - Additio

Equity Incentive Plan - Additional Information (Details) - USD ($)	1 Months Ended	12 Months Ended
	Jan. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2010	Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized		$ 1,001,000	$ 780,000
Fair value of options granted		$ 1,233,000	$ 580,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition		2 years 3 months 7 days	1 year 11 months 12 days
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Exercisable Intrinsic Value		$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant		345,865	93,165
Excess Stock, Shares Authorized				59,414
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value		$ 4.91	$ 6.26
Number of Options, Granted		345,865	93,165
One-year anniversary [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		33%
24-month period [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		0.67%
Holders Owing More Than Ten Percentage Voting Rights [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period				5 years
Holders Owing More Than Ten Percentage Voting Rights [Member] | Minimum
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Percentage of Exercise Price				110%
Holders Owing More Than Ten Percentage Voting Rights [Member] | Maximum
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period				10 years
ESPP [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant		7,806
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized		11,371
2014 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant		110,874
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	806,005	806,005
Excess Stock, Shares Authorized					200,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized	23,333
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period		5,971
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period		0	49,000
Restricted Stock | One-year anniversary [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		33%
Restricted Stock | 24-month period [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		0.67%

Income Taxes (Details)

Income Taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Taxes
Domestic	$ 10,639,818	$ 6,766,157
Foreign	3,323,470	83,558
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Total	$ (13,963,288)	$ (6,849,715)

Income Taxes - Components of in

Income Taxes - Components of income tax expense (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Deferred Taxes
Federal	$ (24,086)	$ (529)
State	(168,517)	12,584
Total Deferred Taxes	(192,603)	12,055
Income Tax Benefit	$ (192,603)	$ 12,055

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of effective tax rate (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Taxes
United States Federal Income Tax Rate	21%	21%
State Taxes, Net of Federal Benefit	3.35%	(1.59%)
Permanent Differences	0.72%	(15.00%)
Goodwill Impairment	(6.07%)
Change in Valuation Allowance	(21.33%)	17.53%
Research and Development Credits	1.09%	1.65%
Tax Rate Differential	1%	(2.12%)
State Non-Income Based Tax	0.01%	0.01%
Stock-Based Compensation		(1.32%)
Gain on Dissolution of Foreign Subsidiary		(15.81%)
Other	1.61%	(4.50%)
Effective Tax Rate (Expense) Benefit	1.38%	(0.15%)

Income Taxes - Deferred tax ass

Income Taxes - Deferred tax assets and liabilities (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Net Deferred Tax Liability
Net Operating Loss Carryforwards	$ 20,689,134	$ 17,042,422
Research and Development Credit Carryforwards	2,853,598	2,695,773
Capitalized Research and Development	5,640,428	6,251,945
Stock-Based Compensation	835,432	781,252
Cash Versus Accrual Adjustments	128,188	223,674
Total Deferred Tax Assets	30,146,780	26,995,066
Valuation Allowance	(28,298,339)	(25,320,159)
Net Deferred Tax Asset	1,848,441	1,674,907
Depreciation and Amortization	(956)	(1,083)
In-Process Research and Development	(2,649,616)	(2,402,750)
Net Deferred Tax Liability	$ (802,131)	$ (728,926)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2018	Dec. 31, 2017
Income Taxes
Operating Loss Carryforwards, Expiration Period	2041
Operating Loss Carryforwards	$ 72,370	$ 51,930
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	$ 2,978	$ (958)
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21%	21%
Unrecognized uncertain income tax	$ 0	$ 0
Domestic Tax Authority [Member]
Income Taxes
Operating Loss Carryforwards	639			$ 46,054
Tax Credit Carryforward, Amount			$ 26,316
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent			80%
Foreign Tax Authority [Member]
Income Taxes
Operating Loss Carryforwards	9,405
State and Local Jurisdiction [Member]
Income Taxes
Operating Loss Carryforwards	49,894	$ 2,037
Tax Credit Carryforward, Amount	$ 503
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	80%
Research Tax Credit Carryforward [Member]
Income Taxes
Operating Loss Carryforwards, Expiration Period	2041
Research Tax Credit Carryforward [Member] | Domestic Tax Authority [Member]
Income Taxes
Tax Credit Carryforward, Amount	$ 2,456

Commitments and Contingencies -

Commitments and Contingencies - Maturities of Lease Liabilities (Details)	Dec. 31, 2021 USD ($)
Commitments and Contingencies
2022	$ 133,339
2023	95,086
Less: Imputed Interest	(19,014)
Lease Liabilities	$ 209,411

Commitments and Contingencies_2

Commitments and Contingencies - Additional Information (Details) $ in Thousands					12 Months Ended
	May 01, 2020 USD ($)	Nov. 17, 2014 USD ($)	Sep. 12, 2013 USD ($)	Jul. 02, 2013 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Nov. 30, 2023 ft²	Oct. 31, 2023 ft²	Mar. 31, 2022 ft²	Sep. 26, 2018 USD ($)
Commitments and Contingencies [Line Items]
Payment of annual fee	$ 5
Cease Payments Not Yet Paid Based On Prevailing Financial Market Conditions					10%
Operating lease expense					$ 215
Imputed interest on the lease liability						$ 174
SentrX Animal Care Inc
Commitments and Contingencies [Line Items]
Intangible Assets Expected Milestone Payable					$ 4,750					$ 4,750
For The First 250 Million Net Sales [Member]
Commitments and Contingencies [Line Items]
Percentage Of Royalties On Net Sales	2%
Between 250 And 500 Million Net Sales [Member]
Commitments and Contingencies [Line Items]
Percentage Of Royalties On Net Sales	1.25%
Net Sales Over 500 Million [Member]
Commitments and Contingencies [Line Items]
Percentage Of Royalties On Net Sales	0.50%
License [Member]
Commitments and Contingencies [Line Items]
Cost of Goods and Services Sold			$ 30	$ 155,000
KIO-101 [Member] | Mediolanum Agreement [Member]
Commitments and Contingencies [Line Items]
Percentage Of Royalties On Net Sales		7%
Contractual Obligation		$ 20,000
Development and commercial milestones term		10 years
Percentage of decreased royalty after patent expiry		5%
Subsequent Event
Commitments and Contingencies [Line Items]
Area of Land | ft²							3,540	1,555
New Valeant Agreement | Subsequent Event
Commitments and Contingencies [Line Items]
Area of Land | ft²									4,516
Licensing Agreements [Member] | License [Member]
Commitments and Contingencies [Line Items]
Percentage Of Royalties On Net Sales			6%	3.25%

Employee Benefit Plans (Details

Employee Benefit Plans (Details) - USD ($)	3 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2021
Employee Benefit Plans
Defined Benefit Plan, Plan Assets, Contributions by Employer	$ 25,905
Defined Benefit Plan Contributions by Employer Accrued		$ 20,334
Defined Benefit Plan, Plan Assets, Matching Contributions by Employer		0%

Acquisitions (Details)

Acquisitions (Details) - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended
	Dec. 18, 2020	Dec. 31, 2021	Dec. 31, 2020	Jan. 03, 2020
Business Acquisition [Line Items]
Share Price				$ 10
Panoptes
Business Acquisition [Line Items]
Percentage of equity interests acquired	100%
Cash consideration paid	$ 445
Fair value of contingent consideration			$ 1,353
Fair value of shares issued	$ 3,169
Threshold period of volume weighted average price	30 days
Volume weighted average price	$ 3.5321
Holdback Shares	$ 1,500
Panoptes | Due to creditor
Business Acquisition [Line Items]
Fair Value at the acquisition date		$ 212
Panoptes | Milestone payments
Business Acquisition [Line Items]
Fair value of contingent consideration	$ 2,280
Panoptes | 18-month Period subject to post-closing adjustments
Business Acquisition [Line Items]
Shares issued as consideration	1,500
Number of shares convertible	424,685
Panoptes | If milestone payments are exercised for shares | Minimum
Business Acquisition [Line Items]
Share Price	$ 2.4725
Panoptes | If milestone payments are exercised for shares | Maximum
Business Acquisition [Line Items]
Share Price	$ 4.5917
Panoptes | Upon the enrollment and randomization of a first patient into the first FDA Phase III pivotal study of a Panoptes product
Business Acquisition [Line Items]
Milestone payments in cash or stock	$ 4,750
Panoptes | Upon the FDA approval of the first New Drug Application of a Panoptes product
Business Acquisition [Line Items]
Milestone payments in cash or stock	$ 4,750
Bayon
Business Acquisition [Line Items]
Percentage of equity interests acquired		100%
Cash consideration paid		$ 97
Shares issued as consideration		33,798
Fair value of shares issued		$ 68
Volume weighted average price		$ 2.01
Bayon | Due to creditor
Business Acquisition [Line Items]
Fair Value at the acquisition date		$ 1,008
Bayon | Earn-out provisions
Business Acquisition [Line Items]
Earnout consideration		$ 7,135
Bayon | If milestone payments are exercised for shares | Phase 1b milestones
Business Acquisition [Line Items]
Share Price		$ 2.01
Bayon | If milestone payments are exercised for shares | Remaining milestones
Business Acquisition [Line Items]
Share Price		$ 3.30
Common Stock | Panoptes
Business Acquisition [Line Items]
Shares issued as consideration	884,222
Series D Convertible Preferred Stock | Panoptes
Business Acquisition [Line Items]
Shares issued as consideration	45.893
Number of shares convertible	13,000

Acquisitions - Purchase price a

Acquisitions - Purchase price allocation (Details) - USD ($)		12 Months Ended
	Oct. 21, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 18, 2020
Panoptes
Business Acquisition [Line Items]
Current Assets				$ 410,863
In-Process R&D				5,624,100
Goodwill				2,105,316
Property, Plant and Equipment				2,042
Accounts Payable and Other Liabilities				(87,777)
Deferred Tax Liability				(351,507)
Assumed Liabilities				(312,852)
Total Consideration				7,390,185
Total		$ 7,390,185
Cash				333,860
Receivables				73,368
Prepaid expenses				$ 3,635
Net losses of acquiree from the acquisition date			$ 34,000
General and administrative expense		50,000	414,000
Acquisition-related costs		50,000	$ 414,000
Bayon
Business Acquisition [Line Items]
Current Assets	$ 5,290
In-Process R&D	1,063,000
Goodwill	406,599
Accounts Payable and Other Liabilities	(36,525)
Deferred Tax Liability	(265,808)
Total	$ 1,172,556	1,172,556
Cash		3,910
Receivables		1,380
Net losses of acquiree from the acquisition date		128,000
General and administrative expense		90,000
Acquisition-related costs		$ 90,000

Acquisitions - Fair value of co

Acquisitions - Fair value of consideration (Details) - USD ($)			12 Months Ended
	Oct. 21, 2021	Dec. 18, 2020	Dec. 31, 2021
Bayon
Business Acquisition [Line Items]
Contingent consideration at fair value			$ 1,007,556
Cash Consideration			$ 97,066
Kiora Common Stock , Number of shares			33,798
Kiora Common Stock , Amount			$ 68,000
Total Fair Value of Consideration	$ 1,172,556		$ 1,172,556
Bayon | Common Stock
Business Acquisition [Line Items]
Kiora Common Stock , Number of shares			33,798
Kiora Common Stock , Price per share			$ 2.01
Kiora Common Stock , Amount			$ 67,934
Panoptes
Business Acquisition [Line Items]
Contingent consideration at fair value			2,279,525
Cash Consideration			$ 441,552
Kiora Common Stock , Amount		$ 3,169,000
Holdback shares , Number of shares			424,685
Holdback shares , Price per share			$ 3.5321
Holdback shares , Amount			$ 1,500,030
Total Fair Value of Consideration			$ 7,390,185
Panoptes | Common Stock
Business Acquisition [Line Items]
Kiora Common Stock , Number of shares			897,222
Kiora Common Stock , Price per share			$ 3.5321
Kiora Common Stock , Amount			$ 3,169,078

Acquisitions - Proforma disclos

Acquisitions - Proforma disclosure (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Panoptes
Business Acquisition [Line Items]
Revenues		$ 558,063
Operating Expenses		8,498,798
Net Loss		(7,942,031)
Bayon
Business Acquisition [Line Items]
Operating Expenses	$ 14,257,347	7,082,768
Net Loss	$ (13,792,265)	$ (6,873,698)

Quarterly Financial Informati_3

Quarterly Financial Information (Unaudited) - Balance sheet (Details) - USD ($)	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
CONSOLIDATED BALANCE SHEETS
Total Current Assets	$ 8,990,770				$ 1,726,221
Property and Equipment, Net	73,999				30,566
Restricted cash	45,000				45,000
Goodwill	0				3,631,212
Intangible Assets and In-Process R&D, Net	10,768,164				9,730,164
Operating Lease Assets with Right-of-Use	209,411				83,928
Other Assets	42,964				57,073
Total Assets	20,130,308				15,304,164
LIABILITIES AND STOCKHOLDERS' EQUITY
Total current liabilities	1,609,608				1,984,608
Contingent Consideration	3,048,955				2,547,074
Deferred Tax Liability	802,131				728,926
Paycheck Protection Program Loan					278,190
Non-Current Operating Lease Liabilities	90,566				35,625
Total Liabilities	5,551,260				5,574,423
Stockholders' Equity:
Preferred Stock, $0.01 par value					41
Common Stock, $0.01 par value	126,640				55,564
Additional paid-in-capital	135,418,188				116,783,602
Accumulated Deficit	(120,879,349)				(107,108,664)
Accumulated Other Comprehensive Income	(86,431)				(802)
Total Stockholders' Equity	14,579,048				9,729,741	$ 6,622,455
Total Liabilities and Stockholders' Equity	$ 20,130,308				$ 15,304,164
Preferred Stock, Par or Stated Value Per Share	$ 0.01				$ 0.01
Common Stock, Par or Stated Value Per Share	$ 0.01				$ 0.01
Correction in Accounting For Acquisitions And Subsequent Intangible Asset Impairment [Member]
CONSOLIDATED BALANCE SHEETS
Total Current Assets	$ 8,990,770	$ 11,870,019	$ 4,415,173	$ 6,991,086
Property and Equipment, Net	73,999	78,833	83,682	84,264
Restricted cash	45,000	45,000	45,000	45,000
Goodwill		3,631,212	3,631,212	3,631,212
Intangible Assets and In-Process R&D, Net	10,768,164	9,711,414	9,717,664	9,723,914
Operating Lease Assets with Right-of-Use	209,411	259,217	308,013	242,730
Other Assets	42,964	44,249	45,921	49,001
Total Assets	20,130,308	25,639,944	18,246,665	20,767,207
LIABILITIES AND STOCKHOLDERS' EQUITY
Total current liabilities	1,609,608	2,171,223	1,648,721	1,637,879
Contingent Consideration	3,048,955	2,118,594	2,050,588	1,976,871
Deferred Tax Liability	802,131	728,926	728,926	728,926
Paycheck Protection Program Loan				278,190
Non-Current Operating Lease Liabilities	90,566	114,475	137,957	159,938
Total Liabilities	5,551,260	5,133,218	4,566,192	4,781,804
Stockholders' Equity:
Preferred Stock, $0.01 par value			41	41
Common Stock, $0.01 par value	126,640	126,193	70,979	70,979
Additional paid-in-capital	135,418,188	135,137,530	125,286,886	125,023,994
Accumulated Deficit	(120,879,349)	(114,697,127)	(111,662,297)	(109,119,282)
Accumulated Other Comprehensive Income	(86,431)	(59,870)	(15,136)	9,671
Total Stockholders' Equity	14,579,048	20,506,726	13,680,473	15,985,403	$ 9,729,741
Total Liabilities and Stockholders' Equity	$ 20,130,308	$ 25,639,944	$ 18,246,665	$ 20,767,207
Preferred Stock, Par or Stated Value Per Share	$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01
Common Stock, Par or Stated Value Per Share	$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01
Correction in Accounting For Acquisitions And Subsequent Intangible Asset Impairment [Member] | As reported
CONSOLIDATED BALANCE SHEETS
Total Current Assets	$ 8,990,770	$ 11,870,019	$ 4,415,173	$ 6,991,086	$ 1,726,221
Property and Equipment, Net	73,999	78,833	83,682	84,264	30,566
Restricted cash	45,000	45,000	45,000	45,000	45,000
Goodwill		3,484,607	3,484,607	3,484,607	3,484,607
Intangible Assets and In-Process R&D, Net	8,695,850	9,711,414	9,717,664	9,723,914	9,730,164
Operating Lease Assets with Right-of-Use	209,411	259,217	308,013	242,730	83,928
Other Assets	42,964	44,249	45,921	49,001	57,073
Total Assets	18,057,994	25,493,339	18,100,060	20,620,602	15,157,559
LIABILITIES AND STOCKHOLDERS' EQUITY
Total current liabilities	1,609,608	1,958,942	1,436,440	1,425,598	1,772,327
Contingent Consideration	6,518,770	5,342,950	5,342,950	5,342,950	5,342,950
Deferred Tax Liability	614,436	728,926	728,926	728,926	728,926
Paycheck Protection Program Loan				278,190	278,190
Non-Current Operating Lease Liabilities	90,566	114,475	137,957	159,938	35,625
Total Liabilities	8,833,380	8,145,293	7,646,273	7,935,602	8,158,018
Stockholders' Equity:
Preferred Stock, $0.01 par value			41	41	41
Common Stock, $0.01 par value	126,640	126,193	70,979	70,979	55,564
Additional paid-in-capital	133,918,158	133,637,500	123,786,856	123,523,964	115,283,572
Accumulated Deficit	(124,733,753)	(116,355,777)	(113,388,953)	(110,919,655)	(108,338,834)
Accumulated Other Comprehensive Income	(86,431)	(59,870)	(15,136)	9,671	(802)
Total Stockholders' Equity	9,224,614	17,348,046	10,453,787	12,685,000	6,999,541
Total Liabilities and Stockholders' Equity	18,057,994	25,493,339	18,100,060	20,620,602	$ 15,157,559
Correction in Accounting For Acquisitions And Subsequent Intangible Asset Impairment [Member] | 2021 Restatement Adjustment
CONSOLIDATED BALANCE SHEETS
Goodwill	(146,605)
Intangible Assets and In-Process R&D, Net	2,072,314
Total Assets	1,925,709
LIABILITIES AND STOCKHOLDERS' EQUITY
Contingent Consideration	(886,220)	(428,480)	(496,486)	(570,203)
Deferred Tax Liability	187,695
Total Liabilities	(698,525)	(428,480)	(496,486)	(570,203)
Stockholders' Equity:
Accumulated Deficit	2,624,234	428,480	496,486	570,203
Total Stockholders' Equity	2,624,234	428,480	496,486	570,203
Total Liabilities and Stockholders' Equity	$ 1,925,709
Correction in Accounting For Acquisitions And Subsequent Intangible Asset Impairment [Member] | 2020 restatements
CONSOLIDATED BALANCE SHEETS
Goodwill		146,605	146,605	146,605
Total Assets		146,605	146,605	146,605
LIABILITIES AND STOCKHOLDERS' EQUITY
Total current liabilities		212,281	212,281	212,281
Contingent Consideration		(2,795,876)	(2,795,876)	(2,795,876)
Total Liabilities		(2,583,595)	(2,583,595)	(2,583,595)
Stockholders' Equity:
Additional paid-in-capital		1,500,030	1,500,030	1,500,030
Accumulated Deficit		1,230,170	1,230,170	1,230,170
Total Stockholders' Equity		2,730,200	2,730,200	2,730,200
Total Liabilities and Stockholders' Equity		$ 146,605	$ 146,605	$ 146,605

Quarterly Financial Informati_4

Quarterly Financial Information (Unaudited) - Statement of Operations and Comprehensive Loss (Details) - USD ($)	3 Months Ended			6 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2021	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
Research and Development						$ 5,350,264	$ 3,566,045
General and Administrative						5,323,649	4,658,769
Change in fair value of contingent consideration						(475,956)	(1,230,170)
Total Operating Expenses						14,235,768	6,880,927
Operating Loss before Other Income						(14,235,768)	(6,868,868)
Other Income, net:
Gain on Forgiveness of Loan						278,190	0
Interest Income						1,141	23,339
Interest Expense						(6,851)	(4,186)
Total other (expense) income						272,480	19,153
Loss Before Income Tax Benefit (Expense)						(13,963,288)	(6,849,715)
Income Tax Benefit (Expense)						(192,603)	12,055
Net Loss						$ (13,770,685)	$ (6,861,770)
Weighted-Average Shares Outstanding- Basic						9,643,961	4,591,491
Weighted-Average Shares Outstanding- Diluted					8,504,465	9,643,961	4,591,491
Net Loss per Common Share - Basic						$ (1.43)	$ (1.49)
Net Loss per Common Share - Diluted					$ (0.89)	$ (1.43)	$ (1.49)
Other comprehensive loss:
Net Loss						$ (13,770,685)	$ (6,861,770)
Foreign Currency Translation Adjustments						(85,629)	(26,550)
Correction in Accounting For Acquisitions And Subsequent Intangible Asset Impairment [Member]
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
Research and Development	$ 1,628,467	$ 1,439,922	$ 1,280,242	$ 2,720,164	$ 4,348,631	5,350,264	3,566,045
General and Administrative	1,338,616	1,305,865	1,300,143	2,606,008	3,944,624	5,323,649	4,658,769
Contingent Consideration Expense (Recovery)			(570,203)
Change in fair value of contingent consideration				(496,486)	(428,480)	475,956	(1,230,170)
Total Operating Expenses	3,035,089	2,819,504	2,010,182	4,829,686	7,864,775	14,235,768	6,880,927
Operating Loss before Other Income	(3,035,089)	(2,819,504)	(2,010,182)	(4,829,686)	(7,864,775)	(14,235,768)	(6,868,868)
Other Income, net:
Gain on Forgiveness of Loan		278,190		278,190	278,190	278,190
Interest Income	259	332	250	582	841	1,141	23,339
Interest Expense		(2,033)	(686)	(2,719)	(2,719)	6,851	4,186
Total other (expense) income	259	276,489	(436)	276,053	276,312	272,480	19,153
Loss Before Income Tax Benefit (Expense)	$ (3,034,830)	$ (2,543,015)	(2,010,618)	(4,553,633)	(7,588,463)	(13,963,288)	(6,849,715)
Income Tax Benefit (Expense)						192,603	(12,055)
Net Loss			$ (2,010,618)	$ (4,553,633)	$ (7,588,463)	$ (13,770,685)	$ (6,861,770)
Weighted-Average Shares Outstanding- Basic	10,668,569	7,466,211	7,357,899	7,409,363	8,504,465	9,643,961	4,591,491
Weighted-Average Shares Outstanding- Diluted	10,668,569	7,466,211	7,357,899	7,409,363		9,643,961	4,591,491
Net Loss per Common Share - Basic	$ (0.28)	$ (0.34)	$ (0.27)	$ (0.61)	$ (0.89)	$ (1.43)	$ (1.49)
Net Loss per Common Share - Diluted	$ (0.28)	$ (0.34)	$ (0.27)	$ (0.61)		$ (1.43)	$ (1.49)
Other comprehensive loss:
Net Loss			$ (2,010,618)	$ (4,553,633)	$ (7,588,463)	$ (13,770,685)	$ (6,861,770)
Net Loss	$ (3,034,830)	$ (2,543,015)	(2,010,618)	(4,553,633)	(7,588,463)
Foreign Currency Translation Adjustments	(44,734)	(24,807)	10,473	(14,334)	(59,068)	(85,629)	(26,550)
Comprehensive Loss	(3,079,564)	(2,567,822)	(2,000,145)	(4,567,967)	(7,647,531)
Correction in Accounting For Acquisitions And Subsequent Intangible Asset Impairment [Member] | As reported
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
Research and Development	1,628,467	1,439,922	1,280,242	2,720,164	4,348,631	5,350,264	3,566,045
General and Administrative	1,338,616	1,305,865	1,300,143	2,606,008	3,944,624	5,323,649	4,658,769
Total Operating Expenses	2,967,083	2,745,787	2,580,385	5,326,172	8,293,255	16,942,461	8,224,814
Operating Loss before Other Income	(2,967,083)	(2,745,787)	(2,580,385)	(5,326,172)	(8,293,255)	(16,942,461)	(8,212,755)
Other Income, net:
Gain on Forgiveness of Loan		278,190		278,190	278,190	278,190
Interest Income	259	332	250	582	841	1,141	23,339
Interest Expense		(2,033)	(686)	(2,719)	(2,719)	6,851	4,186
Total other (expense) income	259	276,489	(436)	276,053	276,312	242,761	132,870
Loss Before Income Tax Benefit (Expense)	$ (2,966,824)	$ (2,469,298)	(2,580,821)	(5,050,119)	(8,016,943)	(16,699,700)	(8,079,885)
Income Tax Benefit (Expense)						304,781	(12,055)
Net Loss			$ (2,580,821)	$ (5,050,119)	$ (8,016,943)	$ (16,394,919)	$ (8,091,940)
Weighted-Average Shares Outstanding- Basic	10,265,108	7,062,750	6,954,438	7,005,902	8,101,004	9,240,500	4,576,058
Weighted-Average Shares Outstanding- Diluted	10,265,108	7,062,750	6,954,438	7,005,902	8,101,004	9,240,500	4,576,058
Net Loss per Common Share - Basic	$ (0.29)	$ (0.35)	$ (0.37)	$ (0.72)	$ (0.99)	$ (1.77)	$ (1.77)
Net Loss per Common Share - Diluted	$ (0.29)	$ (0.35)	$ (0.37)	$ (0.72)	$ (0.99)	$ (1.77)	$ (1.77)
Other comprehensive loss:
Net Loss			$ (2,580,821)	$ (5,050,119)	$ (8,016,943)	$ (16,394,919)	$ (8,091,940)
Net Loss	$ (2,966,824)	$ (2,469,298)	(2,580,821)	(5,050,119)	(8,016,943)
Foreign Currency Translation Adjustments	(44,734)	(24,807)	10,473	(14,334)	(59,068)	(85,629)	(26,550)
Comprehensive Loss	(3,011,558)	(2,494,105)	(2,570,348)	(5,064,453)	(8,076,011)
Correction in Accounting For Acquisitions And Subsequent Intangible Asset Impairment [Member] | 2021 Restatement Adjustment
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
Contingent Consideration Expense (Recovery)			(570,203)
Change in fair value of contingent consideration				(496,486)	(428,480)	475,956
Total Operating Expenses	68,006	73,717	(570,203)	(496,486)	(428,480)	(2,706,693)
Operating Loss before Other Income	(68,006)	(73,717)	570,203	496,486	428,480	2,706,693
Other Income, net:
Total other (expense) income						29,719
Loss Before Income Tax Benefit (Expense)	$ (68,006)	$ (73,717)	570,203	496,486	428,480	2,736,412
Income Tax Benefit (Expense)						(112,178)
Net Loss			$ 570,203	$ 496,486	$ 428,480	$ 2,624,234	1,230,170
Weighted-Average Shares Outstanding- Basic	403,461	403,461	403,461	403,461	403,461	403,461
Weighted-Average Shares Outstanding- Diluted	403,461	403,461	403,461	403,461	403,461	403,461
Other comprehensive loss:
Net Loss			$ 570,203	$ 496,486	$ 428,480	$ 2,624,234	$ 1,230,170
Net Loss	$ (68,006)	$ (73,317)	570,203	496,486	428,480
Comprehensive Loss	$ (68,006)	$ (73,317)	$ 570,203	$ 496,486	$ 428,480

Quarterly Financial Informati_5

Quarterly Financial Information (Unaudited) - Shareholders' equity (Details) - USD ($)	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
Cumulative Effect of Change in Accounting Principle (Note 2)	$ 14,579,048				$ 9,729,741	$ 6,622,455
Preferred Stock, Par or Stated Value Per Share	$ 0.01				$ 0.01
Common Stock, Par or Stated Value Per Share	$ 0.01				$ 0.01
Preferred Stock
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
Cumulative Effect of Change in Accounting Principle (Note 2)	$ 0				$ 41	41
Common Stock
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
Cumulative Effect of Change in Accounting Principle (Note 2)	126,640				55,564	40,778
Additional Paid-In Capital
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
Cumulative Effect of Change in Accounting Principle (Note 2)	135,418,188				116,783,602	106,689,065
Accumulated Deficit
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
Cumulative Effect of Change in Accounting Principle (Note 2)	(120,879,349)				(107,108,664)	(100,246,894)
Accumulated Other Comprehensive Loss
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
Cumulative Effect of Change in Accounting Principle (Note 2)	(86,431)				(802)	$ 139,465
Correction in Accounting For Acquisitions And Subsequent Intangible Asset Impairment [Member]
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
Cumulative Effect of Change in Accounting Principle (Note 2)	$ 14,579,048	$ 20,506,726	$ 13,680,473	$ 15,985,403	$ 9,729,741
Preferred Stock, Par or Stated Value Per Share	$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01
Common Stock, Par or Stated Value Per Share	$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01
Correction in Accounting For Acquisitions And Subsequent Intangible Asset Impairment [Member] | Preferred Stock
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
Cumulative Effect of Change in Accounting Principle (Note 2)			$ 41	$ 41	$ 41
Correction in Accounting For Acquisitions And Subsequent Intangible Asset Impairment [Member] | Common Stock
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
Cumulative Effect of Change in Accounting Principle (Note 2)	$ 126,640	$ 126,193	70,979	70,979	55,564
Correction in Accounting For Acquisitions And Subsequent Intangible Asset Impairment [Member] | Additional Paid-In Capital
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
Cumulative Effect of Change in Accounting Principle (Note 2)	135,418,188	135,137,530	125,286,886	125,023,994	116,783,602
Correction in Accounting For Acquisitions And Subsequent Intangible Asset Impairment [Member] | Accumulated Deficit
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
Cumulative Effect of Change in Accounting Principle (Note 2)	(120,879,349)	(114,697,127)	(111,662,297)	(109,119,282)	(107,108,664)
Correction in Accounting For Acquisitions And Subsequent Intangible Asset Impairment [Member] | Accumulated Other Comprehensive Loss
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
Cumulative Effect of Change in Accounting Principle (Note 2)	(86,431)	(59,870)	(15,136)	9,671	(802)
Correction in Accounting For Acquisitions And Subsequent Intangible Asset Impairment [Member] | As reported
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
Cumulative Effect of Change in Accounting Principle (Note 2)	9,224,614	17,348,046	10,453,787	12,685,000	6,999,541
Correction in Accounting For Acquisitions And Subsequent Intangible Asset Impairment [Member] | As reported | Preferred Stock
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
Cumulative Effect of Change in Accounting Principle (Note 2)			41	41	41
Correction in Accounting For Acquisitions And Subsequent Intangible Asset Impairment [Member] | As reported | Common Stock
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
Cumulative Effect of Change in Accounting Principle (Note 2)	126,640	126,193	70,979	70,979	55,564
Correction in Accounting For Acquisitions And Subsequent Intangible Asset Impairment [Member] | As reported | Additional Paid-In Capital
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
Cumulative Effect of Change in Accounting Principle (Note 2)	133,918,158	133,637,500	123,786,856	123,523,964	115,283,572
Correction in Accounting For Acquisitions And Subsequent Intangible Asset Impairment [Member] | As reported | Accumulated Deficit
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
Cumulative Effect of Change in Accounting Principle (Note 2)	(124,733,753)	(116,355,777)	(113,388,953)	(110,919,655)	(108,338,834)
Correction in Accounting For Acquisitions And Subsequent Intangible Asset Impairment [Member] | As reported | Accumulated Other Comprehensive Loss
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
Cumulative Effect of Change in Accounting Principle (Note 2)	(86,431)	(59,870)	(15,136)	9,671	$ (802)
Correction in Accounting For Acquisitions And Subsequent Intangible Asset Impairment [Member] | 2021 Restatement Adjustment
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
Cumulative Effect of Change in Accounting Principle (Note 2)	2,624,234	428,480	496,486	570,203
Correction in Accounting For Acquisitions And Subsequent Intangible Asset Impairment [Member] | 2021 Restatement Adjustment | Accumulated Deficit
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
Cumulative Effect of Change in Accounting Principle (Note 2)	$ 2,624,234	428,480	496,486	570,203
Correction in Accounting For Acquisitions And Subsequent Intangible Asset Impairment [Member] | 2020 restatements
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
Cumulative Effect of Change in Accounting Principle (Note 2)		2,730,200	2,730,200	2,730,200
Correction in Accounting For Acquisitions And Subsequent Intangible Asset Impairment [Member] | 2020 restatements | Additional Paid-In Capital
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
Cumulative Effect of Change in Accounting Principle (Note 2)		1,500,030	1,500,030	1,500,030
Correction in Accounting For Acquisitions And Subsequent Intangible Asset Impairment [Member] | 2020 restatements | Accumulated Deficit
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
Cumulative Effect of Change in Accounting Principle (Note 2)		$ 1,230,170	$ 1,230,170	$ 1,230,170

Quarterly Financial Informati_6

Quarterly Financial Information (Unaudited) - Cash Flows (Details) - USD ($)			3 Months Ended	6 Months Ended	9 Months Ended	12 Months Ended
	Aug. 11, 2021	Jan. 03, 2020	Mar. 31, 2021	Jun. 30, 2021	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Operating Activities
Net Loss						$ (13,770,685)	$ (6,861,770)
Depreciation and Amortization of Intangible Assets						45,296	33,399
Reduction of Right-of-Use Assets						181,977	166,822
Stock-Based Compensation						842,475	723,856
Change in fair value of contingent consideration						(475,956)	(1,230,170)
Expiration of Prepaid Agreement						0	159,848
Deferred Taxes						(192,603)	12,055
Paycheck Protection Program Loan Forgiveness						(278,190)	0
Goodwill Impairment						4,037,811	0
Increase (Decrease) in Operating Capital [Abstract]
Increase (Decrease) in Prepaid Expense and Other Assets						156,951	146,971
Increase (Decrease) in Income Taxes Receivable						441,196	18,957
Increase (Decrease) in Other Operating Assets						(14,111)	(18,916)
Accounts Payable						(310,665)	136,697
Lease Liabilities						(181,977)	(166,822)
Accrued Expenses						40,882	(144,072)
Net Cash Used in Operating Activities						(10,675,390)	(7,317,169)
Net cash used in investing activities						(157,020)	(244,438)
Financing Activities
Proceeds from Stock Offerings	$ 9,800,000	$ 4,500,000				18,750,016	5,000,000
Stock Issuance Costs						(1,004,809)	(498,687)
Exercise of Warrants						50,001	218,000
Repayment of Loan Payable						(212,282)	0
Net cash provided by financing activities						17,582,926	4,997,503
Effect of Exchange Rate Changes on Cash						(81,503)	(26,931)
Net Cash Increase or decrease						6,669,013	(2,591,035)
Cash, Including Restricted Cash, Beginning of Year			$ 1,230,677	$ 1,230,677	$ 1,230,677	1,230,677	3,821,712
Cash, Including Restricted Cash, End of Year						7,899,690	1,230,677
Correction in Accounting For Acquisitions And Subsequent Intangible Asset Impairment [Member]
Operating Activities
Net Loss			(2,010,618)	(4,553,633)	(7,588,463)	(13,770,685)	(6,861,770)
Depreciation and Amortization of Intangible Assets			10,599	23,203	34,260	45,296	33,399
Reduction of Right-of-Use Assets			39,490	86,387	133,514	181,977	166,822
Stock-Based Compensation			216,945	479,837	629,306	842,475	723,856
Change in Fair Value of Contingent Consideration			(570,203)		(428,480)	(505,675)	1,230,170
Change in fair value of contingent consideration				(496,486)	(428,480)	475,956	(1,230,170)
Expiration of Prepaid Agreement							159,848
Deferred Taxes						(192,603)	12,055
Paycheck Protection Program Loan Forgiveness				(278,190)	(278,190)	(278,190)
Goodwill Impairment						4,037,811
Intangible Asset Impairment							(113,717)
Increase (Decrease) in Operating Capital [Abstract]
Increase (Decrease) in Prepaid Expense and Other Assets			216,078	8,786	107,940	(156,951)	(146,971)
Increase (Decrease) in Income Taxes Receivable			(59,706)	(222,645)	(335,096)	(441,196)	(18,957)
Increase (Decrease) in Other Operating Assets			8,073	11,153	12,826	14,111	18,916
Accounts Payable			22,583	(142,444)	(9,875)	(310,665)	136,697
Lease Liabilities			(39,490)	(86,387)	(133,514)	(181,977)	(166,822)
Accrued Expenses			(403,802)	(315,196)	100,050	40,882	(144,072)
Net Cash Used in Operating Activities			(2,570,051)	(5,485,615)	(7,755,722)	(10,675,390)	(7,317,169)
Net cash used in investing activities			(58,119)	(63,865)	(63,865)	(157,020)	(244,438)
Financing Activities
Proceeds from Stock Offerings			7,988,861	7,988,861	17,745,207	18,750,016
Stock Issuance Costs						(1,004,809)
Exercise of Warrants			50,001	50,001	50,001	50,001
Repayment of Loan Payable						(212,282)
Net cash provided by financing activities			8,038,862	8,038,862	17,795,208	17,582,926	4,997,503
Effect of Exchange Rate Changes on Cash			14,123	(11,835)	(54,371)	(81,503)	(26,931)
Net Cash Increase or decrease			5,424,815	2,477,547	9,921,250	6,669,013	(2,591,035)
Cash, Including Restricted Cash, Beginning of Year			1,230,677	1,230,677	1,230,677	1,230,677	3,821,712
Cash, Including Restricted Cash, End of Year			6,655,492	3,708,224	11,151,927	7,899,690	1,230,677
Correction in Accounting For Acquisitions And Subsequent Intangible Asset Impairment [Member] | As reported
Operating Activities
Net Loss			(2,580,821)	(5,050,119)	(8,016,943)	(16,394,919)	(8,091,940)
Depreciation and Amortization of Intangible Assets			10,599	23,203	34,260	45,296	33,399
Reduction of Right-of-Use Assets			39,490	86,387	133,514	181,977	166,822
Stock-Based Compensation			216,945	479,837	629,306	842,475	723,856
Change in Fair Value of Contingent Consideration						(212,281)
Expiration of Prepaid Agreement							159,848
Deferred Taxes						(304,782)	12,055
Paycheck Protection Program Loan Forgiveness						(278,190)
Goodwill Impairment						4,498,234
Intangible Asset Impairment						1,770,314
Increase (Decrease) in Operating Capital [Abstract]
Increase (Decrease) in Prepaid Expense and Other Assets			216,078	8,786	107,940	(156,951)	(146,971)
Increase (Decrease) in Income Taxes Receivable			(59,706)	(222,645)	(335,096)	(441,196)	(18,957)
Increase (Decrease) in Other Operating Assets			8,073	11,153	12,826	14,111	18,916
Accounts Payable			22,583	(142,444)	(9,875)	(310,665)	136,697
Lease Liabilities			(39,490)	(86,387)	(133,514)	(181,977)	(166,822)
Accrued Expenses			(403,802)	(315,196)	100,050	40,882	(144,072)
Net Cash Used in Operating Activities			(2,570,051)	(5,207,425)	(7,477,532)	(10,887,672)	(7,317,169)
Net cash used in investing activities			(58,119)	(63,865)	(63,865)	(157,020)	(244,438)
Financing Activities
Proceeds from Stock Offerings			7,988,861	7,988,861	17,745,207	18,750,016
Stock Issuance Costs						(1,004,809)
PPP Loan Forgiveness				(278,190)	(278,190)
Exercise of Warrants			50,001	50,001	50,001	50,001
Net cash provided by financing activities			8,038,862	7,760,672	17,517,018	17,795,208	4,997,503
Effect of Exchange Rate Changes on Cash			14,123	(11,835)	(54,371)	(81,503)	(26,931)
Net Cash Increase or decrease			5,424,815	2,477,547	9,921,250	6,669,013	(2,591,035)
Cash, Including Restricted Cash, Beginning of Year			1,230,677	1,230,677	1,230,677	1,230,677	3,821,712
Cash, Including Restricted Cash, End of Year			6,655,492	3,708,224	11,151,927	7,899,690	1,230,677
Correction in Accounting For Acquisitions And Subsequent Intangible Asset Impairment [Member] | 2020 Restatement Adjustment
Operating Activities
Net Loss							1,230,170
Change in fair value of contingent consideration							(1,230,170)
Intangible Asset Impairment							(113,717)
Correction in Accounting For Acquisitions And Subsequent Intangible Asset Impairment [Member] | 2021 Restatement Adjustment
Operating Activities
Net Loss			570,203	496,486	428,480	2,624,234	1,230,170
Change in Fair Value of Contingent Consideration			$ (570,203)		(428,480)	(293,394)	$ 1,230,170
Change in fair value of contingent consideration				(496,486)	(428,480)	475,956
Deferred Taxes						112,179
Paycheck Protection Program Loan Forgiveness				(278,190)	(278,190)
Goodwill Impairment						(460,423)
Intangible Asset Impairment						(1,770,314)
Increase (Decrease) in Operating Capital [Abstract]
Net Cash Used in Operating Activities				(278,190)	(278,190)	212,282
Financing Activities
PPP Loan Forgiveness				278,190	278,190
Repayment of Loan Payable						(212,282)
Net cash provided by financing activities				$ 278,190	$ 278,190	$ (212,282)